Substituted pyrrolidine amide III

By developing a new glucocorticoid receptor modulator compound, using the compounds of general formula (I), the conformational regulation of glucocorticoid receptors has been optimized, and the side effects of glucocorticoid treatment have been solved, achieving more effective and safer anti-inflammatory treatment.

CN113382990BActive Publication Date: 2024-11-19GRUNENTHAL GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080008812.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-06-19
Filing Date
2020-01-13
Publication Date
2024-11-19
Estimated Expiration
2040-01-13

AI Technical Summary

Technical Problem

Glucocorticoid receptor-mediated treatment of disorders such as insulin resistance, diabetes, hypertension, glaucoma, depression and osteoporosis, and sudden discontinuation of glucocorticoids may lead to severe withdrawal symptoms, urgently needed Develop anti-inflammatory drugs with less side effects.

Method used

Develop a novel glucocorticoid receptor modulator compound that modulates glucocorticoid receptors through specific conformations according to the compound of general formula (I), optimizes its relationship between trans-inhibition and transactivation of inflammatory genes Balance to reduce side effects and improve treatment effectiveness.

Benefits of technology

As a highly effective glucocorticoid receptor modulator, this compound can effectively reduce the side effects of glucocorticoid receptor-mediated diseases, improve treatment effect and reduce the risk of withdrawal.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113382990B_ABST
    Figure CN113382990B_ABST
Patent Text Reader

Abstract

The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and are useful for the treatment and / or prevention of disorders mediated at least in part by the glucocorticoid receptor. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to compounds according to the general formula (I)

[0002]

[0003] They act as modulators of the glucocorticoid receptor and can be used to treat and / or prevent disorders that are mediated at least in part by the glucocorticoid receptor.

[0004] Glucocorticoids (GCs) exert potent anti-inflammatory, immunosuppressive, and disease-modifying therapeutic effects mediated by the glucocorticoid receptor (GR). They have been widely used to treat inflammatory and immune diseases for decades and remain the most effective therapy for these conditions. However, GC-associated side effects have hampered chronic GC therapy for inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, acute respiratory distress syndrome, cystic fibrosis, osteoarthritis, polymyalgia rheumatica, and giant cell arteritis. These adverse side effects include insulin resistance, diabetes, hypertension, glaucoma, depression, osteoporosis, adrenal suppression and muscle wasting, of which osteoporosis and diabetes are the most serious side effects from a physician's perspective (Hapgood JP. et al. Pharmacol Ther. 2016 Sep;165:93–113; Buttgereit F. et al. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S29-33; Hartmann K. et al. Physiol Rev. 2016 Apr;96(2):409-47).

[0005] An example of an oral glucocorticoid is prednisone, which is commonly prescribed to treat several inflammatory conditions (DeBosscher K et al., Trends Pharmacol Sci. 2016 Jan; 37(1):4-16; Buttgereit F et al., JAMA. 2016; 315(22):2442-2458). Since GCs cause adrenal suppression, prednisolone withdrawal symptoms can be severe if the drug is stopped abruptly when all signs of the disease have disappeared. Therefore, gradually reducing GCs to physiological doses is often part of the treatment regimen to reduce the risk of relapse and other withdrawal symptoms (Liu D et al., Allergy Asthma Clin Immunol. 2013 Aug 15; 9(1):30). Therefore, there is an urgent medical need to develop new, effective anti-inflammatory drugs with fewer side effects.

[0006] Recent studies have focused on developing partial agonists or selective glucocorticoid receptor modulators that activate pathways that inhibit inflammation, but avoid targeting pathways that cause GC-related side effects. Most of these effects have been shown to be mediated by different GR-dependent genomic mechanisms known as transactivation and transrepression. The anti-inflammatory effects of GC are primarily attributable to transrepression of inflammatory genes, while some side effects are primarily mediated by transactivation of several genes. Depending on the nature of the ligand, GR can be selectively regulated in a specific conformation that favors transrepression rather than transactivation, thereby increasing therapeutic benefit (De Bosscher K et al., Trends Pharmacol Sci. 2016 January; 37(1): 4-16). The concept of this dissociated ligand was defined about two decades ago, and several compounds have been identified and evaluated in preclinical and clinical testing, but none of them has been approved for clinical use.

[0007] Compounds active as modulators of the glucocorticoid receptor are also known, see for example WO 2007 / 122165, WO 2008 / 076048 and WO 2008 / 043789, WO 2009 / 035067, WO 2009 / 142571, WO 2016 / 046260 and WO 2017 / 034006.

[0008] The object of the present invention is to provide novel compounds as modulators of glucocorticoid receptors, which preferably have advantages over prior art compounds. The novel compounds should be particularly suitable for treating and / or preventing disorders or diseases mediated at least in part by glucocorticoid receptors.

[0009] This object has been achieved by the subject matter of the present patent claims.

[0010] It has surprisingly been found that the compounds according to the invention are highly potent modulators of the glucocorticoid receptor.

[0011] The present invention relates to compounds according to the general formula (I),

[0012]

[0013] in

[0014] R1 represents phenyl; -C 1-6 -alkylene-phenyl; 5 or 6 membered heteroaryl; -C 1-6 -alkylene-(5- or 6-membered heteroaryl); or -C 1-10 -alkyl;

[0015] R 1’ Represents H; -C 1-10-alkyl; or -C 3-10 - cycloalkyl;

[0016] R2 represents -C(=O)-C 1-10 -alkyl; -C(=O)-C 3-10 -cycloalkyl; -C(=O)-C 1-6 -Alkylene-C 3-10 -cycloalkyl; -C(=O)-(3- to 7-membered heterocycloalkyl); -C(=O)-C 1-6 -alkylene-(3 to 7 membered heterocycloalkyl); -C(=O)-phenyl; -C(=O)-C 1-6 -alkylene-phenyl; -C(=O)-(5- or 6-membered heteroaryl); -C(=O)-C 1-6 -alkylene-(5- or 6-membered heteroaryl); -S(=O) 1-2 -C 1-10 -alkyl; -S(=O) 1-2 -C 3-10 -cycloalkyl; -S(=O) 1-2 -C 1-6 -Alkylene-C 3-10 -cycloalkyl; -S(=O) 1-2 -(3 to 7 membered heterocycloalkyl); -S(=O) 1-2 -C 1-6 -alkylene-(3 to 7 membered heterocycloalkyl); -S(=O) 1-2 -phenyl; -S(=O) 1-2 -C 1-6 -alkylene-phenyl; -S(=O) 1-2 -(5- or 6-membered heteroaryl); or -S(=O) 1-2 -C 1-6 -alkylene-(5- or 6-membered heteroaryl);

[0017] R3 and R 3’ Independently represent H; F; Cl; -C 1-10 -alkyl; -C 3-6 -cycloalkyl; -CH2-C 3-6 -cycloalkyl; 3- to 7-membered heterocycloalkyl; -CH2-(3- to 7-membered heterocycloalkyl); -CH2-phenyl; or -CH2-(5- or 6-membered heteroaryl);

[0018] Or R3 and R 3’ Together with the carbon atoms to which they are attached, they form C 3-10 -cycloalkyl; or 3 to 7 membered heterocycloalkyl;

[0019] R4 represents -phenyl; -C 1-6 -alkylene-phenyl; -5 or 6 membered heteroaryl; or -C 1-6-alkylene-(5- or 6-membered heteroaryl);

[0020] A, X, Y and Z independently represent N or CH;

[0021] Where R 1’ , R3 and R 3’ At least one of is not H;

[0022] Where -C 1-10 -alkyl and -C 1-6 -Alkylene - is in each case independently of one another straight-chain or branched, saturated or unsaturated;

[0023] Where -C 1-10 -alkyl, -C 1-6 -alkylene-, -C 3-10 -cycloalkyl and 3- to 7-membered heterocycloalkyl are in each case independently of one another unsubstituted or mono- or polysubstituted by one or more substituents selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -CF2Cl; -CFCl2; -C(=O)-C 1-6 -alkyl; -C(=O)-OH; -C(=O)-OC 1-6 -alkyl; -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; =O; -OCF3; -OCF2H; -OCFH2; -OCF2Cl; -OCFCl2; -OC 1-6 -alkyl; -OC(=O)-C 1-6 -alkyl; -OC(=O)-OC 1-6 -alkyl; -O-(CO)-NH(C 1-6 -alkyl); -OC(=O)-N(C 1-6 -alkyl)2; -OS(=O)2-NH2; -OS(=O)2-NH(C 1-6 -alkyl); -OS(=O)2-N(C 1-6 -alkyl)2; -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -NH-C(=O)-C 1-6 -alkyl; -NH-C(=O)-OC 1-6 -alkyl; -NH-C(=O)-NH2; -NH-C(=O)-NH(C 1-6 -alkyl); -NH-C(=O)-N(C 1-6-alkyl)2; -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-OC 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-NH2; -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl)2; -NH-S(=O)2OH; NH-S(=O)2-C 1-6 -alkyl; -NH-S(=O)2-OC 1-6 -alkyl; -NH-S(=O)2-NH2; -NH-S(=O)2-NH(C 1-6 -alkyl); -NH-S(=O)2N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-S(=O)2-OH; -N(C 1-6 -alkyl)-S(=O)2-C 1-6 -alkyl; -N(C 1-6 -alkyl)-S(=O)2-OC 1-6 -alkyl; -N(C 1-6 -alkyl)-S(=O)2-NH2; -N(C 1-6 -alkyl)-S(=O)2-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-S(=O)2-N(C 1-6 -alkyl)2; -SCF3; -SCF2H; -SCFH2; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -S(=O)2-OH; -S(=O)2-OC 1-6 -alkyl; -S(=O)2-NH2; -S(=O)2-NH(C 1-6 -alkyl); -S(=O)2-N(C 1-6 -alkyl)2; -C 3-6 -cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; 5- or 6-membered heteroaryl; -OC 3-6 -cycloalkyl; -O-(3- to 6-membered heterocycloalkyl); -O-phenyl; -O-(5- or 6-membered heteroaryl); -C(=O)-C 3-6-cycloalkyl; -C(=O)-(3- to 6-membered heterocycloalkyl); -C(=O)-phenyl; -C(=O)-(5- or 6-membered heteroaryl); -S(=O)2-(C 3-6 -cycloalkyl); -S(=O)2-(3- to 6-membered heterocycloalkyl); -S(=O)2-phenyl or -S(=O)2-(5- or 6-membered heteroaryl);

[0024] wherein phenyl and 5- or 6-membered heteroaryl are in each case independently of one another unsubstituted or mono- or polysubstituted by one or more substituents selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -CF2Cl; -CFCl2; -C 1-4 -alkylene-CF3; -C 1-4 -alkylene-CF2H; -C 1-4 -alkylene-CFH2; -C(=O)-C 1-6 -alkyl; -C(=O)-OH; -C(=O)-OC 1-6 -alkyl; -C(=O)-NH(OH); -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; =O; -OCF3; -OCF2H; -OCFH2; -OCF2Cl; -OCFCl2; -OC 1-6 -alkyl; -OC 3-6 -cycloalkyl; -O-(3- to 6-membered heterocycloalkyl); -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -NH-C(=O)-C 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl; -NH-C(=O)-NH2; -NH-C(=O)-NH(C 1-6 -alkyl); -NH-C(=O)-N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl)2; -NH-S(=O)2-C 1-6 -alkyl; -SCF3; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6-alkyl; -S(=O)2-NH2; -S(=O)2-NH(C 1-6 -alkyl); -S(=O)2-N(C 1-6 -alkyl)2; -C 3-6 -cycloalkyl; -C 1-4 -Alkylene-C 3-6 -cycloalkyl; 3 to 6 membered heterocycloalkyl; -C 1-4 -alkylene-(3- to 6-membered heterocycloalkyl); phenyl or 5- or 6-membered heteroaryl;

[0025] in the form of a free compound or a physiologically acceptable salt thereof;

[0026] Provided that the following compounds are not included:

[0027] N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide;

[0028] N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide;

[0029] N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide;

[0030] N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-[1,2,4]oxadiazole-3-carboxylic acid amide;

[0031] N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide;

[0032] N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-4-carboxylic acid amide; and

[0033] N-[(2S,3R)-4,4-Dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-4-carboxylic acid amide.

[0034] In a preferred embodiment, the compounds according to the invention are present in the form of free compounds. For the purpose of the specification, "free compound" preferably means that the compounds according to the invention are not present in the form of salts. Methods for determining whether a chemical substance is present as a free compound or as a salt are known to the skilled person, such as 14 N or 15 N solid-state NMR, x-ray diffraction, x-ray powder diffraction, IR, Raman, XPS. Recorded in solution 1 H-NMR can also be used to consider the presence of protonation.

[0035] In another preferred embodiment, the compounds according to the invention are present in the form of physiologically acceptable salts.For the purposes of the present specification, the term "physiologically acceptable salts" preferably refers to salts obtained from compounds according to the invention and physiologically acceptable acids or bases.

[0036] According to the present invention, the compounds according to the present invention may exist in any possible form, including solvates, co-crystals and polymorphs. For the purpose of this specification, the term "solvate" preferably refers to an adduct of (i) a compound according to the present invention and / or a physiologically acceptable salt thereof and (ii) one or more solvents of different molecular equivalents.

[0037] Furthermore, the compounds according to the present invention may exist in the form of racemates, enantiomers, diastereomers, tautomers or any mixtures thereof.

[0038] The present invention also includes isotopic isomers of the compounds of the present invention, wherein at least one atom of the compound is replaced by an isotope of the corresponding atom different from the major isotope occurring in nature, as well as any mixtures of isotopic isomers of such compounds. Preferred isotopes are 2 H (deuterium), 3 H (tritium), 13 C and 14 C. Isotopic isomers of the compounds of the present invention can generally be prepared by conventional procedures known to those skilled in the art.

[0039] According to the present invention, the term "-C 1-10 -alkyl", "-C 1-8 -alkyl", "-C 1-6 -alkyl" and "-C 1-4"-alkyl" preferably means an acyclic, saturated or unsaturated aliphatic (i.e. non-aromatic) hydrocarbon residue which may be linear (i.e. unbranched) or branched and may be unsubstituted or mono- or polysubstituted (e.g. di- or tri-substituted) and contain 1 to 10 (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), 1 to 8 (i.e. 1, 2, 3, 4, 5, 6, 7 or 8), 1 to 6 (i.e. 1, 2, 3, 4, 5 or 6) and 1 to 4 (i.e. 1, 2, 3 or 4) carbon atoms, respectively. In a preferred embodiment, -C 1-10 -alkyl, -C 1-8 -alkyl, -C 1-6 -alkyl and -C 1-4 -The alkyl group is saturated.

[0040] Preferred-C 1-10 -alkyl is selected from the group consisting of methyl, ethyl, ethylidene (vinyl), n-propyl, 2-propyl, 1-propynyl, 2-propynyl, propenyl (-CH2CH=CH2, -CH=CH-CH3, -C(=CH2)-CH3), n-butyl, 1-butynyl, 2-butynyl, 1-butenyl, 2-butenyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 1-pentenyl, 2-pentenyl, 1-pentynyl, 2-pentynyl, 2-methylbutyl, 3-methylbutyl, 3-methylbut-2-yl, 2-methylbut-2-yl, 3-methylbut-1-ynyl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methylpentyl, 4-methylpentyl, 4-methylpent-2-yl, 2-methylpent-2-yl, 3,3-di ... More preferably, methyl, ethyl, n-propyl, 2-propyl, 1-propynyl, 2-propynyl, propenyl (-CH2CH=CH2, -CH=CH-CH3, -C(=CH2)-CH3), n-butyl, 1-butynyl, 2-butynyl, 1-butenyl, 2-butenyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 1-pentenyl, 2-pentenyl, 1-pentynyl, 2-pentynyl, 2-methylbutyl, 3-methylbutyl, 3-methylbut-2-yl, 2-methylbut-2-yl, 3-methylbut-1-ynyl, 2,2-dimethylpropyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl. Particularly preferred -C 1-10 -alkyl is selected from C 1-4 -alkyl.

[0041] Preferred -C 1-8-alkyl is selected from the group consisting of methyl, ethyl, ethylidene (vinyl), n-propyl, 2-propyl, 1-propynyl, 2-propynyl, propenyl (-CH2CH=CH2, -CH=CH-CH3, -C(=CH2)-CH3), n-butyl, 1-butynyl, 2-butynyl, 1-butenyl, 2-butenyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 1-pentenyl, 2-pentenyl, 1-pentynyl, 2-pentynyl, 2-methylbutyl, 3-methylbutyl, 3-methylbut-2-yl, 2-methylbut-2-yl, 3-methylbut-1-ynyl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methylpentyl, 4-methylpentyl, 4-methylpent-2-yl, 2-methylpent-2-yl, 3 More preferably, methyl, ethyl, n-propyl, 2-propyl, 1-propynyl, 2-propynyl, propenyl (-CH2CH=CH2, -CH=CH-CH3, -C(=CH2)-CH3), n-butyl, 1-butynyl, 2-butynyl, 1-butenyl, 2-butenyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 1-pentenyl, 2-pentenyl, 1-pentynyl, 2-pentynyl, 2-methylbutyl, 3-methylbutyl, 3-methylbut-2-yl, 2-methylbut-2-yl, 3-methylbut-1-ynyl, 2,2-dimethylpropyl, n-hexyl, n-heptyl and n-octyl. Particularly preferred are -C 1-8 -alkyl is selected from C 1-4 -alkyl.

[0042] Preferred -C 1-6-alkyl is selected from the group consisting of methyl, ethyl, ethylidene (vinyl), n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methylbutyl, 3-methylbutyl, 3-methylbut-2-yl, 2-methylbut-2-yl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methylpentyl, 4-methylpentyl, 4-methylpent-2-yl, 2-methylpent-2-yl, 3,3-dimethylbutyl, 3,3-dimethylbut-2-yl, 3-methylpentyl, 3-methylpent-2-yl and 3-methylpent-3-yl; more preferably Methyl, ethyl, n-propyl, 2-propyl, 1-propynyl, 2-propynyl, propenyl (-CH2-CH=CH2, -CH=CH-CH3, -C(=CH2)-CH3), n-butyl, 1-butynyl, 2-butynyl, 1-butenyl, 2-butenyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 1-pentenyl, 2-pentenyl, 1-pentynyl, 2-pentynyl, 2-methylbutyl, 3-methylbutyl, 3-methylbut-2-yl, 2-methylbut-2-yl, 3-methylbut-1-ynyl, 2,2-dimethylpropyl, n-hexyl. Particularly preferred are -C 1-6 -alkyl is selected from C 1-4 -alkyl.

[0043] Preferred -C 1-4 -alkyl is selected from methyl, ethyl, ethylidene (vinyl), n-propyl, 2-propyl, 1-propynyl, 2-propynyl, propenyl (-CH2CH=CH2, -CH=CH-CH3, -C(=CH2)-CH3), n-butyl, 1-butynyl, 2-butynyl, 1-butenyl, 2-butenyl, isobutyl, sec-butyl, tert-butyl and 3-methylbut-1-ynyl. More preferably -C 1-4 -Alkyl is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

[0044] Further according to the present invention, the term "-C 1-6 -alkylene-"; "-C 1-4 -alkylene-" and "-C 1-2 "-Alkylene-" refers to a linear or branched (preferably linear) and preferably saturated aliphatic residue, which is preferably selected from the group consisting of methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2- or -C(CH3)2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-) and hexylene (-CH2CH2CH2CH2CH2CH2-); more preferably methylene (-CH2-) and ethylene (-CH2CH2-), and most preferably methylene (-CH2-). Preferably, -C(CH3)2-1-6 -alkylene- is selected from -C 1-4 -alkylene-, more preferably selected from -C 1-2 -alkylene-.

[0045] Still further according to the present invention, the term "-C 3-10 -cycloalkyl" and "-C 3-6 "-Cycloalkyl" preferably means cyclic aliphatic hydrocarbons having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms and 3, 4, 5 or 6 carbon atoms, respectively, where the hydrocarbon can in each case be saturated or unsaturated (but not aromatic), unsubstituted or mono- or polysubstituted.

[0046] Preferably, -C 3-10 -cycloalkyl and -C 3-6 -Cycloalkyl is saturated. 3-10 -cycloalkyl and -C 3-6 -Cycloalkyl can be bound to the respective superordinate general structure via any desired and possible ring member of the cycloalkyl group. 3-10 -cycloalkyl and -C 3-6 -Cycloalkyl may also be fused to further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, i.e. to cycloalkyl, heterocyclyl, aryl or heteroaryl radicals, which in turn may in each case be unsubstituted or mono- or polysubstituted. 3-10 -cycloalkyl and -C 3-6 -Cycloalkyl may be singly or polybridged, as is the case for example with adamantyl, bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl. Preferably, however, -C 3-10 -cycloalkyl and -C 3-6 -Cycloalkyl is neither fused nor bridged to a further ring system. 3-10 -cycloalkyl and -C 3-6 -Cycloalkyl is neither fused nor bridged to further ring systems and is saturated. 3-10 -Cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantly, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]heptyl and bicyclo[2.2.2]octyl. Particularly preferred -C 3-10 -Cycloalkyl is selected from -C 3-6 -cycloalkyl.

[0047] Preferred -C 3-6-Cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl. Particularly preferred -C 3-6 - Cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, most preferably cyclopropyl.

[0048] According to the invention, the terms "3- to 7-membered heterocycloalkyl" and "3- to 6-membered heterocycloalkyl" preferably mean heterocycloaliphatic saturated or unsaturated (but not aromatic) radicals with 3 to 7 (i.e. 3, 4, 5, 6 or 7) ring members and 3 to 6 (i.e. 3, 4, 5 or 6) ring members, respectively, in which in each case at least one (if appropriate also two or three) carbon atoms are replaced by heteroatoms or heteroatom groups which are each independently selected from the group consisting of O, S, S(═O), S(═O)2, N, NH and N(C 1-4 -alkyl) such as N(CH3), wherein the carbon atoms of the ring may be unsubstituted or mono- or poly-substituted. Preferably, the 3- to 7-membered heterocycloalkyl and 3- to 6-membered heterocycloalkyl contain only one heteroatom or heteroatom group in the ring.

[0049] Preferably, 3 to 7-membered heterocycloalkyl and 3 to 6-membered heterocycloalkyl are saturated. 3 to 7-membered heterocycloalkyl and 3 to 6-membered heterocycloalkyl may also be fused with further saturated or (partially) unsaturated cycloalkyl or heterocyclic, aromatic or heteroaromatic ring systems. However, more preferably, 3 to 7-membered heterocycloalkyl and 3 to 6-membered heterocycloalkyl are not fused with further ring systems. Still more preferably, 3 to 7-membered heterocycloalkyl and 3 to 6-membered heterocycloalkyl are not fused with further ring systems and are saturated. If not otherwise specified, 3 to 7-membered heterocycloalkyl and 3 to 6-membered heterocycloalkyl may be combined with the upper general structure via any desired and possible ring members of the heterocycloaliphatic residue. In a preferred embodiment, 3 to 7-membered heterocycloalkyl and 3 to 6-membered heterocycloalkyl are combined with the upper general structure via carbon atoms.

[0050] Preferred 3- to 7-membered heterocycloalkyl groups are selected from the group consisting of tetrahydrofuranyl, azepanyl, dioxepanyl, oxazepanyl, diazepanyl, thiazolidinyl, tetrahydrophenylthio, tetrahydropyridinyl, thiomorpholinyl, tetrahydropyranyl, oxetanyl, oxiranyl, morpholinyl, pyrrolidinyl, 4-methylpiperazinyl, morpholinonyl, azetidinyl, aziridine, dithio 3 to 7 membered heterocycloalkyl is selected from 3 to 6 membered heterocycloalkyl.

[0051] Preferred 3- to 6-membered heterocycloalkyl groups are selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, oxiranyl, thiazolidinyl, tetrahydrophenylthio, tetrahydropyridinyl, thiomorpholinyl, morpholinyl, pyrrolidinyl, 4-methylpiperazinyl, morpholinonyl, azetidinyl, aziridine, dithiolanyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dihydropyridinyl, dihydrofuranyl, dihydroisoxazolyl, dihydrooxazolyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydropyrrolyl, dihydroindolinyl, dihydroisoindolyl and tetrahydroindolinyl. More preferred 3- to 6-membered heterocycloalkyl groups are selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, oxetanyl and oxiranyl; still more preferred is tetrahydrofuranyl.

[0052] According to the invention, the term "5- to 6-membered heteroaryl" preferably means a 5- or 6-membered cyclic aromatic residue containing at least 1 (if appropriate also 2, 3, 4 or 5) heteroatom, wherein the heteroatoms are each independently selected from S, N and O, and if not otherwise specified, the heteroaryl residue may be unsubstituted or mono- or polysubstituted. In the case of substitution on the heteroaryl, the substituents may be identical or different and in any desired and possible position of the heteroaryl. If not otherwise specified, the binding to the superordinate general structure may be carried out via any desired and possible ring member of the heteroaryl residue. Preferably, the 5- to 6-membered heteroaryl is bound to the superordinate general structure via a carbon atom of the heterocycle. The heteroaryl may also be part of a bicyclic or polycyclic system with up to 14 ring members, wherein the ring system may be formed with further saturated or (partially) unsaturated cycloalkyl or heterocycloalkyl, aromatic or heteroaromatic ring systems, which, if not otherwise specified, may again be unsubstituted or mono- or polysubstituted. In a preferred embodiment, the 5- to 6-membered heteroaryl is part of a bicyclic or polycyclic (preferably bicyclic) system. In another preferred embodiment, the 5- to 6-membered heteroaryl is not part of a bicyclic or polycyclic system.

[0053] Preferably, the 5- to 6-membered heteroaryl is selected from the group consisting of pyridyl (i.e., 2-pyridyl, 3-pyridyl, 4-pyridyl), thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, pyridone (pyridinone), pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, isothiazolyl, furanyl, thienyl (phenylthio), triazolyl, thiadiazolyl, 4,5,6,7-tetrahydro-2H-indazolyl, 2,4 , 5,6-tetrahydrocyclopenta[c]pyrazolyl, benzofuranyl, benzimidazolyl, benzothiophenyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzoxazolyl, benzoxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolyl, dibenzofuranyl, dibenzothiophenyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolyl, naphthyridinyl, oxazolyl, phenazinyl, phenothiazinyl, phthalazinyl, purinyl, phenazinyl, tetrazolyl and triazinyl. Particularly preferred 5- to 6-membered heteroaryl groups are selected from the group consisting of pyridyl (i.e., 2-pyridyl, 3-pyridyl, 4-pyridyl), thiazolyl, oxazolyl, isoxazolyl, pyrazolyl and oxadiazolyl. Since pyridone can be considered as a pyridine substituted with =0, for the purposes of this specification, the definition of pyridine optionally substituted with =0 encompasses pyridone.

[0054] The compounds according to the invention are defined by substituents, for example by R1, R2 and R3 (1st generation substituents), which themselves may optionally be substituted (2nd generation substituents). According to the definition, these substituents of the substituents themselves may optionally be substituted again (3rd generation substituents). If, for example, R1 = phenyl (1st generation substituent), the phenyl itself may be substituted, for example by -C 1-6 -alkyl (second generation substituent). This produces the functional group R1 = phenyl-C 1-6 -alkyl. Then -C 1-6 -Alkyl itself can be substituted again, for example by -F (3rd generation substituent). Overall, this results in a functional group R1 = phenyl-C 1-6 -alkyl, where -C 1-6 The -alkyl group is substituted with -F.

[0055] However, in a preferred embodiment, the 3rd generation substituent may not be substituted again, that is, there is no 4th generation substituent. More preferably, the 2nd generation substituent may not be substituted again, that is, there is no 3rd generation substituent.

[0056] If a residue occurs several times in a molecule, it can have different meanings for different substituents: if, for example, R3 and R 3’ Both represent -C 1-10 -alkyl, then -C 1-10 -alkyl for R3 may for example represent ethyl, and for R 3’ May, for example, represent a methyl group.

[0057] Regarding the term “-C 1-10 -alkyl", "-C 1-6 -alkyl", "-C 1-4 -alkyl", "-C 3-10 -cycloalkyl", "-C 3-6 -cycloalkyl", "3 to 7-membered heterocycloalkyl", "3 to 6-membered heterocycloalkyl", "-C 1-6 -alkylene-","-C 1-4 -alkylene-" and "-C 1-2In the case of "-alkylene-", the term "substituted" means in the sense of the invention that one or more hydrogen atoms are each independently of one another singly substituted (monosubstituted) or multiply substituted (polysubstituted), for example disubstituted or trisubstituted, by at least one substituent; more preferably monosubstituted or disubstituted. In the case of multiply substitution, i.e. in the case of polysubstituted residues such as disubstituted or trisubstituted residues, these residues can be polysubstituted on different atoms or on the same atom, for example trisubstituted on the same carbon atom, as in the case of -CF3, -CH2CF3, or disubstituted as in the case of 1,1-difluorocyclohexyl, or at different points, as in the case of -CH(OH)-CH=CH-CHCl2 or 1-chloro-3-fluorocyclohexyl. Multiple substitution can be carried out using the same substituent or using different substituents.

[0058] The terms "phenyl", "heteroaryl" and "5- to 6-membered heteroaryl" in the sense of the present invention mean that one or more hydrogen atoms are each independently of one another singly substituted (monosubstituted) or multiply substituted (polysubstituted), for example disubstituted or trisubstituted, by at least one substituent. Multiple substitution can be carried out using the same substituent or using different substituents.

[0059] According to the present invention, preferably -C 1-10 -alkyl-, -C 1-6 -alkyl, -C 1-4 -alkyl, -C 3-10 -cycloalkyl, -C 3-6 -cycloalkyl, 3- to 7-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, -C 1-6 -alkylene-, -C 1-4 -alkylene- and -C 1-2 -Alkylene- is in each case independently of one another unsubstituted or mono- or polysubstituted by one or more substituents selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -CF2Cl; -CFCl2; -C(=O)-C 1-6 -alkyl; -C(=O)-OH; -C(=O)-OC 1-6 -alkyl; -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; =O; -OCF3; -OCF2H; -OCFH2; -OCF2Cl; -OCFCl2; -OC 1-6 -alkyl; -OC(=O)-C 1-6 -alkyl; -OC(=O)-OC 1-6-alkyl; -O-(CO)-NH(C 1-6 -alkyl); -OC(=O)-N(C 1-6 -alkyl)2; -OS(=O)2-NH2; -OS(=O)2-NH(C 1-6 -alkyl); -OS(=O)2-N(C 1-6 -alkyl)2; -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -NH-C(=O)-C 1-6 -alkyl; -NH-C(=O)-OC 1-6 -alkyl; -NH-C(=O)-NH2; -NH-C(=O)-NH(C 1-6 -alkyl); -NH-C(=O)-N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-OC 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-NH2; -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl)2; -NH-S(=O)2OH; -NH-S(=O)2-C 1-6 -alkyl; -NH-S(=O)2-OC 1-6 -alkyl; -NH-S(=O)2-NH2; -NH-S(=O)2-NH(C 1-6 -alkyl); -NH-S(=O)2N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-S(=O)2-OH; -N(C 1-6 -alkyl)-S(=O)2-C 1-6 -alkyl; -N(C 1-6 -alkyl)-S(=O)2-OC 1-6 -alkyl; -N(C 1-6 -alkyl)-S(=O)2-NH2; -N(C 1-6 -alkyl)-S(=O)2-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-S(=O)2-N(C 1-6 -alkyl)2; -SCF3; -SCF2H; -SCFH2; -SC1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -S(=O)2-OH; -S(=O)2-OC 1-6 -alkyl; -S(=O)2-NH2; -S(=O)2-NH(C 1-6 -alkyl); -S(=O)2-N(C 1-6 -alkyl)2; -C 3-6 -cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; 5- or 6-membered heteroaryl; -OC 3-6 -cycloalkyl; -O-(3- to 6-membered heterocycloalkyl); -O-phenyl; -O-(5- or 6-membered heteroaryl); -C(=O)-C 3-6 -cycloalkyl; C(=O)-(3- to 6-membered heterocycloalkyl); -C(=O)-phenyl; -C(=O)-(5- or 6-membered heteroaryl); -S(=O)2-(C 3-6 -cycloalkyl); -S(=O)2-(3- to 6-membered heterocycloalkyl); -S(=O)2-phenyl and -S(=O)2-(5- or 6-membered heteroaryl).

[0060] -C 1-10 -alkyl, -C 1-6 -alkyl, -C 1-4 -alkyl, -C 3-10 -cycloalkyl, -C 3-6 -cycloalkyl, 3- to 7-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, -C 1-6 -alkylene- and -C 1-4 Preferred substituents for -alkylene- are selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; -OCF3; -OCF2H; -OCFH2; -OC 1-6 -alkyl; -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -SCF3; -SCF2H; -SCFH2; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -C 3-6-cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl and 5- or 6-membered heteroaryl; and particularly preferably -F, -CN, -CH3, -CH2CH3, -CF3; -CF2H; -CFH2; -C(=O)-NH2; -C(=O)-NH(CH3); -C(=O)-N(CH3)2; -OH, -NH2, -OCH3, -SCH3, -S(=O)2(CH3), -S(=O)(CH3), -N(CH3)2, cyclopropyl and oxetanyl. According to this embodiment, -C 1-10 -alkyl, -C 1-6 -alkyl, -C 1-4 -alkyl, -C 3-10 -cycloalkyl, -C 3-6 -cycloalkyl, 3- to 7-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl are preferably each independently unsubstituted, monosubstituted, disubstituted or trisubstituted, more preferably unsubstituted or monosubstituted or disubstituted by a substituent selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; -OCF3; -OCF2H; -OCFH2; -OC 1-6 -alkyl; -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -SCF3; -SCF2H; -SCFH2; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -C 3-6 -cycloalkyl; 3 to 6-membered heterocycloalkyl; phenyl and 5 or 6-membered heteroaryl; more preferably -F; -Cl; -Br; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -OH; -OCF3; -OCF2H; and -OCFH2; and -F; -Cl; -Br are particularly preferred. Preferably, -C 1-6 -alkylene- and -C 1-4 -Alkylene- is unsubstituted.

[0061] According to the invention, preferably phenyl and 5- or 6-membered heteroaryl are in each case independently of one another unsubstituted or mono- or polysubstituted; preferably unsubstituted, mono-, di- or tri-substituted, still more preferably unsubstituted, mono- or di-substituted; wherein one or more substituents are selected from -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -CF2Cl; -CFCl2; -C 1-4 -alkylene-CF3; C 1-4 -alkylene-CF2H; -C 1-4 -alkylene-CFH2; -C(=O)-C 1-6 -alkyl; -C(=O)-OH; -C(=O)-OC 1-6 -alkyl; -C(=O)-NH(OH); -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; =O; -OH; -OCF3; -OCF2H; -OCFH2; -OCF2Cl; -OCFCl2; -OC 1-6 -alkyl; -OC 3-6 -cycloalkyl; -O-(3- to 6-membered heterocycloalkyl); -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -NH-C(=O)-C 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl; -NH-C(=O)-NH2; -NH-C(=O)-NH(C 1-6 -alkyl); -NH-C(=O)-N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl)2; -NH-S(=O)2-C 1-6 -alkyl; -SCF3; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -S(=O)2-NH2; -S(=O)2-NH(C 1-6 -alkyl); -S(=O)2-N(C 1-6 -alkyl)2; -C 3-6 -cycloalkyl; -C1-4 -Alkylene-C 3-6 -cycloalkyl; 3 to 6 membered heterocycloalkyl; -C 1-4 -alkylene-(3- to 6-membered heterocycloalkyl); phenyl or 5- or 6-membered heteroaryl.

[0062] Preferred substituents for phenyl and 5- or 6-membered heteroaryl are selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -C 1-4 -alkylene-CF3; -C 1-4 -Alkylene--CF2H; -C 1-4 -alkylene-CFH2; -OH; -OCF3; -OCF2H; -OCFH2; -OC 1-6 -alkyl; -OC 3-6 -cycloalkyl and -C 3-6 -cycloalkyl; and more preferably -F; -Cl; -Br; -CN; -CH3; -CH2CH3; -CF3; -CF2H; -CFH2; -CH2-CF3; =O; -OH; -OCF3; -OCF2H; -OCFH2; -O-CH3; -O-cyclopropyl and cyclopropyl; still more preferably -F; -Cl; -Br; -CH3; -CH2CH3; -CF3; -CF2H; -CFH2; =O; -OH; -OCF3; and -O-CH3; and particularly preferably -F; -Cl; -Br; -CH3; =O; and -O-CH3. According to this embodiment, phenyl and 5- or 6-membered heteroaryl are preferably each independently of one another unsubstituted, monosubstituted, disubstituted or trisubstituted, more preferably unsubstituted or mono- or disubstituted by a substituent selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -C 1-4 -alkylene-CF3; -C 1-4 -alkylene-CF2H; -C 1-4 -alkylene-CFH2; =O; -OH; -OCF3; -OCF2H; -OCFH2; -OC 1-6 -alkyl; -OC 3-6 -cycloalkyl and -C 3-6 -cycloalkyl. A particularly preferred substituted 5- or 6-membered heteroaryl is N-methyl-2-oxo-pyridyl.

[0063] In a preferred embodiment, the compounds according to the invention have a stereochemistry according to the general formula (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX)

[0064]

[0065]

[0066] In a preferred embodiment, the compounds according to the invention have a stereochemistry according to the general formula (II), (III), (VI) or (VII), such that the residues -R1 and -NH-R2 on the pyrrolidone ring are trans-oriented. Preferably, the compounds according to the invention have a stereochemistry according to the general formula (II) or (VI). Preferably, the compounds according to the invention have a stereochemistry according to the general formula (III) or (VII). The stereochemistry according to the general formula (II) or (VI) is particularly preferred.

[0067] In another preferred embodiment, the compounds according to the invention have a stereochemistry according to formula (IV), (V), (VIII) or (IX) such that the residues -R1 and -NH-R2 on the pyrrolidone ring are cis-oriented. Preferably, the compounds according to the invention have a stereochemistry according to formula (IV) or (VIII). Preferably, the compounds according to the invention have a stereochemistry according to formula (V) or (IX).

[0068] In a particularly preferred embodiment, the compounds according to the invention have a stereochemistry according to the general formula (II) or (VI), more preferably (II).

[0069] In the compounds of the present invention according to any of the general formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), R1 represents phenyl; -C 1-6 -alkylene-phenyl; 5 or 6 membered heteroaryl; -C 1-6 -alkylene-(5- or 6-membered heteroaryl); or -C 1-10 -alkyl.

[0070] In a preferred embodiment, R1 represents phenyl or ethyl; more preferably phenyl.

[0071] In a particularly preferred embodiment, R1 represents phenyl which is unsubstituted or mono- or di-substituted by substituents selected independently of one another from the group consisting of: -F, -Cl, -Br, -OCH3; -CH3, -CF3, -CN and cyclopropyl; more preferably -F, -OCH3; and -CH3.

[0072] In the compounds of the present invention according to any of the general formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), R 1’ Represents H; -C 1-10-alkyl; or -C 3-10 -cycloalkyl.

[0073] In a preferred embodiment, R 1’ represents H; methyl, ethyl, n-propyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; more preferably H, methyl, ethyl, cyclopropyl or cyclobutyl; still more preferably H, methyl or cyclopropyl.

[0074] In a particularly preferred embodiment, R 1’ Represents H.

[0075] In the compounds of the present invention according to the general formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), R2 represents -C(=O)-C 1-10 -alkyl; -C(=O)-C 3-10 -cycloalkyl; -C(=O)-C 1-6 -Alkylene-C 3-10 -cycloalkyl; -C(=O)-(3- to 7-membered heterocycloalkyl); -C(=O)-C 1-6 -alkylene-(3 to 7 membered heterocycloalkyl); -C(=O)-phenyl; -C(=O)-C 1-6 -alkylene-phenyl; -C(=O)-(5- or 6-membered heteroaryl); -C(=O)-C 1-6 -alkylene-(5- or 6-membered heteroaryl); -S(=O) 1-2 -C 1-10 -alkyl; -S(=O) 1-2 -C 3-10 -cycloalkyl; -S(=O) 1-2 -C 1-6 -Alkylene-C 3-10 -cycloalkyl; -S(=O) 1-2 -(3 to 7 membered heterocycloalkyl); -S(=O) 1-2 -C 1-6 -alkylene-(3 to 7 membered heterocycloalkyl); -S(=O) 1-2 -phenyl; -S(=O) 1-2 -C 1-6 -alkylene-phenyl; -S(=O) 1-2 -(5- or 6-membered heteroaryl); or -S(=O) 1-2 -C 1-6 -alkylene-(5- or 6-membered heteroaryl).

[0076] In a preferred embodiment, R2 represents -C(=O)-C 1-10 -alkyl; -C(=O)-C 3-10 -cycloalkyl; -C(=O)-C 1-6-Alkylene-C 3-10 -cycloalkyl; -C(=O)-(3- to 7-membered heterocycloalkyl); -C(=O)-(5- or 6-membered heteroaryl); -S(=O)2-C 1-10 -alkyl; -S(=O)2-C 3-10 -cycloalkyl; -S(=O)2-C 1-6 -Alkylene-C 3-10 -cycloalkyl; -S(=O)2-(3- to 7-membered heterocycloalkyl); or -S(=O)2-(5- or 6-membered heteroaryl).

[0077] In a particularly preferred embodiment, R2 represents

[0078] (i) -C(=O)-C which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl and -Br 1-10 -alkyl;

[0079] (ii) -C(=O)-cyclopropyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN and -OCH3;

[0080] (iii) unsubstituted -C(═O)-2-tetrahydrofuranyl;

[0081] (iv) -C(═O)-(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is selected from the group consisting of thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, 1-oxa-2,4-diazolyl, 1,2,5-oxadiazolyl and isothiazolyl, wherein the 5- to 6-membered heteroaryl is in each case unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN, ═O and -OCH3;

[0082] (v) Unsubstituted -S(=O)2-C 1-10 -alkyl;

[0083] (vi) unsubstituted -S(=O)2-cyclopropyl;

[0084] (vii) Unsubstituted -S(=O)2-CH 2- Cyclopropyl;

[0085] (viii) -S(=O)2-2-tetrahydrofuranyl; or

[0086] (ix) -S(=O)2-(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is selected from the group consisting of thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, 1-oxa-2,4-diazolyl, 1,2,5-oxadiazolyl and isothiazolyl, wherein the 5- to 6-membered heteroaryl is in each case unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN, =O and -OCH3.

[0087] In the compounds of the present invention according to formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), R3 and R 3’ Independently represent H; F; Cl; -C 1-10 -alkyl; -C 3-6 -cycloalkyl; -CH2-C 3-6 -cycloalkyl; 3- to 7-membered heterocycloalkyl; -CH2-(3- to 7-membered heterocycloalkyl); -CH2-phenyl; or -CH2-(5- or 6-membered heteroaryl); or R3 and R 3’ Together with the carbon atoms to which they are attached, they form C 3-10 -cycloalkyl or 3- to 7-membered heterocycloalkyl.

[0088] In a preferred embodiment, R3 and R 3’ Both represent -C 1-10 In a particularly preferred embodiment, R3 and R 3’ All represent -CH3.

[0089] In another preferred embodiment, R3 and R 3’ R3 and R4 are independently H; F; -CH3; cyclopropyl; -CH2-cyclopropyl; or -CH2-phenyl. 3’ Both represent F.

[0090] In another preferred embodiment, R3 and R 3’ In another preferred embodiment, at least one of R3 and R 3’ One of them represents H.

[0091] In yet another preferred embodiment, R3 and R 3’ Together with the carbon atom to which they are attached they form a cyclopropyl group.

[0092] In the compounds of the invention according to general formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), R4 represents phenyl; -C 1-6 -alkylene-phenyl; 5 or 6 membered heteroaryl; or -C1-6 -alkylene-(5- or 6-membered heteroaryl).

[0093] In a preferred embodiment, R4 represents phenyl or a 5- or 6-membered heteroaryl.

[0094] In a particularly preferred embodiment, R4 represents

[0095] Phenyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN and -OCH3; or

[0096] A 5- or 6-membered heteroaryl group selected from the group consisting of pyridyl, pyrazolyl and pyrimidinyl, wherein the 5- to 6-membered heteroaryl group is in each case unsubstituted or mono- or disubstituted by substituents selected independently of one another from the group consisting of =O, -F, -Cl, -Br, -CH3, -CF3, -CN and -OCH3.

[0097] In a particularly preferred embodiment, R4 does not represent N-methylpyridone.

[0098] In the compounds of the invention according to the general formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), A, X, Y and Z independently of one another represent N or CH. In a preferred embodiment, A represents N.

[0099] In a preferred embodiment, X represents CH.

[0100] In a preferred embodiment, Y represents CH.

[0101] In a preferred embodiment, Z represents CH.

[0102] In a preferred embodiment of the present invention,

[0103] (i) A represents N, X represents CH, Y represents CH; and Z represents CH; or

[0104] (ii) A represents N, X represents N, Y represents CH; and Z represents CH; or

[0105] (iii) A represents N, X represents CH, Y represents N; and Z represents CH; or

[0106] (iv) A represents N, X represents CH, Y represents CH; and Z represents N; or

[0107] (v) A represents N, X represents N, Y represents N; and Z represents CH; or

[0108] (vi) A represents N, X represents N, Y represents CH; and Z represents N; or

[0109] (vii) A represents N, X represents CH, Y represents N; and Z represents N; or

[0110] (viii) A represents N, X represents N, Y represents N; and Z represents N; or

[0111] (ix) A represents CH, X represents CH, Y represents CH; and Z represents CH; or

[0112] (x) A represents CH, X represents N, Y represents CH; and Z represents CH; or

[0113] (xi) A represents CH, X represents CH, Y represents N; and Z represents CH; or

[0114] (xii) A represents CH, X represents CH, Y represents CH; and Z represents N; or

[0115] (xiii) A represents CH, X represents N, Y represents N; and Z represents CH; or

[0116] (xiv) A represents CH, X represents N, Y represents CH; and Z represents N; or

[0117] (xv) A represents CH, X represents CH, Y represents N; and Z represents N; or

[0118] (xvi) A represents CH, X represents N, Y represents N; and Z represents N.

[0119] In particularly preferred embodiments of the present invention according to any of the general formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX)

[0120] R1 represents phenyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3 and -OCH3; and / or

[0121] R 1’ represents H, CH3 or cyclopropyl, and / or

[0122] R2 represents -C(=O)-C 1-6 -alkyl; -C(=O)-cyclopropyl; or -C(=O)-(5- to 6-membered heteroaryl) which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br; and -CH3; and / or

[0123] R4 represents fluoro-phenyl or N-methyl-2-oxo-pyridyl.

[0124] In a preferred embodiment, the compounds according to the invention are selected from the group consisting of

[0125] 1N-[(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0126] 2N-[(2S,3R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0127] 3N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide

[0128] 4 2,2-Difluoro-N-[(2S,3R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide

[0129] 5N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-indol-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide

[0130] 6N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-2-carboxylic acid amide

[0131] 7N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-isoxazole-3-carboxylic acid amide

[0132] 8N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0133] 9N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0134] 10 2,2-Difluoro-N-[(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide

[0135] 12N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide

[0136] 13N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-oxazole-5-carboxylic acid amide

[0137] 14N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-[1,2,4]oxadiazole-3-carboxylic acid amide

[0138] 15N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-5-carboxylic acid amide

[0139] 16N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0140] 17N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-4-carboxylic acid amide

[0141] 18N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-4-carboxylic acid amide

[0142] 21N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-oxazole-5-carboxylic acid amide

[0143] 22N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-isoxazole-3-carboxylic acid amide

[0144] 24N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-5-carboxylic acid amide

[0145] 26N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-2-carboxylic acid amide

[0146] 30N-[rac-(6R,7S)-5-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide

[0147] 31N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide

[0148] 32N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide

[0149] 33N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide

[0150] 34a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)methanesulfonamide

[0151] 34b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)methanesulfonamide

[0152] 35a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanesulfonamide

[0153] 35b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanesulfonamide

[0154] 36a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)oxazole-5-carboxamide

[0155] 36b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)oxazole-5-carboxamide

[0156] 37N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-1-methyl-1H-pyrazole-3-carboxamide

[0157] 38aN-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methylthiazole-5-carboxamide

[0158] 38b N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methylthiazole-5-carboxamide

[0159] 39a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-5-methylthiazole-4-carboxamide

[0160] 39b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-5-methylthiazole-4-carboxamide

[0161] 40a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-3-methylisoxazole-4-carboxamide

[0162] 40b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-3-methylisoxazole-4-carboxamide

[0163] 41a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-1-methyl-1H-pyrazole-4-carboxamide

[0164] 41b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-1-methyl-1H-pyrazole-4-carboxamide

[0165] 42a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)nicotinamide

[0166] 42b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)nicotinamide

[0167] 43a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)pyrimidine-2-carboxamide

[0168] 43b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)pyrimidine-2-carboxamide

[0169] 44a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-2-methyloxazole-5-carboxamide

[0170] 44b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-2-methyloxazole-5-carboxamide

[0171] 45a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methyloxazole-5-carboxamide

[0172] 45b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methyloxazole-5-carboxamide

[0173] 46N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0174] 47N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0175] 48N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(3-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0176] 49N-[rac-(2R,3S,4S)-2-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0177] 60N-[rac(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0178] 61N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-methanesulfonic acid amide

[0179] 62N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0180] 63N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0181] 64N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide

[0182] 65N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0183] 66N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0184] 67N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0185] 68N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0186] 69N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0187] 70N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0188] 71N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0189] 72N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide

[0190] 73N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0191] 74 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0192] 75N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide

[0193] 76N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0194] 77 2,2-Difluoro-N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-propionamide

[0195] 78N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0196] 79N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0197] 80 2,2-Difluoro-N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide

[0198] 81 2,2-Difluoro-N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-propionamide

[0199] 82N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0200] 83N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide

[0201] 84N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0202] 85N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0203] 86N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0204] 87N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0205] 88N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0206] 89N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0207] 90N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0208] 91N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0209] 92N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0210] 93N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0211] 94N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide

[0212] 95N-((2R,3R,4S)-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0213] 96N-((2R,3R)-4,4-difluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0214] 97 2,2-Difluoro-N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-propionamide

[0215] 98 2,2-Difluoro-N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-propionamide

[0216] 99N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0217] 100 2,2-Difluoro-N-[rac-(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide

[0218] 101N-[rac-(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0219] 102 2,2-Difluoro-N-[rac-(2R,3S)-2-methyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide

[0220] 103N-[rac-(2R,3S)-2-methyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0221] 104 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide

[0222] 105 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0223] 106 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0224] 107N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0225] 108 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0226] 109 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0227] 110 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide

[0228] 111N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0229] 112N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0230] 113N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0231] 114 N-[(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0232] 115 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0233] 116 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide

[0234] 117 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide

[0235] 118 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide

[0236] 119 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide

[0237] 120 2,2-Difluoro-N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-propionamide

[0238] 121N-[rac-(2R,3S,4S)-4-(cyclopropyl-methyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0239] 122N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide

[0240] 123N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0241] 124 N-[rac-(2S,3S,4R)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0242] 125N-[rac-(2S,3S,4R)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide

[0243] 126 N-[rac-(2R,3S,4S)-4-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0244] 127N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide, diastereomer 2

[0245] 128 N-[rac-(2R,3R,4R)-4-fluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0246] 129N-[rac-(2R,3R,4S)-4-fluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0247] 130 N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide, diastereomer 1

[0248] 131N-((2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0249] 132N-((2R,3S,4R)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0250] 133N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide

[0251] 134 N-(rac-(2R,3S,4R)-4-ethyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0252] 135N-((7R,8S)-6-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-7-phenyl-6-azaspiro[3.4]octan-8-yl)cyclopropanecarboxamide

[0253] 136 N-(rac(2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0254] 137 N-(rac-(2R,3R,4S)-4-benzyl-2-ethyl-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide

[0255] 138 N-((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0256] 139 N-((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((1-methyl-1H-pyrazol-4-yl)methyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0257] 142N-(rac-(2R,3S)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0258] 143N-(rac-(2R,3R)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0259] 144N-(rac-(2R,3S)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-2,2-difluoropropionamide

[0260] 145N-(rac-(2R,3R)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-2,2-difluoropropionamide

[0261] 146N-(rac-(2R,3S)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)oxetane-3-carboxamide

[0262] 147N-(rac-(2R,3R)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)oxetane-3-carboxamide

[0263] 148 N-(rac-(2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0264] 149 N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0265] 150 N-((2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenyl-4-(thiazol-2-ylmethyl)pyrrolidin-3-yl)cyclopropanecarboxamide

[0266] 151N-((2S,3S)-2-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide

[0267] In each case, it is in the form of the free compound or its physiologically acceptable salts.

[0268] Can be by the standard reaction in the organic chemistry field known to those skilled in the art or in the mode as described herein (referring to reaction scheme below) or similar mode synthesizing the compound according to the present invention.Reaction conditions in the synthetic route described herein are known to those skilled in the art, and also illustrate in the embodiments described herein in some cases.

[0269] Reaction scheme 1:

[0270]

[0271] The substituted indazole moiety in the compounds of formula (D) and formula (F) is introduced by subjecting lactam (B) or lactam (E) to a regioselective metal-catalyzed CN coupling reaction with a corresponding indazole halide (C) (preferably with a corresponding indazole iodide). Metal-catalyzed CN coupling reactions are generally known in the art (Current Organic Synthesis, 2011, 8, 53). A favorable CN coupling reaction is a palladium and copper-catalyzed cross-coupling reaction (Chem. Rev., 2016, 116, 12564; Chem. Soc. Rev., 2014, 43, 3525; Chem. Sci., 2010, 1, 13). Regioselective CN coupling with aryl halides is known in the art (Chem. Sci., 2011, 2, 27; J. Am. Chem. Soc., 2001, 123, 7727).

[0272] Primary amines (A) and (G) are converted to the corresponding amides and sulfonamides (acylation and sulfonamide formation) (B) and (D) using commercially available acids (acids activated using, for example, HATU) or acid chlorides under standard amide coupling reaction conditions (March's Advanced Organic Chemistry, 2007, 6th edition, pp. 1427-1474).

[0273] The introduction of different orthogonal protecting groups PG (eg Boc, Cbz) to convert (A) to (E) and the deprotection of compounds of formula (E) to (A) are well described in the literature (TW Green, PGM Wuts, Protective Groups in Organic Synthesis, Wiley-Interscience, New York, 1999).

[0274] Reaction scheme 1.1:

[0275] Compounds (A) and (E) can be synthesized according to procedures described in the literature.

[0276]

[0277] Route 1: The synthesis of compounds of formula (I) starting from compounds of formula (H) is described in the literature (Org. Lett., 2011, 13, 6406, Org. Lett, 2009, 4512, ACS Sustainable Chem. Eng. 2015, 1873). For R3 and R3′=Me, the synthesis of the corresponding acid of (H) is described (Journal of Chemical and Engineering Data, 1966, 11, 617), and can be synthesized similarly to the above references. The removal of PG=PMB is well known in the art (Greene's Protective Groups in Organic Synthesis, 2007, 4th edition, page 905ff). The reduction of the nitro group is well known in the art (March's Advanced Organic Chemistry, 2007, 6th edition, page 1815f).

[0278] Route 2: The synthesis of compounds of formula (J) is described in the literature (Org. Lett., 2007, 9, 4077). The introduction of substituents R3 and R3' can be achieved via alkylation. C-alkylation of pyrrolidone (Tetrahedron, 1999, 55, 13321) and elimination of sulfonium salts (Tetrahedron Letters 1983, 24, 4331) are well known in the art. The Curtis rearrangement can be used as a key step to synthesize compounds of formula (A) and (E) to convert the carboxylic acid (L) into the corresponding primary amine (A) or (E). The Curtis rearrangement is well known in the art (Tetrahedron Letters, 2010, 51, 385).

[0279] Route 3: The synthesis of compounds of formula (N) starting from compounds of formula (M) is described in the literature (J.Am.Chem.Soc., 2008, 130, 16146). Cleavage of phosphoamidoesters is described in the literature (J.Am.Chem.Soc., 2008, 130, 16146). Compounds of formula (A) and (E) can be synthesized using Curtis rearrangement as a key step to convert carboxylic acid (L) into the corresponding primary amine (A) or (E). Curtis rearrangement is well known in the art (Tetrahedron Letters, 2010, 51, 385).

[0280] Reaction Scheme 2:

[0281]

[0282] The compound of formula (D) can be synthesized via regioselective CN coupling of compound (O). For heterocycles containing NH, suitable CN coupling reactions are known in the art (Synthesis, 2011, 829; Chem. Sci., 2011, 2, 27; Beilstein J. Org. Chem., 2011, 7, 59; J. Org. Chem., 2004, 69, 5578). The compound of formula (O) is synthesized via deprotection of compound (N) under acidic conditions.

[0283] The compounds according to the invention may be prepared in the manner described herein or in an analogous manner.

[0284] In a preferred embodiment, the compounds according to the invention are modulators of the glucocorticoid receptor. In the sense of the present invention, the term "selective modulator of the glucocorticoid receptor (glucocorticoid receptor modulator)" preferably means that the corresponding compound shows an EC50 or IC50 value of at most 15 μM (10·10 -6 mol / L) or at most 10 μM; more preferably at most 1 μM; still more preferably at most 500 nM (10 -9 mol / L); more preferably at most 300nM; even more preferably at most 100nM; most preferably at most 10nM; and in particular at most 1nM. In a preferred embodiment, the compounds according to the invention show EC50 or IC50 values ​​for the glucocorticoid receptor in a cell target engagement assay for agonist or antagonist efficacy of the glucocorticoid receptor in the range of 1μM to 15μM, more preferably 100nM to 1μM, and most preferably below 100nM.

[0285] Those skilled in the art know how to test the modulation (agonism or antagonism) of the activity of the compound to the glucocorticoid receptor. The preferred target engagement assay for the agonism or antagonism potency (EC50, IC50) of the test compound to the glucocorticoid receptor is described below:

[0286] Glucocorticoid receptor cell-based assay

[0287] The potential selective glucocorticoid receptor modulator of the present invention can be tested for the regulation of the activity of glucocorticoid receptor by cell-based assay. These assays relate to Chinese hamster ovary (CHO) cell lines, which contain fragments and fusion proteins of glucocorticoid receptor. The glucocorticoid receptor fragment used can bind to ligands (e.g., beclomethasone) to confirm the molecules that compete with glucocorticoid receptor ligands for binding. In more detail, the glucocorticoid receptor ligand binding domain is fused to the DNA binding domain (DBD) (GAL4 DBD-GR) of the transcription factor GAL4, and stably integrated into the CHO cell line containing the GAL4-UAS-luciferase reporter construct. In order to confirm the selective glucocorticoid receptor modulator, the reporter cell line is incubated with the molecule for several hours using 8-point half-logarithmic compound dilution curves. After cell lysis, the luminescence produced by luciferase after adding substrate is detected, and EC50 or IC50 values ​​can be calculated. The binding of a molecule that induces gene expression via the glucocorticoid receptor bound to DNA results in the expression of the luciferase gene under the control of the fusion protein GAL4 DBD-GR and thus in a dose-dependent increase in the luminescent signal. The binding of a molecule that inhibits the gene expression of the beclomethasone-induced luciferase gene under the control of the fusion protein GAL4 DBD-GR results in a dose-dependent decrease in the luminescent signal.

[0288] In a preferred embodiment, the compounds according to the invention show EC50 or IC50 values ​​for the glucocorticoid receptor of at most 1 μM (10 -6 mol / L); still more preferably at most 500 nM (10 -9 mol / L); yet more preferably at most 300 nM; even more preferably at most 100 nM; most preferably at most 50 nM; and in particular at most 10 nM or at most 1 nM.

[0289] In a preferred embodiment, the compounds according to the invention show EC50 or IC50 values ​​for glucocorticoid receptor in the range of 1 μM to 15 μM, more preferably 100 nM to 1 μM, most preferably below 100 nM in a cell target engagement assay for agonist or antagonist efficacy on the glucocorticoid receptor.

[0290] In a preferred embodiment, the compounds according to the invention show EC50 or IC50 values ​​for glucocorticoid receptor in a cell target engagement assay for agonist or antagonist efficacy against glucocorticoid receptor in the range of 0.1 nM (10 -9 mol / L) to 1000 nM; still more preferably 1 nM to 800 nM; still more preferably 1 nM to 500 nM; even more preferably 1 nM to 300 nM; most preferably 1 nM to 100 nM; and in particular 1 nM to 80 nM.

[0291] Human Glucocorticoid Receptor (hGR) Ligand Binding Assay

[0292] The binding affinity of the potential selective glucocorticoid receptor modulators of the present invention to the glucocorticoid receptor can be tested using the binding assay described below.

[0293] Preferably, the glucocorticoid receptor extracted from the cytosol of IM9 cells is used for competitive radioligand binding assay to calculate the inhibition percentage of radiolabeled ligand 3H-dexamethasone binding to human glucocorticoid receptor. Preferably, a fixed concentration of radioligand 3H-dexamethasone and 1 μM of a compound according to the present invention (as an unlabeled competitor of dexamethasone) are mixed with the extracted glucocorticoid receptor to measure the inhibition percentage of 3H-dexamethasone binding.

[0294] In a preferred embodiment, the compounds according to the invention show at least 40%, more preferably at least 60%, most preferably at least 85% inhibition of 3H-dexamethasone binding in the hGR ligand binding assay at 1 μM. In a preferred embodiment, the compounds according to the invention show at least 40% inhibition of 3H-dexamethasone binding in the hGR ligand binding assay at 1 μM, more preferably greater than 60% to 85%, most preferably greater than 85%.

[0295] Preferably, the compounds according to the invention can be used as selective modulators of the glucocorticoid receptor.

[0296] The compounds according to the invention can therefore preferably be used for the in vivo treatment or prevention of diseases in which the involvement of the glucocorticoid receptor is implicated.

[0297] The present invention therefore further relates to compounds according to the invention for use in modulating glucocorticoid receptor activity.

[0298] Therefore, another aspect of the present invention relates to compounds for treating and / or preventing a condition at least in part mediated by a glucocorticoid receptor according to the present invention.Another aspect of the present invention relates to a method for treating a condition at least in part mediated by a glucocorticoid receptor, comprising administering an effective amount of a compound according to the present invention to a subject (preferably a person) in need thereof.

[0299] A further aspect of the invention relates to a compound according to the invention for use as a medicament.

[0300] Another aspect of the present invention relates to a pharmaceutical dosage form comprising a compound according to the present invention. Preferably, the pharmaceutical dosage form comprises a compound according to the present invention and one or more pharmaceutical excipients, such as physiologically acceptable carriers, additives and / or auxiliary substances; and optionally one or more further pharmacologically active ingredients. Examples of suitable physiologically acceptable carriers, additives and / or auxiliary substances are fillers, solvents, diluents, colorants and / or binders. These substances are known to those skilled in the art (see HP Fiedler, Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete, Editio Cantor Aulendoff).

[0301] The pharmaceutical dosage form according to the invention is preferably for systemic, external or local administration, preferably for oral administration. Thus, the pharmaceutical dosage form may be in liquid, semisolid or solid form, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, tablets, patches, films, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions, aerosols, or in multiparticulate form, for example in the form of pellets or granules, where appropriate pressed into tablets, poured into capsules or suspended in liquids, and may also be administered as such.

[0302] The pharmaceutical dosage form according to the present invention is preferably prepared by means of conventional means, devices, methods and processes known in the art. The amount of the compound according to the present invention to be administered to the patient can vary, and this depends, for example, on the patient's weight or age, and also on the type of administration, indications and severity of the disease. Preferably, 0.001 to 100 mg / kg, more preferably 0.05 to 75 mg / kg, most preferably 0.05 to 50 mg of the compound according to the present invention is administered per kg of patient body weight.

[0303] It is believed that the glucocorticoid receptor has the potential to ameliorate a variety of diseases or conditions in mammals such as humans. These include, in particular, inflammatory diseases.

[0304] Another aspect of the invention relates to compounds according to the invention for use in the treatment and / or prevention of pain and / or inflammation; more preferably inflammatory pain.

[0305] A further aspect of the invention relates to a method of treating pain and / or inflammation; more preferably inflammatory pain.

[0306] The following examples further illustrate the present invention but should not be construed as limiting its scope.

[0307] The following abbreviations are used in the description of the experiments: AcOH = acetic acid; Cbz = carboxybenzyl; DCM = dichloromethane; DEA = diethylamine; DIPEA = N,N-diisopropylethylamine; DMAP = 4-(dimethylamino)-pyridine; DMF = N,N-dimethylformamide; DMSO = dimethyl sulfoxide; DPPA = diphenylphosphoryl azide; EtOAc = ethyl acetate; EtOH = ethanol; HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; h = hour; MeOH = methanol; min = minute; sat. = saturated; RT = room temperature; R t = retention time; tert = tert-term; TEA = triethylamine; TFA = trifluoroacetic acid; THF = tetrahydrofuran.

[0308] Synthesis of trans-4,4-dimethyl-(5-oxo-2-phenylpyrrolidin-3-yl)benzyl carbamate (Intermediate A1)

[0309]

[0310] Step 1: A solution of benzaldehyde (95.18 g, 0.898 mol), 4-methylbenzenethiol (111.37 g, 0.898 mol), maleic anhydride (88.04 g, 0.898 mol) and 2,4-dimethoxybenzylamine (150.00 g, 0.898 mol) in toluene (600 ml) was stirred at ambient temperature for 2 h and then heated to 120° C. for 16 h. After completion of the reaction (monitored by TLC, mobile phase 5% MeOH-DCM, Rf 0.4), the reaction mixture was cooled to ambient temperature and concentrated under reduced pressure to give a crude product, which was triturated with MTBE to give 1-(2,4-dimethoxy-benzyl)-5-oxo-2-phenyl-3-p-tolylsulfonyl-pyrrolidine-3-carboxylic acid (150.0 g, 35%) as an off-white solid.

[0311] Step 2:To a suspension of 1-(2,4-dimethoxy-benzyl)-5-oxo-2-phenyl-3-p-tolylsulfonyl-pyrrolidine-3-carboxylic acid (500.0g, 1.05mol) in acetone (5L), K2CO3 (579.0g, 4.19mol) was added, followed by methyl iodide (261.0ml, 4.19mol). The resulting suspension was stirred at ambient temperature for 16h. The reaction mixture was then filtered and the filtrate was concentrated. The residue was absorbed in EtOAc (1.5L) and washed with water. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give 1-(2,4-dimethoxy-benzyl)-5-oxo-2-phenyl-3-p-tolylsulfonyl-pyrrolidine-3-carboxylic acid methyl ester (480.0g, 94%) as an off-white solid.

[0312] Step 3: To a solution of 1-(2,4-dimethoxy-benzyl)-5-oxo-2-phenyl-3-p-tolylsulfonyl-pyrrolidine-3-carboxylic acid methyl ester (50.0 g, 0.101 mol) in DMF (0.5 L) was added sodium hydride (50% in mineral oil, 24.4 g, 0.509 mol) at 0 ° C. The resulting reaction mixture was stirred at 0 ° C for 30 minutes. After 30 minutes, methyl iodide (31.7 ml, 0.509 mol) was slowly added. The resulting reaction mixture was then stirred at 0 ° C for 30 minutes. After the reaction was completed (monitored by TLC, the mobile phase was 30%-ethyl acetate-hexane, Rf 0.3), the reaction was quenched with saturated ammonium chloride solution and extracted with EtOAc (2.0 L). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to give the crude compound, which was purified by column chromatography (silica gel, 100-200 mesh, 10-20% EtOAc / hexanes) to give 1-(2,4-dimethoxy-benzyl)-4,4-dimethyl-5-oxo-2-phenyl-4,5-dihydro-1H-pyrrole-3-carboxylic acid methyl ester (28.0 g, 70%) as a light yellow solid.

[0313] Step 4: To a solution of 1-(2,4-dimethoxy-benzyl)-4,4-dimethyl-5-oxo-2-phenyl-4,5-dihydro-1H-pyrrole-3-carboxylic acid methyl ester (26.0 g, 0.117 mol) in methanol (300 ml) was added 10% palladium / carbon (50% water, 13.4 g, 0.063 mol), and the resulting mixture was stirred at ambient temperature under hydrogen pressure (balloon pressure) for 16 h. After completion of the reaction (monitored by TLC, mobile phase was 30%-ethyl acetate-hexane, R f0.30), the reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure to give the crude compound, which was triturated with diethyl ether to give 1-(2,4-dimethoxy-benzyl)-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidine-3-carboxylic acid methyl ester (25.0 g, 96%).

[0314] Step 5: A stirred suspension of 1-(2,4-dimethoxy-benzyl)-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidine-3-carboxylic acid methyl ester (25.0 g, 0.063 mol) in TFA (250 ml) was heated to 90° C. for 16 h. After completion of the reaction (monitored by TLC, 50% ether-hexane, R f -0.3), reactant is cooled to environment temperature, and concentrated under reduced pressure.Residue is alkalized with saturated NaHCO3 solution, then EtOAc (1L) is added, and gained mixture is stirred for 30 minutes.Filter out the solid obtained, and dry under high vacuum, obtain 4,4-dimethyl-5-oxo-2-phenyl-pyrrolidine-3-carboxylic acid methyl esters (18.0g, crude product), which is used for next step.

[0315] Step 6: 2M NaOH (174ml) was added to a suspension of 4,4-dimethyl-5-oxo-2-phenyl-pyrrolidine-3-carboxylic acid methyl ester (43.0g, 0.174mmol) in MeOH (400ml) at 0°C. The resulting suspension was stirred at 100°C for 4h. After the starting material was consumed (monitored by TLC, the mobile phase was 5% MeOH / DCM, Rf 0.2), the reaction mixture was concentrated, the residue was diluted with water, and washed with ethyl acetate (2x75ml). The aqueous layer was then acidified to pH 3 with 6N HCl and extracted with 10% MeOH / DCM (2x75ml). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain trans-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidine-3-carboxylic acid (22.0g, 55.0%) as a brown solid.

[0316] Step 7:To a stirred solution of trans-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidine-3-carboxylic acid (22.0 g, 0.095 mol) in benzene-THF (4: 1, 125 ml) was added DPPA (25.0 ml, 0.114 mol) at ambient temperature, followed by TEA (13.35 ml, 0.095 mol), and the mixture was stirred for 2 h. Benzyl alcohol (14.8 ml, 0.142 mol) was then added, and the reaction mixture was heated to 90 ° C for 4 h. After the reaction was completed (monitored by TLC), the reaction mixture was diluted with water (10 ml) and extracted with ethyl acetate (3x100 ml). The combined organic layer was washed with 10% citric acid solution (100 ml), followed by saturated NaHCO3 solution (2x100 ml), then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was ground with diethyl ether (2x80 ml). The resulting solid was filtered off and dried under high vacuum to afford Intermediate A1 (25.0 g, 78%) as an off-white solid.

[0317] Synthesis of N-((trans)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (Intermediate A2)

[0318]

[0319] Step 1: Pd / C (10.0 g, 10% water) was added to a stirred solution of intermediate A1 (5.0 g, 14.775 mmol, 1.0 equiv) in methanol:THF (80 mL, 2:1) at ambient temperature, and the reaction was stirred for 2 h under a hydrogen balloon. After completion (monitored by TLC, the TLC system was 5% methanol in DCM, Rf-0.2), the reaction mixture was filtered through a diatomaceous earth pad, and the diatomaceous earth pad was then washed 2-3 times with THF. The filtrate was concentrated to give (trans)-4-amino-3,3-dimethyl-5-phenylpyrrolidone as a brown gum (3.0 g, 99%).

[0320] Step 2:To a stirred solution of cyclopropanecarboxylic acid (0.253 g, 2.941 mmol, 1.2 eq) in DMF (10 mL) at 0 °C were added HATU (1.86 g, 4.90 mmol, 2.0 eq), DIPEA (2.0 ml 12.25 mmol, 5.0 eq) and (trans)-4-amino-3,3-dimethyl-5-phenylpyrrolidin-2-one (0.50 g, 2.45 mmol, 1.0 eq) and the reaction was stirred at ambient temperature for 16 h. After completion of the reaction (monitored by TLC, TLC system was 5% methanol in DCM, Rf-0.3), the reaction mixture was diluted with EtOAc (50 mL), washed with ice-cold water (3x25 mL), dried over Na2SO4 and concentrated to give a residue, which was purified via column chromatography (230-400 mesh silica gel; 0 to 2% MeOH-DCM) to give intermediate A2 (0.46 g, 70%).

[0321] Synthesis of N-((trans)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-2,2-difluoropropionamide (Intermediate A3)

[0322]

[0323] Step 1: To a stirred solution of 2,2-difluoropropionic acid (0.647 g, 5.88 mmol, 1.2 eq) in DMF (15 mL) at 0 °C were added HATU (3.72 g, 9.80 mmol, 2.0 eq), DIPEA (4.0 ml 24.50 mmol, 5.0 eq) and (trans)-4-amino-3,3-dimethyl-5-phenylpyrrolidin-2-one (1.0 g, 4.90 mmol, 1.0 eq) and the reaction was stirred at ambient temperature for 16 h. After completion of the reaction (monitored by TLC, TLC system was 5% methanol in DCM, Rf-0.3), the reaction mixture was diluted with ethyl acetate (50 mL), washed with ice-cold water (3x25 mL), dried over Na2SO4 and concentrated to give a residue, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH-DCM) to give intermediate A3 (0.93 g, 64%).

[0324] Synthesis of 5-(5-((4S,5R)-4-amino-3,3-dimethyl-2-oxo-5-phenylpyrrolidin-1-yl)-1H-indazol-1-yl)-1-methylpyridin-2(1H)-one (Intermediate A4-enantiomer 1) and 5-(5-((4R,5S)-4-amino-3,3-dimethyl-2-oxo-5-phenylpyrrolidin-1-yl)-1H-indazol-1-yl)-1-methylpyridin-2(1H)-one (Intermediate A4-enantiomer 2)

[0325]

[0326] Step 1: To a stirred solution of trans-4,4-dimethyl-(5-oxo-2-phenylpyrrolidin-3-yl)benzylcarbamate (2.0g, 5.91mmol) in 1,4-dioxane (80ml) in a sealed tube, 5-(5-iodo-indazole-1-yl)-1-methyl-1H-pyridine-2-one (2.28g, 6.5mmol) was added, followed by potassium phosphate (2.51g, 11.83mmol). The mixture was degassed for 30 minutes under an argon atmosphere. Trans-N, N'-dimethylcyclohexane-1,2-diamine (0.37ml, 2.36mmol) and CuI (225mg, 1.18mmol) were added, and the mixture was heated to 90 °C for 16h. After the reaction was completed (monitored by LCMS), the reaction mixture was filtered through a diatomaceous earth bed, and the diatomaceous earth bed was washed with 1,4-dioxane (100ml). The filtrate was then concentrated under reduced pressure. The reaction was carried out in parallel in four batches (2.0 g each), and the residues of all batches were purified together by column chromatography (silica gel, 100-200 mesh, 1-2% MeOH / DCM) to give ((trans)-4,4-dimethyl-1-(1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-carbamic acid benzyl ester (12.8 g, 48%) as a light yellow solid.

[0327] Step 2:By ((trans)-4,4-dimethyl-1-(1-(1-methyl-6-oxo-1,6-dihydropyridine-3-yl)-1H-indazole-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-benzyl carbamate (3.0g, 5.35mmol) stirred suspension in TFA (30ml) is heated to 90 DEG C for 3h. After the reaction is completed (monitored by LCMS, 5% MeOH in DCM), the reaction mixture is cooled to ambient temperature and concentrated under reduced pressure. Then the residue is azeotroped with toluene (2x50ml). The obtained residue is alkalized with saturated NaHCO solution, and the mixture is extracted with 5% MeOH / DCM (2x150ml). The combined organic layer is dried over anhydrous NaSO, filtered and concentrated under reduced pressure to obtain a crude compound. The reaction was carried out in parallel in four batches (3.0 g each), and the combined crude compounds were purified by column chromatography (100-200 silica gel, 1.5-2% MeOH / DCM as eluent) to give 5-(5-((trans)-4-amino-3,3-dimethyl-2-oxo-5-phenylpyrrolidin-1-yl)-1H-indazol-1-yl)-1-methylpyridin-2(1H)-one (7.0 g, 76%) as a grey solid.

[0328] The racemic compound (7.0 g) in the normal phase was subjected to chiral separation (Chiralpak IC (21.0x250 mm), 5 μm, mobile phase was DCM:EtOH 50:50, flow rate 18.0 mL / min) to give (Intermediate A4-enantiomer 1, retention time 5.56 minutes) and (Intermediate A4-enantiomer 2, retention time 6.41 minutes).

[0329] Synthesis of N-[rac-((6R,7S)-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl)]cyclopropanecarboxamide (Intermediate A5)

[0330]

[0331] Step 1: To a stirred solution of (2,4-dimethoxy-benzyl)-5-oxo-2-phenyl-3-p-tolylsulfonyl-pyrrolidine-3-carboxylic acid methyl ester (56.0 g 152.42 mmol) in DMF (560 ml) was slowly added NaH (18.3 g, 60% dispersion in mineral oil, 457.24 mmol) at 0°C, followed by 1,2-dibromoethane (17.13 ml, 198.14 mmol). The resulting reaction mixture was stirred at 0°C for 3 h. After completion of the reaction (monitored by TLC, mobile phase was 20%-ethyl acetate-hexane, R f0.4), the reaction mixture was poured into a cold saturated solution of NH4Cl. The mixture was then extracted with EtOAc (2x1L). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give a crude compound, which was purified by column chromatography (100-200 mesh silica gel, 10% ethyl acetate-hexane as eluent) to give 5-(2,4-dimethoxybenzyl)-4-oxo-6-phenyl-5-azaspiro[2.4]hept-6-ene-7-carboxylic acid methyl ester (34.0 g, 57%) as an off-white solid.

[0332] Step 2: 10% Pd / C (3.0 g, 50% moisture) and catalytic amount of AcOH were added to a stirred solution of 5-(2,4-dimethoxybenzyl)-4-oxo-6-phenyl-5-azaspiro [2.4] hept-6-ene-7-carboxylic acid methyl ester (7.5 g, 19.08 mmol) in MeOH (125 ml). The reaction mixture was stirred under hydrogen pressure (using a balloon) until the starting material was consumed (monitored by LCMS). The reaction was carried out in parallel in two batches, which were uniformly post-processed. The combined reaction mixture was filtered through a diatomaceous earth bed and the diatomaceous earth bed was washed with MeOH (75 ml). The filtrate was then concentrated to give crude 5-(2,4-dimethoxybenzyl)-4-oxo-6-phenyl-5-aza-spiro [2.4] heptane-7-carboxylic acid methyl ester (12.0 g), which was used in the next step without further purification.

[0333] Step 3: The stirred suspension of 5-(2,4-dimethoxybenzyl)-4-oxo-6-phenyl-5-aza-spiro [2.4] heptane-7-carboxylic acid methyl esters (16.0g, 40.5mmol) in TFA (80ml) is heated to 50 DEG C for 14h. After the reaction is completed (monitored by LCMS), the reaction mixture is cooled to ambient temperature and concentrated under reduced pressure. The residue is azeotroped with toluene, then alkalized with NaHCO solution, then extracted with ethyl acetate (2x125ml). The combined organic layer is dried over anhydrous NaSO, filtered and concentrated under reduced pressure to obtain 4-oxo-6-phenyl-5-aza-spiro [2.4] heptane-7-carboxylic acid methyl esters (9.0g crude product), which is a brown solid.

[0334] Step 4:2M NaOH (60ml, 3.0 equivalents) was added to a suspension of 4-oxo-6-phenyl-5-aza-spiro [2.4] heptane-7-carboxylic acid methyl ester (9.0g crude product) in MeOH (90ml) at 10°C. The resulting suspension was then stirred for 4h at 100°C. After the reaction was completed (monitored by TLC, the mobile phase was 50% EtOAc-hexane, Rf 0.1), the reaction mixture was concentrated. The residue was diluted with water and washed with EtOAc. The alkaline aqueous layer was acidified to pH 2-3 with 6N HCl, and then extracted with 10% MeOH / DCM (3x60ml). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain trans-4-oxo-6-phenyl-5-azaspiro [2.4] heptane-7-carboxylic acid (40g, 32% over 3 steps), which was a brown solid.

[0335] Step 5: To a stirred solution of trans-4-oxo-6-phenyl-5-azaspiro[2.4]heptane-7-carboxylic acid (5.0 g, 21.6 mmol) in benzene-THF (4:1, 80 ml) and DPPA (5.6 ml, 25.9 mmol) was added TEA (3 ml, 21.6 mmol) at ambient temperature. The resulting reaction mixture was stirred at ambient temperature for 2 h, followed by the addition of benzyl alcohol (3.4 ml, 32.4 mmol) and heated to 90 °C for 4 h. After completion of the reaction (monitored by TLC, mobile phase was 5% MeOH in DCM, R f The product was stirred for 2 hours at 4 ℃ for 10 minutes.Then the reaction mixture was diluted with water and extracted with ethyl acetate (3x20ml).The combined organic layers were washed with 10% citric acid solution, then with saturated NaHCO3, dried over anhydrous Na2SO4, and concentrated under reduced pressure.The resulting residue was ground with 10% DCM-hexane and then ground with MTBE (25ml).The solid obtained was filtered out and dried to give 6.5g of crude compound, which was purified by preparative HPLC to give N-(trans-4-oxo-6-phenyl-5-aza-spiro[2.4]hept-7-yl)benzylcarbamate (1.16g, 16%) as an off-white solid.

[0336] Step 6: To a stirred solution of N-(trans-4-oxo-6-phenyl-5-aza-spiro[2.4]hept-7-yl)benzylcarbamate (3.2 g, 9.52 mmol) in MeOH (300 ml) was added 10% Pd / C (1.7 g, 50% water) and the reaction mixture was stirred at ambient temperature under a hydrogen atmosphere using a balloon. After completion of the reaction (monitored by TLC, mobile phase was 10% MeOH / DCM, R f0.2), the reaction mixture was filtered through a celite bed, and then the celite bed was washed with MeOH (50ml x2). The filtrate was concentrated under reduced pressure. The resulting residue was ground with diethyl ether (5ml) to give a crude trans-7-amino-6-phenyl-5-azaspiro[2.4]heptan-4-one (1.6g), which was used in the next step without further purification.

[0337] Step 7: At 0 ℃, to the stirred suspension of trans-7-amino-6-phenyl-5-azaspiro [2.4] heptane-4-one (1.1g, 5.44mmol) in DCM (25ml), TEA (1.3ml, 1.7 equivalents) was added, followed by cyclopropanecarbonyl chloride (0.65ml, 1.3 equivalents). Then the resulting reaction mixture was stirred for 1h at the same temperature. After the reaction was completed (monitored by TLC, the mobile phase was 5% MeOH / DCM), the reaction mixture was concentrated and diluted with water. The resulting mixture was stirred at ambient temperature for 30 minutes, resulting in a white solid precipitate. The solid was filtered out, washed with diethyl ether (10ml x 2) and dried to give crude N- (trans-4-oxo-6-phenyl-5-azaspiro [2.4] heptane-7-yl) cyclopropanecarboxamide (1.2g). The reaction was carried out in parallel in two batches. The solids from the two batches were combined together and purified by reverse phase preparative HPLC to afford Intermediate A5 (436.9 mg, 13%) as an off-white solid.

[0338] Synthesis of benzyl (trans-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)carbamate (Intermediate A6)

[0339]

[0340] Step 1 : To acetophenone (5g, 41.614mmol, 1.0 equivalent) in EtOH (50mL) and hydroxylamine hydrochloride (8.68g, 124.844mmol, 3.0 equivalent) stirring solution, add sodium acetate (17.07g, 208.07mmol, 5 equivalents), and the mixture is heated to reflux 12h. After completion (monitored by TLC), the reaction mixture is evaporated to remove EtOH, and diluted with EtOAc (2x300mL) and water (300mL). The organic layer extracted is washed with salt water (300mL), through anhydrous Na2SO4 dry, and under reduced pressure concentrated to obtain crude product. The crude product is passed through column chromatography (230-400 mesh silica gel, TLC system: EtOAc / hexane (2:8); R f =0.3) to give (E)-1-phenylethan-1-one oxime (4.73 g, 84%).

[0341] Step 2: To a stirred solution of (E)-1-phenylethan-1-one oxime (5 g, 36.993 mmol, 1 eq.) in DCM (50 mL) was added TEA (5.7 mL, 40.692 mmol, 1.2 eq.) followed by chlorodiphenylphosphine (7.3 mL, 40.692 mmol, 1.1 eq.) at -40 °C. The reaction mixture was then stirred at RT for 16 h. After completion of the reaction (monitored by TLC, 50% EtOAc in hexanes, R f =0.3), the reaction mixture was quenched with ice and extracted with EtOAc. The organic layer was washed with water (200 mL), brine (200 mL), dried over Na2SO4, filtered and evaporated under reduced pressure to give a crude product, which was purified by column chromatography using 230-400 silica gel and 30 to 50% EtOAc in hexanes to give (E)-P,P-diphenyl-N-(1-phenylethylidene)phosphinamide (10.1 g, 86%) as a brown gum.

[0342] Step 3: To a stirred solution of (E)-P,P-diphenyl-N-(1-phenylethylidene)phosphinamide (5 g, 15.657 mmol, 1 eq) in THF (75 mL) was added (2E)-1,4-diethyl but-2-enedioate (6.75 g, 39.143 mmol, 2.5 eq), Cu(OAc) (285 mg, 1.5657 mmol, 0.1 eq), PPh3 (410 mg, 1.5657 mmol, 0.1 eq) at RT and the mixture was stirred at RT for 20 min. Pinacol borane (5.62 g, 43.839 mmol, 2.8 eq) was then added at RT and the reaction mixture was stirred at RT for 48 h. After completion of the reaction (monitored by TLC, 50% EtOAc in hexanes, R f =0.4), the reaction mixture was diluted with EtOAc, washed with water (100 mL) and brine (100 mL), dried over Na2SO4 and concentrated to give the crude product, which was purified by column chromatography using 230-400 silica gel and 20-40% EtOAc in hexanes to give pure desired 1-(diphenylphosphoryl)-2-methyl-5-oxo-2-phenylpyrrolidine-3-carboxylic acid ethyl ester (4 g, 57%).

[0343] Step 4:To a solution of ethyl 1-(diphenylphosphoryl)-2-methyl-5-oxo-2-phenylpyrrolidine-3-carboxylate (5 g, 11.174 mmol, 1 eq.) in EtOH (50 mL) was added concentrated HCl (6 ml) at RT. The mixture was stirred at 90 °C for 16 h. After completion of the reaction (monitored by TLC, 50% EtOAc in hexane, R f =0.6), the reaction mixture was evaporated under reduced pressure, neutralized with saturated sodium bicarbonate solution, extracted with EtOAc, dried over Na2SO4 and concentrated to give ethyl 2-methyl-5-oxo-2-phenylpyrrolidine-3-carboxylate (1.1 g, 40%) as an off-white solid.

[0344] Step 5: To a solution of ethyl 2-methyl-5-oxo-2-phenylpyrrolidine-3-carboxylate (4 g, 16.1753 mmol, 1 eq.) in THF:H2O (3:1) (80 mL) was added LiOH·H2O (1.36 g, 32.351 mmol, 2 eq.) at RT. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC, 5% MeOH in DCM, R f =0.1), the organic solvent was evaporated under reduced pressure, dissolved in water, washed with ether, and acidified with HCl. A solid precipitate formed, which was filtered, washed with water and hexane, and dried on a rotary evaporator to give 2-methyl-5-oxo-2-phenylpyrrolidine-3-carboxylic acid (3 g, 85%) as a white solid.

[0345] Step 6: To a stirred solution of 2-methyl-5-oxo-2-phenylpyrrolidine-3-carboxylic acid (3 g, 13.684 mmol, 1.0 eq) in toluene (60 mL) was added TEA (2 mL, 14.368 mmol, 1.05 eq) and DPPA (4.5 g, 16.4203 mmol, 1.2 eq) and the reaction mixture was stirred at 90 °C for 30 min. Benzyl alcohol (2.8 g, 27.3672 mmol, 2.0 eq) was then added to the reaction mixture and the mixture was heated to reflux for 16 h. After completion (monitored by TLC, TLC system was 5% MeOH in DCM, R f -0.3), the reaction mixture was concentrated under reduced pressure and diluted with EtOAc (100 mL), washed with water (2×100 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (230-400 mesh silica gel; 0-3% MeOH in DCM) to give benzyl (trans-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)carbamate (1.8 g, 41%).

[0346] Synthesis of (4S,5R)-4-amino-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3,3-dimethyl-5-phenylpyrrolidin-2-one (Intermediate A7-enantiomer 1) and (4R,5S)-4-amino-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3,3-dimethyl-5-phenylpyrrolidin-2-one (Intermediate A7-enantiomer 2)

[0347]

[0348] Step 1: To a stirred solution of benzyl (trans-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)carbamate (2.0 g, 5.91 mmol) in 1,4-dioxane (100 mL) in a sealed tube was added 1-(4-fluoro-phenyl)-5-iodo-1H-indazole (2.4 g, 7.10 mmol), followed by potassium phosphate (2.51 g, 11.83 mmol), and the mixture was degassed using argon for 30 minutes. Then, trans-N,N'-dimethylcyclohexane-1,2-diamine (0.4 ml, 2.37 mmol) and copper (I) iodide (225 mg, 1.18 mmol) were added, and the mixture was heated to 100-110°C for 16 h. After the completion of the reaction (monitored by LCMS, 5% MeOH in DCM), the reaction mixture was filtered through a diatomaceous earth bed, and the diatomaceous earth bed was washed with 1,4-dioxane (100 mL), and the filtrate was then concentrated under reduced pressure. The reaction was carried out in parallel in 10 batches (2 g per batch). The combined crude material was purified by column chromatography (silica gel, 100-200 mesh, 2-2.5% MeOH / DCM) to obtain (trans-1-(1-(4-fluorophenyl)-1H-indazole-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidine-3-yl) benzyl carbamate (14.5 g, 45%), which was a light yellow solid.

[0349] Step 2:10% Pd / C (50% moisture, 2.0 g) was added to a stirred solution of (trans-1-(1-(4-fluorophenyl)-1H-indazole-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)benzylcarbamate (4.0 g, 7.68 mmol) in THF / MeOH (500 mL, 1:1), and the resulting mixture was stirred at ambient temperature and H2 balloon pressure until the reaction was complete (monitored by TLC, 5% MeOH in DCM). The reaction mixture was then filtered through diatomaceous earth, and the diatomaceous earth bed was washed with THF. The filtrate was then concentrated under reduced pressure. The reaction was carried out in parallel in four batches (4 g each), and the combined crude material was purified by column chromatography (silica gel, 100-200 mesh, 1.5-2.% MeOH / DCM as eluent) to give trans-4-amino-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3,3-dimethyl-5-phenylpyrrolidin-2-one (7.1 g, 56%) as an off-white solid.

[0350] The racemic compound (7.1 g) in the normal phase was subjected to chiral separation (Chiralpak IC (21.0x250 mm), 5 μm, mobile phase was n-hexane / EtOAc / EtOH / isopropylamine 70 / 15 / 15 / 0.1, flow rate 21.0 mL / min) to give (intermediate A7-enantiomer 1, retention time 6.10 minutes) and (intermediate A7-enantiomer 2, retention time 7.30 minutes).

[0351] Synthesis of 2-methyl-3-nitropropionic acid methyl ester

[0352]

[0353] Step 1: Preparation of 3-nitro-methyl propionate: at 0 ℃, to 3-bromopropionic acid methyl ester (200g, 1.19mol) in DMSO (3l), NaNO (120.6g, 1.74mol) was added in portions. The resulting solution was stirred at room temperature for 24h. After judging that the reaction was completed, the mixture was diluted with cold brine (1.5L), and extracted with MTBE (3x1500 ml). The organic matter was washed with cold water (500ml x 2) and then with salt water (500ml), through Na SO Drying, and concentrated under reduced pressure (bath temperature 30C), to obtain thick 3-nitro-methyl propionate. The thick material was purified by column chromatography (using 100-200 mesh silica gel, 10% EA-hexane as eluent). An oil was obtained which was further distilled under reduced pressure (120 °C, 0.1-0.5 mm Hg) to give 3-nitro-propionic acid methyl ester (45 g, 28%) as a light yellow oil.

[0354] Step 2: 2-Methyl-3-nitropropionic acid methyl ester: LDA (2M in THF, 188ml, 376mmol 2.0 equivalents) was added to a stirred solution of 3-nitro-propionic acid methyl ester (25g, 187.97mmol) in THF (400ml) at -78°C and stirred for 30 minutes at the same temperature. MeI (23.4ml, 375.93mmol, 2.0 equivalents) was added at -78°C. The reaction mixture was gradually warmed to 25°C and continued to stir for 16h. The reaction mixture was quenched with NH4Cl aqueous solution at 0°C. The layers were separated and the aqueous portion was extracted with ethyl acetate (600ml x 3). The combined organic layer was washed with brine (300ml), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography using 100-200 silica gel, 5-10% ethyl acetate-hexanes as eluent to give methyl 2-methyl-3-nitropropanoate (10 g, 36%).

[0355] Intermediate A8 ((rac-(2R,3S,4S)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)carbamic acid benzyl Synthesis of esters

[0356]

[0357] Step 1: Synthesis of rac-(3S,4S,5R)-1-(4-methoxybenzyl)-3-methyl-4-nitro-5-phenylpyrrolidin-2-one: To a stirred solution of benzaldehyde (10.82 g, 102.04 mmol) in toluene (100 ml) was added 4-methoxybenzylamine (13.99 g, 102.04 mmol) at rt and stirred at rt for 2 h. To this reaction mixture was added methyl 2-methyl-3-nitropropionate (10 g, 68.03 mmol) followed by benzoic acid (12.46 g, 102.04 mmol) and stirring was continued at 70°C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was diluted with ethyl acetate (400 ml) and washed with water (100 ml x 2) followed by saturated NaHCO3 (100 ml x 2). The organic layer was dried over anhydrous Na2SO4 and concentrated. The crude product was purified by column chromatography (using 100-200 mesh silica gel; 25-30% ethyl acetate in hexanes as eluent) to give rac-(3S,4S,5R)-1-(4-methoxybenzyl)-3-methyl-4-nitro-5-phenylpyrrolidin-2-one (10 g, 43%) as a light brown solid.

[0358] Step 2:Synthesis of rac-(3S,4S,5R)-3-methyl-4-nitro-5-phenylpyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-1-(4-methoxybenzyl)-3-methyl-4-nitro-5-phenylpyrrolidin-2-one (10 g, 29.41 mmol) in acetonitrile (100 ml) was added dropwise a solution of CAN (48.37 g, 88.24 mmol) in water (100 ml) at 0°C. The reaction mixture was slowly warmed to 15°C and stirring was continued for 3-4 h. After completion (monitored by TLC, 50% ethyl acetate / hexane, R f 0.2), the reaction mixture was diluted with ethyl acetate (500 ml) and washed with water (100 ml x 2) followed by brine (250 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 40-50% ethyl acetate in hexanes as eluent) to give rac-(3S,4S,5R)-3-methyl-4-nitro-5-phenylpyrrolidin-2-one (4.00 g, 62%) as a light yellow solid.

[0359] Step 3: Synthesis of rac-(3S,4S,5R)-4-amino-3-methyl-5-phenylpyrrolidin-2-one: To a stirred solution of rac-(3S,4S,5R)-3-methyl-4-nitro-5-phenylpyrrolidin-2-one (4.5 g, 20.45 mmol) in EtOAc-MeOH (2:1, 450 ml) was added 6 M aqueous HCl (102.2 ml) at 0°C. To this reaction mixture was added Zn powder (80.25 g, 1.227 mol) in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was quenched with saturated NaHCO3 solution at 0°C, stirred for 1 h, filtered through celite, and washed with EtOAc-MeOH (500 ml, 2:1). The filtrate was concentrated to give rac-(3S,4S,5R)-4-amino-3-methyl-5-phenylpyrrolidin-2-one (3.9 g crude, deemed 100% yield) which was used without further purification.

[0360] Step 4:At 0 ℃, sodium bicarbonate (9.95g, 118.42mmol) was added to a stirred suspension of rac-(3S, 4S, 5R)-4-amino-3-methyl-5-phenylpyrrolidin-2-one (3.9g crude product, 20.45mmol) in THF: water (1:1, 225ml), and stirred for 30 minutes. Benzyl chloroformate (11.8ml, 35.53mmol, 50% in toluene) was added to the reaction mixture at 0 ℃, and stirring was continued for 16h at rt. After completion (monitored by LCMS), the reaction mixture was diluted with water (300ml) and extracted with ethyl acetate (3x500ml). The combined organic matter was washed with water (200ml x 2), then with brine (200ml), and dried over Na2SO4. After removal of the solvent, the crude material was purified by column chromatography (using 100-200 mesh silica gel; 2-2.5% MeOH in DCM as eluent) to give intermediate A8 (rac-(2R,3S,4S)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)carbamic acid benzyl ester (3.5 g, 53% in two steps).

[0361] Intermediate A10-trans((rac(2R,3S,4S)-4-methyl-5-oxo-2-(m-tolyl)pyrrolidin-3-yl) benzyl carbamate) and intermediate A10-cis((rac(2S,3S,4S)-4-methyl-5-oxo-2-(m-tolyl)pyrrole Synthesis of benzyl 3-alkyl)carbamate

[0362]

[0363] Step 1: Synthesis of rac-(4S,5R)-1-(4-methoxybenzyl)-3-methyl-4-nitro-5-(m-tolyl)pyrrolidin-2-one: To a stirred solution of 3-methyl-benzaldehyde (11.02 g, 91.75 mmol) in toluene (90 ml) was added 4-methoxybenzylamine (12.58 g, 91.75 mmol) at rt and stirred for 2 h. To this reaction mixture was added methyl 2-methyl-3-nitropropionate (9.00 g, 61.27 mmol) followed by benzoic acid (11.2 g, 91.75 mmol) and stirred at 70°C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was diluted with ethyl acetate (500 ml) and washed with water (200 ml x 2) followed by saturated NaHCO3 (150 ml x 2). The organic layer was dried over anhydrous Na2SO4 and concentrated to give rac-(4S,5R)-1-(4-methoxybenzyl)-3-methyl-4-nitro-5-(m-tolyl)pyrrolidin-2-one (7.1 g, 32.7%) as a brown resin.

[0364] Step 2:Synthesis of rac-(4S,5R)-3-methyl-4-nitro-5-(m-tolyl)pyrrolidin-2-one: To a stirred solution of rac-(4S,5R)-1-(4-methoxybenzyl)-3-methyl-4-nitro-5-(m-tolyl)pyrrolidin-2-one (4 g, 11.28 mmol) in acetonitrile (42 ml) was added dropwise a solution of CAN (18.56 g, 33.86 mmol) in water (42 ml) at 0°C. The reaction mixture was slowly warmed to 15°C and stirring was continued for 3-4 h. Upon completion (monitored by LCMS), the reaction mixture was diluted with ethyl acetate (300 ml) and washed with water (100 ml x 2) followed by brine (200 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 1-1.5% MeOH in DCM) to afford rac-(4S,5R)-3-methyl-4-nitro-5-(m-tolyl)pyrrolidin-2-one (1.5 g, 56.8%) as an off-white solid.

[0365] Step 3: Synthesis of rac-(4S,5R)-4-amino-3-methyl-5-(m-tolyl)pyrrolidin-2-one: To a stirred solution of rac-(4S,5R)-3-methyl-4-nitro-5-(m-tolyl)pyrrolidin-2-one (1.5 g, 6.37 mmol) in EtOAc-MeOH (2:1, 136 ml) at 0°C was added 6N HCl aqueous solution (34 ml). To this reaction mixture was added Zn powder (25.01 g, 382.55 mmol) in small portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was quenched with saturated NaHCO3 solution at 0°C (until alkaline reaction), stirred for 1 h, filtered through celite, and washed with EtOAc:MeOH (250 ml, 2:1). The filtrate was concentrated to give rac-(4S,5R)-4-amino-3-methyl-5-(m-tolyl)pyrrolidin-2-one (1.3 g crude product, considered as 100% yield).

[0366] Step 4:Synthesis of Intermediate A10-trans and A10-cis a. To a stirred suspension of rac-(4S,5R)-4-amino-3-methyl-5-(m-tolyl)pyrrolidin-2-one (1.3 g crude, 6.37 mmol) in THF-water (1:1, 160 ml) was added sodium bicarbonate (2.67 g, 31.89 mmol) at 0°C and stirred for 30 minutes. To this reaction mixture was added benzyl chloroformate (50% in toluene, 3.7 ml) at 0°C and stirred at rt for 16 h. Upon completion (monitored by LCMS), the reaction mixture was diluted with water (75 ml) and extracted with ethyl acetate (3x75 ml). The combined organics were washed with water (50 ml x 2), followed by brine (50 ml x 2), dried over Na2SO4 and concentrated. The crude material was mixed with another batch of the same amount and purified by column chromatography (using 100-200 mesh silica gel; 1-2% MeOH in DCM as eluent) to give intermediate A10-trans(benzyl(rac-(2R,3S,4S)-4-methyl-5-oxo-2-(m-tolyl)pyrrolidin-3-yl)carbamate, 1.39 g, 20.8% for two steps), and impure fractions which were further purified by preparative HPLC to give intermediate A10-cis(benzyl(rac-(2R,3S,4S)-4-methyl-5-oxo-2-(m-tolyl)pyrrolidin-3-yl)carbamate 690 mg, 10.3% for two steps).

[0367] Intermediate A12-trans(rac-(2R,3S,4S)-2-(2-chlorophenyl)-4-methyl-5-oxopyrrolidin-3-yl) Benzyl carbamate and intermediate A12-cis(rac-(2S,3S,4S)-2-(2-chlorophenyl)-4-methyl-5-oxopyrrolidine- Synthesis of Benzyl 3-aminocarbamate

[0368]

[0369] Step 1:Synthesis of rac-(4S,5R)-5-(2-chlorophenyl)-1-(4-methoxybenzyl)-3-methyl-4-nitropyrrolidin-2-one. To a stirred solution of 2-chloro-benzaldehyde (11.46 g, 81.56 mmol) in toluene (80 ml) was added 4-methoxybenzylamine (11.2 g, 81.56 mmol) at rt and stirred for 2 h. To this reaction mixture was added methyl 2-methyl-3-nitropropionate (8 g, 54.37 mmol) followed by benzoic acid (9.96 g, 81.56 mmol) and stirred at 70°C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was diluted with ethyl acetate (500 ml) and washed with water (150 ml x 2) followed by saturated aqueous NaHCO3 (150 ml x 2). The organic layer was dried over anhydrous Na2SO4 and concentrated to give rac-(4S,5R)-5-(2-chlorophenyl)-1-(4-methoxybenzyl)-3-methyl-4-nitropyrrolidin-2-one (8.2 g, 40.3%) as a brown solid.

[0370] Step 2: Synthesis of rac-(4S,5R)-5-(2-chlorophenyl)-3-methyl-4-nitropyrrolidin-2-one. To a stirred solution of rac-(4S,5R)-5-(2-chlorophenyl)-1-(4-methoxybenzyl)-3-methyl-4-nitropyrrolidin-2-one (8 g, 21.33 mmol) in acetonitrile (80 ml) was added dropwise an aqueous solution of CAN (35 g, 64 mmol) in water (80 ml) at 0°C. The reaction mixture was slowly warmed to 15°C and stirring was continued for 3-4 h. Upon completion (monitored by LCMS), the reaction mixture was diluted with ethyl acetate (500 ml) and washed with water (100 ml x 2) followed by brine (200 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 25-30% ethyl acetate in hexanes as eluent) to afford rac-(4S,5R)-5-(2-chlorophenyl)-3-methyl-4-nitropyrrolidin-2-one (2.5 g, 46%) as an off-white solid.

[0371] Step 3:rac-(4S,5R)-4-amino-5-(2-chlorophenyl)-3-methylpyrrolidin-2-one. To a stirred solution of rac-(4S,5R)-5-(2-chlorophenyl)-3-methyl-4-nitropyrrolidin-2-one (2.5 g, 10.684 mol) in EtOAc / MeOH (2:1, 250 ml) was added 6N HCl aqueous solution (53 ml) at 0°C. To this reaction mixture was added Zn powder (41.92 g, 641 mmol) in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion of the reaction (monitored by LCMS), the mixture was quenched with saturated NaHCO3 solution at 0°C (until alkaline reaction), stirred for 1 h, filtered through celite, and washed with EtOAc / MeOH (250 ml, 2:1). The filtrate was concentrated to give rac-(4S,5R)-4-amino-5-(2-chlorophenyl)-3-methylpyrrolidin-2-one (2.2 g crude, deemed 100% yield). The crude product was used in the next step without further purification.

[0372] Step 4: Synthesis of Intermediate A12-trans and Intermediate A12-cis. To a stirred suspension of rac-(4S,5R)-4-amino-5-(2-chlorophenyl)-3-methylpyrrolidin-2-one (1.9 g crude, 8.48 mmol) in THF-water (1:1, 100 ml) was added sodium bicarbonate (3.56 g, 86.36 mmol) at 0°C and the mixture was stirred for 30 minutes. To this reaction mixture was added benzyl chloroformate (50% in toluene, 4.3 ml) at 0°C and stirred at rt for 16 h. After the reaction was judged complete (monitored by LCMS), the reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with water (100 ml x 2) followed by brine (100 ml), dried over Na2SO4 and concentrated. The crude product was mixed with 1.5 g of another batch and the combined material was purified by column chromatography (using 100-200 mesh silica gel; 1-2% MeOH in DCM as eluent) to give an isomeric mixture of Intermediate A12-trans and Intermediate A12-cis (3.3 g). Preparative HPLC purification gave Intermediate A12-trans(rac-(2R,3S,4S)-2-(2-chlorophenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamic acid benzyl ester (815 mg, 14.9% in two steps after preparative purification) and another fraction (1.7 g) which was further purified by preparative HPLC to give Intermediate A12-cis(rac-(2R,3S,4S)-2-(2-chlorophenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamic acid benzyl ester (810 mg, 14.8%).

[0373] Intermediate A14 (rac-(2R,3S,4S)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)amine Synthesis of Benzyl Formate

[0374]

[0375] Step 1: Synthesis of rac-(3S,4S,5R)-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-3-methyl-4-nitropyrrolidin-2-one. To a stirred solution of 4-methoxy-benzaldehyde (13.88 g, 101.95 mmol) in toluene (100 ml) was added 4-methoxybenzylamine (13.98 g, 101.95 mmol) at rt and the mixture was stirred for 2 h. To this reaction mixture was added 2-methyl-3-nitropropanoate (10.0 g, 67.96 mmol) followed by benzoic acid (12.45 g, 101.95 mmol) and stirred at 70°C for 16 h. After completion of the reaction (monitored by LCMS), the mixture was diluted with ethyl acetate (250 ml) and washed with water (100 ml) followed by saturated aqueous NaHCO3 solution (100 ml x 2). The organic layer was dried over anhydrous Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 20-25% ethyl acetate / hexanes eluent) to give rac-(3S,4S,5R)-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-3-methyl-4-nitropyrrolidin-2-one (11.5 g, 45.7%) as a brown solid.

[0376] Step 2:Synthesis of rac-(3S,4S,5R)-5-(4-methoxyphenyl)-3-methyl-4-nitropyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-3-methyl-4-nitropyrrolidin-2-one (14.5 g, 39.04 mmol) in acetonitrile (150 ml) was added dropwise a solution of CAN (64.2 g, 117.12 mmol) in water (150 ml) at 0°C. The reaction mixture was slowly warmed to 15°C and stirring was continued for 3-4 h. After the starting material was consumed (monitored by TLC, 50% ethyl acetate / hexane, Rf 0.2), the reaction mixture was diluted with ethyl acetate (300 ml) and washed with water (100 ml x 2) followed by brine (150 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 20-30% ethyl acetate / hexanes as eluent) to give rac-(3S,4S,5R)-5-(4-methoxyphenyl)-3-methyl-4-nitropyrrolidin-2-one (3.82 g, 39%) as a light yellow solid.

[0377] Step 3: Synthesis of rac-(3S,4S,5R)-4-amino-5-(4-methoxyphenyl)-3-methylpyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-5-(4-methoxyphenyl)-3-methyl-4-nitropyrrolidin-2-one (3.8 g, 15.2 mmol) in EtOAc / MeOH (2:1, 380 ml) was added 6N HCl aqueous solution (76 ml) at 0°C. To this reaction mixture was added Zn powder (59.64 g, 912 mmol) in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was quenched with saturated NaHCO3 solution at 0°C, stirred for 1 h, filtered through celite, and washed with EtOAc / MeOH (300 ml, 2:1). The filtrate was concentrated to give rac-(3S,4S,5R)-4-amino-5-(4-methoxyphenyl)-3-methylpyrrolidin-2-one (3.52 g crude, deemed 100% yield). The crude product was used in the next step without further purification.

[0378] Step 4:To a stirred suspension of rac-(3S,4S,5R)-4-amino-5-(4-methoxyphenyl)-3-methylpyrrolidin-2-one (3.52 g crude, 15.2 mmol) in THF-water (1:1, 200 ml) was added sodium bicarbonate (7.25 g, 86.36 mmol) at 0°C and stirred for 30 minutes. To this reaction mixture was added benzyl chloroformate (50% in toluene, 8.66 ml) at 0°C and stirring was continued for 16 h at rt. Upon completion (monitored by LCMS), the reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate (3 x 150 ml). The combined organics were washed with water (150 ml x 2) followed by brine (200 ml), dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 1-2% MeOH in DCM as eluent) to give intermediate A14 as an off-white solid. (2.5 g, 39% in two steps)

[0379] Intermediate A16 (rac-(2S,3S,4S)-2-(5-chlorothiophen-2-yl)-4-methyl-5-oxopyrrolidin-3-yl) Synthesis of Benzyl Carbamate

[0380]

[0381] Step 1: Synthesis of rac-(3S,4S,5S)-5-(5-chlorothiophen-2-yl)-1-(4-methoxybenzyl)-3-methyl-4-nitropyrrolidin-2-one. To a stirred solution of 5-chloro-thiophene-2-carbaldehyde (10 g, 0.068 mol) in toluene (250 ml) was added 4-methoxybenzylamine (10.26 g, 0.0748 mol) at rt and stirred for 2 h. To this reaction mixture was added 2-methyl-3-nitropropionate (11 g, 0.0748 mol) followed by benzoic acid (12.46 g, 0.102 mol) and stirred at 80°C for 16 h. After completion of the reaction (monitored by TLC, 30% EA / hexane), the reaction mixture was diluted with ethyl acetate (200 ml) and washed with water (500 ml) followed by saturated aqueous NaHCO3 solution (300 ml x 3). The organic layer was dried over anhydrous Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 25-30% ethyl acetate / hexane as eluent) to give rac-(3S,4S,5S)-5-(5-chlorothiophen-2-yl)-1-(4-methoxybenzyl)-3-methyl-4-nitropyrrolidin-2-one (8 g, 28%) as a brown resin.

[0382] Step 2:Synthesis of rac-(3S,4S,5S)-5-(5-chlorothiophen-2-yl)-3-methyl-4-nitropyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5S)-5-(5-chlorothiophen-2-yl)-1-(4-methoxybenzyl)-3-methyl-4-nitropyrrolidin-2-one (5 g, 0.013 mol) in CH3CN (50 ml) was added dropwise a solution of CAN (21.38 g, 0.039 mol) in water (50 ml) at 0°C. The reaction mixture was stirred at the same temperature for 2 h. Upon completion (Rf 0.3 by TLC monitoring in 50% EA-hexane), the reaction mixture was diluted with ethyl acetate and washed with water followed by brine. The organic layer was dried over Na2SO4 and concentrated. The crude material obtained was purified by column chromatography (using 100-200 mesh silica gel, 70% EA-hexanes as eluent) to give rac-(3S,4S,5S)-5-(5-chlorothiophen-2-yl)-3-methyl-4-nitropyrrolidin-2-one (2.3 g, 82%) as an off-white solid.

[0383] Step 3: Synthesis of rac-(3S,4S,5S)-4-amino-5-(5-chlorothiophene-2-yl)-3-methylpyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5S)-5-(5-chlorothiophene-2-yl)-3-methyl-4-nitropyrrolidin-2-one (1.8 g, 6.9 mmol) in EtOAc / MeOH (360 ml, 2:1) was added 6N HCl aqueous solution (35 ml) at 0°C. Zn powder (27.07 g, 414 mmol) was added to the mixture in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion (monitored by LCMS), the reaction mixture was quenched with saturated NaHCO3 solution at 0°C, stirred for 1 h, filtered through celite, and washed with EtOAc / MeOH (500 ml, 2:1). The filtrate was concentrated to give rac-(3S,4S,5S)-4-amino-5-(5-chlorothien-2-yl)-3-methylpyrrolidin-2-one (1.6 g, crude) as an off-white solid. The crude product was used in the next step without further purification.

[0384] Step 4:Synthesis of intermediate A16. Sodium bicarbonate (5.46 g, 0.065 mol) was added to a stirred suspension of rac-(3S, 4S, 5S)-4-amino-5-(5-chlorothiophene-2-yl)-3-methylpyrrolidine butan-2-one (3 g, 0.013 mol) in THF / water (60 ml, 1:1) at 0 ° C, and stirred for 30 minutes. Benzyl chloroformate (50% solution in toluene, 6.65 g, 0.0195 mol) was added to this at the same temperature, and stirring was continued for 16 h at rt. After completion (monitored by LCMS), the reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate (3X 90 ml). The combined organic matter was washed with water (90 ml), followed by brine (90 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 2-2.5% MeOH / DCM as eluent) to afford intermediate A16 (rac-(2S,3S,4S)-benzyl 2-(5-chlorothien-2-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate (3 g, 79% over 2 steps) as an off-white solid.

[0385] Intermediate A18 (rac-(2S,3S,4S)-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxopyrrolidine- Synthesis of Benzyl 3-aminocarbamate

[0386]

[0387] Step 1: Preparation of rac-(3S,4S,5S)-1-(4-methoxybenzyl)-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)-4-nitropyrrolidin-2-one. To a stirred solution of 1-methyl-1H-pyrazole-3-carbaldehyde (5 g, 45.46 mmol) in toluene (75 ml) was added 4-methoxybenzylamine (6.86 g, 50.01 mmol) at rt and stirred for 2 h. To this reaction mixture was added 2-methyl-3-nitropropionate (8.68 g, 59.09 mmol) followed by benzoic acid (8.33 g, 687.18 mmol) and stirring was continued at 70°C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was diluted with ethyl acetate (200 ml) and washed with water (200 ml) followed by saturated aqueous NaHCO3 solution (75 ml x 2). The organic layer was washed with anhydrous Na2SO 4 The crude product was purified by column chromatography (using 100-200 mesh silica gel; 25-30% ethyl acetate / hexane as eluent) to give rac-(3S,4S,5S)-1-(4-methoxybenzyl)-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)-4-nitropyrrolidin-2-one (4 g, 26%) as an off-white solid.

[0388] Step 2: Preparation of rac-(3S,4S,5S)-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)-4-nitropyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5S)-1-(4-methoxybenzyl)-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)-4-nitropyrrolidin-2-one (2 g, 5.814 mmol) in CH3CN (40 ml) was added dropwise a solution of CAN (6.37 g, 11.63 mmol) in water (40 ml) at 0°C. The reaction mixture was stirred at the same temperature for 2 h. After completion (Rf 0.3 by TLC monitoring in 50% EA-hexanes), the reaction mixture was diluted with ethyl acetate and washed with water followed by brine. The organic layer was dried over Na2SO4 and concentrated. Two more identical batches were carried out using the above procedure. The crude material of the composite batch was purified by column chromatography (using 100-200 mesh silica gel, 70% EA-hexanes as eluent) to give rac-(3S,4S,5S)-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)-4-nitropyrrolidin-2-one (2.4 g, 61.4%) as an off-white solid.

[0389] Step 3: Preparation of rac-(3S,4S,5S)-4-amino-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5S)-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)-4-nitropyrrolidin-2-one (2.5 g, 11.16 mmol) in EtOAc / MeOH (2;1, 200 ml) was added 6N HCl aqueous solution (56 ml) at 0°C. To this reaction mixture was added Zn powder (43.8 g, 669.64 mmol) in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion (monitored by TLC in 10% MeOH-DCM, Rf 0.4), the reaction mixture was quenched with saturated aqueous NaHCO3 at 0°C and filtered through celite, washed with EtOAc / MeOH (500 ml, 2:1) and concentrated to give rac-(3S,4S,5S)-4-amino-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one (2.5 g, crude). The crude product was used in the next step without further purification.

[0390] Step 4:Preparation of intermediate A18. To a stirred suspension of rac-(3S,4S,5S)-4-amino-3-methyl-5-(1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one (2.5 g crude, 12.87 mmol) in THF / water (1; 1, 250 ml) was added sodium bicarbonate (5.41 g, 64.43 mmol) at 0°C and stirred for 30 minutes. To this reaction mixture was added benzyl chloroformate (6.4 ml, 19.32 mmol, 50% in toluene) at 0°C and stirred at rt for 16 h. After completion of the reaction (monitored by LCMS), the mixture was diluted with water (500 ml) and extracted with ethyl acetate (3 x 500 ml). The combined organic layers were washed with water (250 ml x 2) followed by brine (500 ml). The organic portion was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 2-2.5% MeOH / DCM as eluent) to afford intermediate A18 (rac-(2S,3S,4S)-benzyl 4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxopyrrolidin-3-yl)carbamate (1.99 g, 54.3% for two steps) as an off-white solid.

[0391] Intermediate A20 (rac-(2R,3S,4S)-4-benzyl-2-ethyl-5-oxopyrrolidin-3-yl)carbamic acid benzyl ester Synthesis

[0392]

[0393] Step 1: Synthesis of 2-benzyl-3-nitropropionic acid methyl ester.To a stirred solution of LDA (2M in THF, 22.5ml, 45.09mmol) in THF (30ml) at -78°C, add a solution of 3-nitropropionic acid methyl ester (3g, 22.54mmol) and DMPU (27.3ml, 222.49mmol) in THF (20ml), and continue stirring at the same temperature for 30 minutes.Add a solution of (bromomethyl)benzene (2.69ml, 22.54mmol) in THF (15ml) at -78°C, and stir for 2h at the same temperature.Make the mixture gradually reach 25°C, and stir for 16h.The reaction mixture is quenched with 1N HCl (100ml) at 0°C, and extracted with ethyl acetate (100ml x 2). The combined organic layers were washed with water (100 ml), saturated aqueous NaHCO3 (100 ml), then brine (100 ml), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (using 100-200 silica gel, 10-12% ethyl acetate-hexane as eluent) to give methyl 2-benzyl-3-nitropropanoate (3.3 g, 65.65%) as a light yellow oil.

[0394] Step 2: Synthesis of rac-(3S,4S,5R)-3-benzyl-5-ethyl-1-(4-methoxybenzyl)-4-nitropyrrolidin-2-one. To a stirred solution of propionaldehyde (3.61 ml, 50.39 mmol) in toluene (75 ml) was added 4-methoxybenzylamine (6.91 g, 50.39 mmol) at 25°C and stirring was continued for 2 h. To this reaction mixture was added methyl 2-benzyl-3-nitropropionate (7.5 g, 33.59 mmol) followed by benzoic acid (6.15 g, 50.39 mmol) and stirred at 70°C for 7-8 h. After completion of the reaction (monitored by TLC, 30% EA / hexane, Rf=0.4), the reaction mixture was diluted with ethyl acetate (300 ml) and washed with water (300 ml) followed by saturated aqueous NaHCO3 solution (200 ml x 2). The organic layer was dried over anhydrous Na2SO4 and concentrated. The crude product was purified by column chromatography (using 100-200 mesh silica gel; 25-30% ethyl acetate / hexane as eluent) to give rac-(3S,4S,5R)-3-benzyl-5-ethyl-1-(4-methoxybenzyl)-4-nitropyrrolidin-2-one (3.5 g, 28.3%) as a brown oil.

[0395] Step 3: Synthesis of rac-(3S,4S,5R)-3-benzyl-5-ethyl-4-nitropyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-3-benzyl-5-ethyl-1-(4-methoxybenzyl)-4-nitropyrrolidin-2-one (3.6 g, 9.77 mmol) in acetonitrile (36 ml) was added dropwise a solution of CAN (16.1 g, 29.31 mmol) in water (36 ml) at 0°C. The reaction mixture was slowly warmed to 10-15°C and stirring was continued for 3-4 h. After completion of the reaction (monitored by TLC, 40% acetone in hexane, Rf 0.3), the mixture was diluted with ethyl acetate (200 ml) and washed with water (200 ml) followed by brine (200 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 35-40% ethyl acetate / hexanes as eluent) to afford rac-(3S,4S,5R)-3-benzyl-5-ethyl-4-nitropyrrolidin-2-one (1.53 g, 63%) as a light yellow solid.

[0396] Step 4: Synthesis of rac-(3S,4S,5R)-4-amino-3-benzyl-5-ethylpyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-3-benzyl-5-ethyl-4-nitropyrrolidin-2-one (2.8 g, 11.27 mmol) in EtOAc / MeOH (252 ml, 2:1) was added 6M HCl aqueous solution (80 ml) at 0°C. Zn powder (44.24 g, 676.68 mmol) was added thereto in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was quenched with saturated NaHCO3 solution at 0°C, stirred for 1 h, filtered through celite, and washed with EtOAc / MeOH (300 ml, 2:1). The filtrate was concentrated to give rac-(3S,4S,5R)-4-amino-3-benzyl-5-ethylpyrrolidin-2-one (2.43 g crude, deemed 100% yield) as an off-white solid which was used as such in the next step.

[0397] Step 5: Synthesis of intermediate A20. To a stirred suspension of rac-(3S,4S,5R)-4-amino-3-benzyl-5-ethylpyrrolidin-2-one (2.43 g crude 11.18 mmol) in THF / water (300 ml, 1:1) was added sodium bicarbonate (4.69 g, 55.91 mmol) at 0°C and stirred for 30 minutes. To this was added benzyl chloroformate (5.58 ml, 16.77 mmol, 50% in toluene) at 0°C and stirred for 16 h at rt. After completion of the reaction (monitored by LCMS), the reaction mixture was diluted with water (300 ml) and extracted with ethyl acetate (3X300 ml). The combined organic layers were washed with water (300 ml), then with brine (300 ml), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (using 100-200 mesh silica gel; 1.5-2% MeOH / DCM as eluent) to give intermediate A20 (rac-(2R,3S,4S)-4-benzyl-2-ethyl-5-oxopyrrolidin-3-yl)carbamic acid benzyl ester (2.95 g, 74.9%) as an off-white solid.

[0398] Intermediate A9 rac-(3S,4S,5R)-4-amino-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3-methyl- Synthesis of 5-phenylpyrrolidin-2-one

[0399]

[0400] Step 1:Synthesis of benzyl N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]carbamate. In a microwave vial, benzyl N-[rac(2R,3S,4S)-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]carbamate (500 mg, 1.54 mmol) was added to 1-(4-fluorophenyl)-5-iodo-indazole (537 mg, 1.70 mmol), K3PO4 (654 mg, 3.08 mmol) and CuI (58.7 mg, 0.308 mmol). The vial was sealed and purged with nitrogen. 1,4-dioxane (15.4 mL) was then added to the mixture, followed by (1R,2R)-N,N'-dimethyl-1,2-cyclohexanediamine (87.7 mg, 0.617 mmol). The mixture was heated to 100 ° C overnight and then heated to 110 ° C for 5 h. After the reaction control system (UPLC) showed complete conversion of the starting material, the slurry was cooled to room temperature and ethyl acetate was added, followed by saturated NaHCO3 solution. The mixture was stirred for 5 minutes, the layers were separated, and the aqueous layer was extracted once with ethyl acetate. The combined organic layers were washed with brine and dried over MgSO4. The crude material was subjected to flash chromatography (40 g silica-column, cyclohexane / ethyl acetate gradient as eluent) to afford N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]carbamate (465 mg, 0.870 mmol, 56%) as a white solid.

[0401] Step 2: In a sealed tube, a solution of N-[rac-(2R, 3S, 4S)-1-[1-(4-fluorophenyl) indazole-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl] carbamate (465mg, 0.870mmol) in acetonitrile (23ml) was added to NaI (783mg, 5.22mmol). Trimethylsilyl chloride (0.442mL, 3.48mmol) was added dropwise to this mixture. The reaction mixture was stirred at room temperature overnight and slowly added to ethanol (28ml) after completion of the reaction control system (UPLC). The resulting solution was loaded on a 5g SCX column, washed twice with ethanol (15ml each time), and eluted with 2M ammonia in methanol. The fractions of methanol were combined. The solvent was evaporated to give (rac-3S,4S,5R)-4-amino-1-[1-(4-fluorophenyl)indazol-5-yl]-3-methyl-5-phenyl-pyrrolidin-2-one intermediate A9 (316 mg, 0.789 mmol, 91%) as a white solid.

[0402] Using different building blocks, the intermediates in the following table were synthesized similarly to the above intermediate 9.

[0403]

[0404]

[0405] Intermediate A15-cis(rac-(2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxy phenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamic acid benzyl ester and intermediate A15-trans (rac-(2R,3S,4S)- 1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)amino Synthesis of Benzyl Formate

[0406]

[0407] Step 1:Synthesis of benzyl (rac-(2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate and benzyl (rac-(2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate. In a microwave vial, intermediate A14 (500 mg, 1.54 mmol) was added to 1-(4-fluorophenyl)-5-iodo-indazole (524 mg, 1.55 mmol, 1.1 equiv), K3PO4 (599 mg, 2.82 mmol, 2.0 equiv) and CuI (53.7 mg, 0.282 mmol, 0.2 equiv). The vial was sealed and purged with nitrogen. 1,4-dioxane (14.1 mL) was subsequently added to the mixture, followed by (1R, 2R)-N, N'-dimethyl-1,2-cyclohexanediamine (80.3 mg, 0.564 mmol, 0.4 equiv). The mixture was heated to 100 ° C overnight and to 110 ° C for 5 h. After the reaction control system (UPLC) showed that the starting material was completely converted, the slurry was cooled to room temperature, and ethyl acetate was added, followed by saturated NaHCO3 solution. The mixture was stirred for 5 minutes, the layers were separated, and the aqueous layer was extracted once with ethyl acetate. The combined organic layers were washed with brine and dried over MgSO4. The crude material was subjected to flash chromatography (40 g silica-column, cyclohexane / ethyl acetate gradient as eluent) to afford benzyl (rac-(2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate (545 mg, 0.965 mmol, 68%) and the diastereomer benzyl (rac-(2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate (116 mg, 0.206 mmol, 15%).

[0408] Step 2: Intermediate A15 - trans-benzyl (rac-(2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate was obtained according to the procedure described for Intermediate A9, Step 2, using (rac-(2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate.

[0409] Step 3: Intermediate A15-cis-benzyl ((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate was obtained according to the procedure described for Intermediate A9, Step 2, using (rac-(2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate.

[0410] Intermediate A17-cis (3R, 4S, 5S)-4-amino-5-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H- Indazol-5-yl)-3-methylpyrrolidin-2-one and intermediate A17-trans (3S, 4S, 5S)-4-amino-5-(5-chlorothiophene-2- Synthesis of 1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3-methylpyrrolidin-2-one

[0411]

[0412] Step 1: Synthesis of benzyl (rac-(2S,3S,4S)-2-(5-chlorothien-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate and benzyl (rac-(2S,3S,4R)-2-(5-chlorothien-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate: Intermediate A16 (500 mg, 1.37 mmol) was reacted with 1-(4-fluorophenyl)-5-iodo-indazol-5-yl in a 3% CO 2 solution of 1% ethyl acetate and 1% ethyl acetate in a 5% CO 2 solution. (510 mg, 1.51 mmol, 1.1 equiv) was coupled to give benzyl (rac-(2S,3S,4S)-2-(5-chlorothien-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate (644 mg, 1.12 mmol, 82%) and the diastereomer (rac-(2S,3S,4R)-2-(5-chlorothien-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate (118 mg, 0.205 mmol, 15%).

[0413] Step 2 Deprotection of ((2S,3S,4S)-2-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate according to the procedure described for Intermediate A9, Step 2, afforded Intermediate A17 - trans-(3S,4S,5S)-4-amino-5-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3-methylpyrrolidin-2-one.

[0414] Step 3: Deprotection of ((2S,3S,4R)-2-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxopyrrolidin-3-yl)carbamate was carried out according to the procedure described for Intermediate A9, Step 2 to afford Intermediate A17-cis (3R,4S,5S)-4-amino-5-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-3-methylpyrrolidin-2-one.

[0415] Synthesis of 1-(4-fluorophenyl)-5-iodo-1H-indole (Intermediate B1)

[0416]

[0417] Step 1: 5-Bromo-1H-indole (750.0 mg, 3.826 mmol, 1.0 eq.), 1-fluoro-4-iodo-benzene (891.7 mg, 4.017 mmol, 1.05 eq.), K3PO4 (1624.1 mg, 6.513 mmol, 2.0 eq.) and copper iodide (582.9 mg, 3.061 mmol, 0.8 eq.) were weighed into a vial, a stirring bar was added, the vial was sealed, and purged with nitrogen. Then, 1,4-dioxane (19.1 mL) and trans-N,N-dimethylcyclohexane-1,2-diamine (54,4 mg, 0.3826 mmol, 0.1 eq.) were added, and the reaction mixture was heated to 100 °C for 16 h. The reaction mixture was then cooled to ambient temperature, diluted with DCM and saturated NaHCO3 solution, and filtered through a hydrophobic frit. The organic solvent was removed and the residue was purified via silica gel chromatography to give 5-bromo-1-(4-fluorophenyl)-1H-indole in 35% yield.

[0418] Step 2:5-Bromo-1-(4-fluorophenyl)indole (2300 mg, 7.927 mmol, 1.0 eq), NaI (5941 mg, 39.6 mmol, 5.0 eq), K3PO4 (3365 mg, 15.8 mmol, 2.0 eq) and copper iodide (1207 mg, 6.3419 mmol, 0.8 eq) were weighed into a flask, a stirring bar was added, the vial was sealed, and purged with nitrogen. Then, 1,4-dioxane (58.4 mL) and trans-N,N-dimethylcyclohexane-1,2-diamine (112.8 mg, 0.793 mmol, 0.1 eq) were added, and the reaction mixture was heated to 100 ° C for one week. The reaction mixture was then cooled to ambient temperature, diluted with DCM and saturated NaHCO3 solution, and filtered through a hydrophobic frit. The organic solvent was removed and the residue was purified via silica gel chromatography to give 1580 mg of intermediate Bl (53%).

[0419] Synthesis of 5-bromo-1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine (Intermediate B2)

[0420]

[0421] Step 1: The preparation of intermediate B2 is similar to the synthesis of intermediate B4, using 5-bromo-2-fluoro-pyridine-3-carboxaldehyde instead of 6-bromo-3-fluoro-pyridine-2-carboxaldehyde. Yield: 66%

[0422] Synthesis of 5-bromo-1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine (Intermediate B3)

[0423]

[0424] Step 1: The preparation of intermediate B3 is similar to the synthesis of intermediate B4, using 2-bromo-5-fluoro-pyridine-4-carboxaldehyde instead of 6-bromo-3-fluoro-pyridine-2-carboxaldehyde. Yield: 79%

[0425] Synthesis of 5-bromo-1-(4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate B4)

[0426]

[0427] Step 1:6-bromo-3-fluoro-pyridine-2-carboxaldehyde (300.0 mg, 1.471 mmol, 1.0 equivalent) and (4-fluorophenyl) hydrazine hydrochloride (239.1 mg, 1.471 mmol, 1.0 equivalent) were dissolved in NMP (3.0 mL), and the reaction mixture was stirred for 90 minutes. Then, Cs2CO3 (1437.8 mg, 4.412 mmol, 3.0 equivalent) was added, and the reaction mixture was heated to 115 ° C for 90 minutes. The reaction mixture was then warmed to ambient temperature and diluted with EtOAc and water. The layers were separated and the aqueous phase was extracted twice with EtOAc. The combined organic layer was washed with water and brine, dried over MgSO4, and the solvent was removed under reduced pressure. The residue obtained was then purified by LC to obtain 297.0 mg (69%) of 5-bromo-1-(4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine.

[0428] Intermediate C1N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidine- Synthesis of 3-yl)cyclopropanecarboxamide.

[0429]

[0430] Step 1: Maleic anhydride (9.8g, 100mmol, 1.0 equivalent), p-thiocresol (12.4g, 100mmol, 1.0 equivalent), ammonium acetate (7.8g, 100mmol, 1.0 equivalent) and benzaldehyde (10mL, 100mmol, 1.0 equivalent) are put into a sealed tube, and 100ml toluene is added. The reaction mixture is stirred for 1h at RT, and then stirred for 16h at 150 ℃. After cooling to RT, the solvent is evaporated under reduced pressure, and the residue is alkalized with saturated NaHCO solution and extracted with DCM. The aqueous layer is acidified with 2N HCl under ice cooling, and the crude product is extracted twice with EtOAc. The combined organic layer is washed with salt water, dried over Na2SO4, filtered and concentrated to obtain crude 5-oxo-2-phenyl-3-(p-tolylthio)pyrrolidine-3-carboxylic acid (10.0g, crude product).

[0431] Step 2:Potassium carbonate (16.8g, 122.32mmol, 4.0 equivalents) and methyl iodide (7.6ml, 122.32mmol, 4.0 equivalents) are added to a stirred solution of crude 5-oxo-2-phenyl-3-(p-tolylthio) pyrrolidine-3-carboxylic acid (10.0g, 30.58mmol, 1.0 equivalents) in acetone (100mL) at 0°C, and the reaction is stirred for 16h at RT. The solvent is removed under reduced pressure, and the residue is distributed between DCM and water. The water layer is extracted twice with DCM. The combined organic layer is washed with brine, dried over Na2SO4, filtered and concentrated. The crude product is purified by column chromatography (100-200 silica gel, 50% EtOAc: hexane) to obtain 5-oxo-2-phenyl-3-(p-tolylthio) pyrrolidine-3-carboxylic acid methyl esters (4.0g, 38%), which are off-white solids.

[0432] Step 3: To 5- oxo -2- phenyl -3- (p-tolylthio) pyrrolidine -3- carboxylic acid methyl esters (4.0g, 11.73mmol, 1.0 equivalent) in EtOH: THF (100mL, 2: 1) in stirring solution, add Raney nickel (1g), and reactant mixture is stirred to 2h at RT. After completion, reactant mixture is filtered by diatomaceous earth bed, and diatomaceous earth bed is washed 2-3 times with EtOAc. The organic layer merged is concentrated, and by column chromatography (100-200 silica gel, 50% EtOAc: hexane) crude product is purified, 5- oxo -2- phenylpyrrolidine -3- carboxylic acid methyl esters (2.2g, 88%, cis: trans 1: 1 mixture) is obtained, it is off-white solid.

[0433] Step 4: 2N NaOH solution (5mL) was added to a stirred solution of 5-oxo-2-phenylpyrrolidine-3-carboxylic acid methyl ester (1.0 g, 4.56 mmol, 1.0 equivalent) in MeOH (25 mL), and the reaction mixture was stirred for 2 h at 80 ° C. After the reaction was completed (monitored by LCMS), the reaction mixture was concentrated, acidified with 2N HCl solution, and extracted with 30% isopropanol-DCM. The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain required trans-5-oxo-2-phenylpyrrolidine-3-carboxylic acid (0.8 g, 85%).

[0434] Step 5:To a stirred solution of trans-5-oxo-2-phenylpyrrolidine-3-carboxylic acid (0.5 g, 2.43 mmol, 1.0 eq.) in benzene:THF (25 mL, 4:1) was added TEA (0.68 ml, 4.87 mmol, 2.0 eq.) and DPPA (0.68 ml, 3.17 mmol, 1.3 eq.) and the reaction mixture was stirred at RT for 2 h. Benzyl alcohol (0.33 mL, 3.17 mmol, 1.3 eq.) was then added and the reaction mixture was heated to reflux for 16 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give the crude compound, which was extracted with water and EtOAc. The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (100-200 mesh silica gel; 2% MeOH-DCM; R f Value -0.5) was purified to give benzyl trans-(5-oxo-2-phenylpyrrolidin-3-yl)carbamate (0.38 g, 50%).

[0435] Step 6: To trans-(5-oxo-2-phenylpyrrolidine-3-yl) benzyl carbamate (1.7g, 5.48mmol, 1.0 equivalent) in MeOH (20mL, 2: 1) stirring solution, add Pd / C (0.058g, 0.548mmol, 0.1 equivalent), and stir the reaction 2h at RT with hydrogen balloon.After completion, filter the reaction mixture by diatomaceous earth bed, and wash diatomaceous earth bed 2-3 times with EtOAc.Concentrate the organic layer merged, obtain required trans-4-amino-5-phenylpyrrolidine-2-one, be brown jelly (0.9g, 93%).

[0436] Step 7: To a stirred solution of cyclopropanecarboxylic acid (0.59 g, 6.818 mmol, 1.2 eq) in DMF (15 mL) at 0 °C were added HATU (4.32 g, 11.363 mmol, 2.0 eq), DIPEA (5.0 mL, 28.409 mmol, 5.0 eq) and Intermediate A2 (1.00 g, 5.681 mmol, 1.0 eq), and the reaction mixture was stirred at ambient temperature for 16 h. After completion of the reaction (monitored by TLC, TLC system was 5% MeOH in DCM, Rf-0.3), the reaction mixture was diluted with EtOAc (35 mL) and washed with ice-cold water (3x25 mL), dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 4% MeOH-DCM) to give N-(trans-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (0.45 g, 32%).

[0437] Step 8: A stirred solution of N-(trans-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (0.450 g, 1.844 mmol, 1.0 eq), 1-(4-fluorophenyl)-5-iodo-1H-indazole (0.748 g, 2.213 mmol, 1.2 eq) and K3PO4 (0.781 g, 3.688 mmol, 2.0 eq) in 1,4-dioxane (30 mL) was degassed with argon for 30 min. Then, trans-N,N'-dimethylcyclohexane-1,2-diamine (0.104 g, 0.737 mmol, 0.4 eq) and CuI (0.070 g, 0.368 mmol, 0.2 eq) were added, and the reaction mixture was stirred in a sealed tube at 90°C for 16 h. After completion of the reaction (monitored by TLC, TLC system was 5% MeOH in DCM, Rf-0.4), the reaction mixture was filtered through a celite bed and the celite bed was washed 2-3 times with 1,4-dioxane. The combined organic layers were concentrated to give a crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH in DCM) to give a racemic product. The enantiomers were further separated by preparative chiral HPLC to give pure N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (0.267 g, 32%; RT = 5.56 min; column name: Chiralpak IA (250x4.6mm) 5μm, mobile phase: hexane / isopropanol / DCM / DEA: 70 / 15 / 15 / 0.1, flow rate: 1.0ml / min) and intermediate C1-enantiomer 1N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (0.254g, 30%; RT=7.13min; column name: Chiralpak IA (250x4.6mm) 5μm, mobile phase: hexane / isopropanol / DCM / DEA: 70 / 15 / 15 / 0.1, flow rate: 1.0ml / min).

[0438] Examples 1 and 2: N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo 2-(2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (Example 1) and N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indole oxazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (Example 2)

[0439]

[0440] Step 1:A stirred solution of intermediate A2 (0.35 g, 1.286 mmol, 1.0 eq.), 1-(4-fluorophenyl)-5-iodo-1H-indazole (0.520 g, 1.54 mmol, 1.2 eq.), K3PO4 (0.545 g, 2.572 mmol, 2.0 eq.) in 1,4-dioxane (20 mL) was degassed with argon for 30 minutes. Then, trans-N,N'-dimethylcyclohexane-1,2-diamine (0.073 g, 0.514 mmol, 0.4 eq.) and CuI (0.049 g, 0.257 mmol, 0.2 eq.) were added and the reaction was stirred in a sealed tube at 90°C for 16 h. After the reaction was completed (monitored by TLC, TLC system was 5% MeOH in DCM, Rf-0.4), the reaction mixture was filtered through a pad of celite, and then the pad of celite was washed 2-3 times with 1,4-dioxane. The combined organic layers were concentrated to give a crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH in DCM) to give a racemic compound, and the enantiomers were further separated via preparative chiral HPLC (column: Chiralpak IC (4.6x250 mm), 5 μm, mobile phase: hexane: ethyl acetate: EtOH: isopropylamine 70:15:15:0.1, flow rate: 1.0 mL / min) to give Example 1 (0.055 g, 9%, retention time: 4.62 minutes) and Example 2 (0.057 g, 9%, retention time 6.48 minutes).

[0441] 1 H NMR (400MHz, DMSO-d6): δ=8.46(d,1H),8.29(s,1H),7.74-7.71(m,3H),7.67(d,1H),7.46(m,1H),7.39(d,2H),7.34-7.32( m,2H),7.22(t,2H),7.14(t,2H),5.11(d,1H),4.29(t,1H),1.69-1.63(m,1H),1.21(s,3H),1.12(s,3H),0.7-0.52(m,4H).

[0442] Example 5: N-trans-(5-(1-(4-fluorophenyl)-1H-indol-5-yl)-4-oxo-6-phenyl-5-azaspiro [2.4]hept-7-yl)cyclopropanecarboxamide

[0443]

[0444] Step 1:Intermediate A5 (50.0 mg, 0.185 mmol, 1.0 eq), intermediate B1 (65.5 mg, 0.194 mmol, 1.05 eq), K3PO4 (78.5 mg, 0.370 mmol, 2.0 eq) and copper iodide (28.2 mg, 0.148 mmol, 0.8 eq) were weighed into a vial, a stirring bar was added, the vial was sealed, and purged with nitrogen. Then, 1,4-dioxane (0.9 mL) and trans-N,N'-dimethylcyclohexane-1,2-diamine (2.5 mg, 0.019 mmol, 0.1 eq) were added, and the reaction mixture was heated to 100 °C for six days. The reaction mixture was then cooled to ambient temperature, diluted with DCM and saturated NaHCO3 solution, and filtered through a hydrophobic glass frit. The organic solvent was removed, and the residue was purified via silica gel chromatography to give 4.0 mg (4%) of Example 5.

[0445] 1 H NMR(DMSO-d6)δ:8.88(d,1H),7.74–7.70(m,1H),7.62–7.54(m,3H),7.45–7.35(m,6H),7.33(dd,2H),7.27–7.19(m,1H),6.63(d ,1H),5.22(d,1H),4.01(dd,1H),1.72–1.64(m,1H),1.28–1.05(m,2H),0.97–0.89(m,2H),0.79–0.73(m,1H),0.73–0.68(m,3H).

[0446] Example 7: N-((2R,3S)-4,4-dimethyl-1-(1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)- 1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-5-methylisoxazole-3-carboxamide

[0447]

[0448] Step 1: 5-methylisoxazole-3-carboxylic acid (22.3mg, 0.175mmol, 1.5 equivalents) is dissolved in DCM (1.2mL), followed by the addition of triethylamine (0.05mL, 0.351mmol, 3.0 equivalents). Propylphosphonic anhydride solution (≥50% by weight in ethyl acetate, 0.14mL, 2.0 equivalents) is then added, and the mixture is stirred at ambient temperature for 20 minutes. Then, intermediate A4 enantiomer 1 (50.0mg, 0.117mmol, 1.0 equivalents) is added, and the mixture is stirred at ambient temperature for 48 hours. Then, saturated NaHCO3 solution and more DCM are added, and the mixture is stirred for 10 minutes. The mixture is then filtered through a hydrophobic glass frit, and then the organic solvent is removed. The crude residue is purified via silica gel chromatography to obtain 36.0mg (57%) of Example 7.

[0449] 1 H NMR(DMSO-d6)δ:9.09(d,1H),8.26(d,1H),8.17(d,1H),7.72–7.67(m,2H),7.59(d,1H),7.39(dd,1H),7.38–7.36(m,2H),7.26–7.20 (m,2H),7.18–7.12(m,1H),6.54(d,1H),6.51(d,1H),5.50(d,1H),4.47(t,1H),3.50(s,3H),2.47(d,3H),1.32(s,3H),1.17(s,3H).

[0450] Example 31: N-[rac-((6R,7S)-5-(1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)- 4-Oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl)]cyclopropanecarboxamide

[0451]

[0452] Step 1: 5-Bromo-1-(4-fluorophenyl)pyrazolo[3,4-b]pyridine (64.8 mg, 0.222 mmol, 1.2 eq), Intermediate A5 (50.0 mg, 0.185 mmol, 1.0 eq), K3PO4 (78.5 mg, 0.370 mmol, 2.0 eq), CuI (7.0 mg, 0.037 mmol, 0.2 eq) and NaI (55.4 mg, 0.370 mmol, 2.0 eq) were weighed into a microwave vial. A stirring bar was added, and the vial was sealed and purged with nitrogen. Then, 1,4-dioxane (1.0 mL) and trans-N,N'-dimethylcyclohexane-1,2-diamine (0.012 mL, 0.074 mmol, 0.4 eq) were added, and the mixture was stirred at 110 °C for 16 hours. The mixture was then cooled to ambient temperature and diluted with saturated NaHCO3 solution and DCM. The mixture was then filtered through a hydrophobic glass frit. The organic layer was evaporated under reduced pressure and the residue was purified by LC to give 42.0 mg (47%) of N-[rac-((6R, 7S)-5-(1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl)]cyclopropanecarboxamide

[0453] 1H NMR(DMSO-d6): δ=8.92–8.86(m,2H),8.44(d,1H),8.40(s,1H),8.25–8.16(m,2H),7.44–7.37(m,4H),7.35(t,2H),7.29–7.23 (m,1H),5.37(d,1H),4.13(dd,1H),1.71–1.63(m,1H),1.25(dd,1H),1.18–1.11(m,1H),1.05–0.96(m,2H),0.78–0.68(m,4H)

[0454] Example 32: N-[rac-((6R,7S)-5-(1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)- 4-Oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl)]cyclopropanecarboxamide

[0455]

[0456] The preparation of Example 32 was similar to the synthesis described for Example 31, using Intermediate B3 instead of Intermediate B2, and requiring additional HPLC purification. Yield: 35%

[0457] 1 H NMR (DMSO-d6): δ=8.99(p,1H),8.90(d,1H),8.76(q,1H),8.54(q,1H),7.88–7.81(m,2H),7.43–7.36(m,2H),7.36–7.26(m,4 H),7.23–7.17(m,1H),5.79(s,1H),3.95(dd,1H),1.72–1.64(m,1H),1.25–1.12(m,2H),1.04–0.91(m,2H),0.81–0.66(m,4H)

[0458] Example 33: N-[rac-((6R,7S)-5-(1-(4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- 4-Oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl)]cyclopropanecarboxamide

[0459]

[0460] Example 33 was prepared similarly to the synthesis described for Example 31, using Intermediate B4 instead of Intermediate B2. Yield: 32%

[0461] 1H NMR (DMSO-d6): δ=8.91(d,1H),8.62(d,1H),8.39–8.34(m,2H),7.84–7.77(m,2H),7.47–7.40(m,2H),7.40–7.34(m,2H),7.32(t,2H),7. 22(t,1H),5.80(d,1H),3.98–3.94(m,1H),1.72–1.62(m,1H),1.26–1.14(m,2H),1.05–0.96(m,2H),0.83–0.75(m,1H),0.75–0.65(m,3H)

[0462] Example 34a: N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo- 2-phenylpyrrolidin-3-yl)methanesulfonamide

[0463]

[0464] Step 1: (4S, 5R) -4-amino-1- (1- (4-fluorophenyl) -1H- indazol-5-yl) -3, 3- dimethyl -5-phenylpyrrolidin-2-one (50.0 mg, 0.121 mmol, 1.0 equiv) was weighed out into a vial under a nitrogen atmosphere, followed by the addition of DCM (1.2 mL) and triethylamine (0.067 mL, 0.483 mmol, 4.0 equiv). The mixture was then cooled to 0 ° C, and methanesulfonyl chloride (0.019 mL, 0.241 mmol, 2.0 equiv) was then added, and the mixture was stirred at this temperature for 10 minutes. The reaction mixture was then diluted with saturated NaHCO3 solution and DCM. The mixture was then filtered through a hydrophobic frit, and the organic layer was evaporated to dryness under reduced pressure. The resulting residue was purified via LC to afford 59.4 mg (76%) of N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)methanesulfonamide.

[0465] 1 H NMR(DMSO-d6): δ=8.28(d,1H),8.02(d,1H),7.76–7.69(m,3H),7.69–7.63(m,1H),7.52–7.47(m,2H),7.44–7 .35(m,3H),7.29(dd,2H),7.23–7.18(m,1H),5.07(d,1H),3.70(t,1H),2.03(s,3H),1.26(s,3H),1.14(s,3H)

[0466] The examples in the following table were synthesized similarly to Example 34a above using different intermediates.

[0467] Individual reaction times vary.

[0468]

[0469]

[0470]

[0471]

[0472] Examples 95 and 96 (2-(((2R,3R,4S)-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo 2-((2R,3R)-4,4-difluoro- 1-(1-(4-Fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (Example 96)

[0473]

[0474] Step 1: Under inert atmosphere, in a dry container, intermediate C1-enantiomer 1 (150 mg, 0.33 mmol) was dissolved in anhydrous THF (3.3 ml). The solution was cooled to -78 °C and a solution of LDA (1 M in THF / heptane / ethylbenzene, 1.32 ml, 4.0 eq.) was added dropwise. After stirring at -78 °C for 15 min, N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (NFSI, 229 mg, 0.726 mmol, 2.2 eq.) dissolved in anhydrous THF (1.7 mL) was added dropwise. The mixture was stirred at -78 °C for two hours before subsequently adding additional amounts of LDA (330 μl, 1 eq.) and NFSI (100 mg, 1 eq.). After stirring at -78 °C for another 30 min, the reaction was quenched with saturated NH4Cl solution and ethyl acetate was added after stirring for 5 min. The layers were separated, the organic layer was dried over sodium sulfate, and the solvent was removed in vacuo. The crude material was purified by flash chromatography (silica, cyclohexane / ethyl acetate gradient as eluent) and subsequent preparative HPLC (water / acetonitrile gradient) to afford Example 95 (25.5 mg, 0.054 mmol, 16%) and Example 96 (3.0 mg, 0.006 mmol, 2%) as white solids.

[0475] Embodiment 95: 1 H NMR(chloroform-d3)δ:8.07(d,1H),7.76(dd,0.7Hz,1H),7.67–7.50(m,2H),7.58–7.45(m,1H),7.39(dd,1H),7 .41–7.06(m,6H),6.31(d,1H),5.86(dd,1H),5.54(dd,1H),3.98(dq,1H),1.44(tt,1H),0.86(dtd,2H).

[0476] Embodiment 96:1 H NMR (CHLOROFORM-d3) δ: 8.10 (s, 1H), 7.52 (d, 1H), 7.41 (dd, 1H), 7.43–7.19 (m, 5H), 7.28–7.11 (m, 2H), 6.42 (s, 1H), 5.14 (d, 1H), 4.88 (dddd, 1H), 1.51 (tq, 1H), 1.05 (tq, 1H), 0.96–0.74 (m, 2H).

[0477] Example 100: 2,2-difluoro-N-(trans-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxazol- (2-phenylpyrrolidin-3-yl)propanamide

[0478]

[0479] Step 1: To a stirred solution of intermediate A6 (1 g, 3.08 mmol, 1.0 equiv) in methanol (30 mL) was added Pd—C (820 g, 10% water) and the reaction was stirred with a hydrogen balloon at RT for 2 h. After completion (monitored by TLC, TLC system was 5% MeOH in DCM, R f -0.2), the reaction mixture was filtered through a celite bed and washed 2-3 times with MeOH. The filtrate was concentrated to give the desired trans-4-amino-5-methyl-5-phenylpyrrolidin-2-one as an off-white solid (0.693 g, 94%).

[0480] Step 2: To a stirred solution of 2,2-difluoropropionic acid (0.304 g, 2.759 mmol, 1.5 eq) in DMF (10 mL) was added DIPEA (1.6 mL 9.14 mmol, 5.0 eq), HATU (1.4 g, 3.678 mmol, 2.0 eq) and trans-4-amino-5-methyl-5-phenylpyrrolidin-2-one (350 mg, 1.839 mmol, 1 eq) under ice-cold conditions and the reaction was stirred at RT for 16 h. After completion of the reaction (monitored by TLC, TLC system was 5% MeOH in DCM, R f -0.3), the reaction mixture was diluted with EtOAc (20 mL), washed with ice-cold water (3×25 mL), dried over Na 2 SO 4 and concentrated to give the crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH-DCM) to give 2,2-difluoro-N-(trans-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)propanamide (0.350 g, 67%).

[0481] Step 3:A stirred solution of 2,2-difluoro-N-(trans-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)propanamide (0.250 g, 0.885 mmol, 1 eq.), 1-(4-fluorophenyl)-5-iodo-1H-indazole (0.359 g, 1.0627 mmol, 1.2 eq.), K3PO4 (0.376 g, 1.770 mmol, 2 eq.) in 1,4-dioxane (10 mL) was degassed with argon for 30 min. N,N'-dimethylethylenediamine (0.032 g, 0.354 mmol, 0.4 eq.) and CuI (0.033 g, 0.177 mmol, 0.2 eq.) were added and the reaction mixture was stirred at 90 °C in a sealed tube for 72 h. After completion of the reaction (monitored by TLC, TLC system was 5% MeOH in DCM, R f -0.4), the reaction mixture was filtered through a celite bed and washed 2-3 times with dioxane. The combined organic layers were concentrated to give the crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH in DCM) to give 2,2-difluoro-N-(trans-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)propanamide (0.046 g, 11%) as an off-white solid.

[0482] 1 H NMR(400MHz, DMSO-d6)δ9.49(d,J=8.84Hz,1H),8.32(s,1H),7.78-7.73(m,3H),7.49-7.30(m,9H ),4.53-4.49(m,1H),3.00-2.93(m,1H),2.47-2.42(m,1H),1.78(t,J=19.52Hz,3H),1.44(s,3H).

[0483] Example 101: N-(trans-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxo-2-phenyl Pyrrolidin-3-yl)cyclopropanecarboxamide

[0484]

[0485] Step 1: To a stirred solution of trans-4-amino-5-methyl-5-phenylpyrrolidin-2-one (350 mg, 1.84 mmol, 1 eq.) in DMF (10 mL) was added TEA (1.2 mL, 9.14 mmol, 5.0 eq.), cyclopropanecarbonyl chloride (288 mg, 2.76 mmol, 1.5 eq.) under ice-cold conditions, and the reaction mixture was stirred at RT for 2 h. After completion of the reaction (monitored by TLC, TLC system was 5% MeOH in DCM, R f-0.3), the reaction mixture was diluted with EtOAc (50 mL), washed with ice-cold water (3×25 mL), dried over Na 2 SO 4 and concentrated to give the crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH-DCM) to give N-(trans-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (350 mg, 74%).

[0486] Step 2: A stirred solution of N-(trans-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (0.250 g, 0.967 mmol, 1 eq.), 1-(4-fluorophenyl)-5-iodo-1H-indazole (0.393 g, 1.16 mmol, 1.2 eq.), K3PO4 (0.410 g, 1.93 mmol, 2 eq.) in 1,4-dioxane (10 mL) was degassed with argon for 30 min. N,N'-dimethylethylenediamine (0.034 g, 0.387 mmol, 0.4 eq.) and CuI (0.037 g, 0.193 mmol, 0.2 eq.) were added and the reaction mixture was stirred at 90 °C in a sealed tube for 72 h. After completion of the reaction (monitored by TLC, TLC system was 5% MeOH in DCM, R f -0.4), the reaction mixture was filtered through a celite bed and washed 2-3 times with dioxane. The combined organic layers were concentrated to give the crude product, which was purified by column chromatography (230-400 mesh silica gel; 0 to 2% MeOH in DCM) to give N-(trans-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (0.046 g, 10%) as an off-white solid.

[0487] 1 H NMR(400MHz, DMSO-d6)δ8.81(d,J=8.88Hz,1H),8.35(s,1H),7.79-7.74(m,3H),7.52(s,1H),7.48-7.32(m,8H), 4.50-4.45(m,1H),2.91-2.85(m,1H),2.30-2.26(m,1H),1.66-1.63(m,1H),1.44(s,3H),0.69(d,J=6.2Hz,4H).

[0488] Example 121 N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-1-(1-(4-fluorophenyl)-1H-indazole-5-yl)- yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide.

[0489]

[0490] Step 1:Synthesis of 3-cyclopropyl-2-(nitromethyl) methyl propionate.At -78 ℃, add LDA (2M in THF, 112.7ml, 225.5mmol) to the stirred solution of 3-nitropropionic acid methyl ester (15g, 112.74mmol) in THF (105ml), and the resulting solution is stirred for 1h at the same temperature.At -78 ℃, add (bromomethyl) cyclopropane (21.28ml, 225.5mmol).Make the reaction mixture reach rt gradually, and continue to stir for 16h.The reaction mixture is quenched with NH4Cl aqueous solution at 0 ℃.Separate each layer, and extract the water-containing part with ethyl acetate (600ml x 3).The organic layer merged is washed with brine (300ml), through Na2SO4, dried and concentrated. The crude product was purified by column chromatography using 100-200 mesh silica gel, 6-8% ethyl acetate-hexanes as eluent to give 3-cyclopropyl-2-(nitromethyl)propanoate as a brown oil.

[0491] Step 2: Synthesis of rac-(3S,4S,5R)-3-(cyclopropylmethyl)-1-(4-methoxybenzyl)-4-nitro-5-phenylpyrrolidin-2-one. To a stirred solution of benzaldehyde (6.07ml, 60.09mmol) in toluene (112.5ml) was added 4-methoxybenzylamine (8.24g, 60.09mmol) at rt and stirred for 2h. 3-Cyclopropyl-2-(nitromethyl)methyl propionate (7.5g, 40.06mmol) was added to the reaction mixture, followed by benzoic acid (7.34g, 60.09mmol) and the resulting mixture was stirred at 70°C for 7-8h. After the reaction was complete (monitored by LCMS), the mixture was diluted with ethyl acetate (300ml) and washed with water (200ml), followed by saturated NaHCO (100ml x 2). The organic layer was dried over anhydrous NaSO and concentrated. The crude product was purified by column chromatography (using 100-200 mesh silica gel; 12-15% ethyl acetate in hexanes as eluent) to give 4rac-(3S,4S,5R)-3-(cyclopropylmethyl)-1-(4-methoxybenzyl)-4-nitro-5-phenylpyrrolidin-2-one (7.5 g, 49.1%) as a brown oil.

[0492] Step 3:rac-(3S,4S,5R)-3-(cyclopropylmethyl)-4-nitro-5-phenylpyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-3-(cyclopropylmethyl)-1-(4-methoxybenzyl)-4-nitro-5-phenylpyrrolidin-2-one (6 g, 15.77 mmol) in acetonitrile (120 ml) was added dropwise a solution of CAN (25.93 g, 47.31 mmol) in water (120 ml) at 0°C. The reaction mixture was slowly warmed to 10-15°C and stirring was continued for 3-4 h. After completion of the reaction (monitored by TLC, 30% ethyl acetate / hexane, Rf 0.3), the mixture was diluted with ethyl acetate (400 ml) and washed with water (200 ml) followed by brine (200 ml). The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by column chromatography (using 100-200 mesh silica gel; 25-30% ethyl acetate in hexanes as eluent) to give rac-(3S,4S,5R)-3-(cyclopropylmethyl)-4-nitro-5-phenylpyrrolidin-2-one (3.51 g, 85.6%) as a colorless oil.

[0493] Step 4: Rac-(3S,4S,5R)-4-amino-3-(cyclopropylmethyl)-5-phenylpyrrolidin-2-one. To a stirred solution of rac-(3S,4S,5R)-3-(cyclopropylmethyl)-4-nitro-5-phenylpyrrolidin-2-one (4 g, 15.36 mmol) in ethyl acetate-methanol (360 ml, 2:1) was added 6N HCl aqueous solution (118 ml) at 0 °C. Zinc powder (60.29 g, 922.04 mmol) was added in portions at the same temperature. The resulting suspension was stirred at room temperature for 16 h. After the reaction was completed (monitored by LCMS), it was quenched with saturated NaHCO3 solution at 0 °C, stirred for 1 h, filtered through celite, and washed with ethyl acetate-methanol (500 ml, 2:1). The filtrate was concentrated to give rac-(3S,4S,5R)-4-amino-3-(cyclopropylmethyl)-5-phenylpyrrolidin-2-one (3.53 g crude, deemed 100% yield) as an off-white solid which was used in the next step without further purification.

[0494] step5: Synthesis of tert-butyl (rac-(2R,3S,4S)-4-(cyclopropylmethyl)-5-oxo-2-phenylpyrrolidin-3-yl)carbamate. To a stirred suspension of rac-(3S,4S,5R)-4-amino-3-(cyclopropylmethyl)-5-phenylpyrrolidin-2-one (3.53 g crude, 15.34 mmol) in THF-water (1:1, 400 ml) was added sodium bicarbonate (3.86 g, 46.04 mmol) at 0°C, and the resulting mixture was stirred at the same temperature for 30 minutes. Di-tert-butyl dicarbonate (10.6 ml, 46.04 mmol) was added to the reaction mixture at 0°C, and stirring was continued for 16 h at rt. After the reaction was complete (monitored by LCMS), the mixture was diluted with water (200 ml) and extracted with ethyl acetate (3x300 ml). The combined organic layers were washed with water (300 ml) followed by brine (300 ml). After drying over Na2SO4 and concentration, the crude material was purified by column chromatography (using 100-200 mesh silica gel; 1.5-2% MeOH in DCM as eluent) to give (rac-(2R,3S,4S)-4-(cyclopropylmethyl)-5-oxo-2-phenylpyrrolidin-3-yl)carbamate (3.52 g, 69.5%) as an off-white solid.

[0495] Step 6: Synthesis of rac-(3S,4S,5R)-4-amino-3-(cyclopropylmethyl)-5-phenylpyrrolidin-2-one hydrochloride. To a stirred suspension of (rac-(2R,3S,4S)-4-(cyclopropylmethyl)-5-oxo-2-phenylpyrrolidin-3-yl)carbamate (2 g, 6.05 mmol) in 1,4-dioxane (10 ml) was added 4N HCl in 1,4-dioxane at 0°C and stirring was continued for 16 h at rt. After completion of the reaction (monitored by LCMS), the mixture was concentrated and triturated with ether to give rac-(3S,4S,5R)-4-amino-3-(cyclopropylmethyl)-5-phenylpyrrolidin-2-one hydrochloride (1.62 g, crude) as an off-white solid.

[0496] Step 7:Synthesis of N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide. To a stirred solution of 4-amino-3-(cyclopropylmethyl)-5-phenylpyrrolidin-2-one hydrochloride (7) (1.62 g, 6.06 mmol) in DCM (30 ml) was added Et3N (2.54 ml, 18.21 mmol) at 0°C and the resulting mixture was stirred at the same temperature for 20 minutes. A solution of cyclopropanecarbonyl chloride (0.56 ml, 6.06 mmol) in DCM (5 ml) was added and stirring was continued at 0°C-10°C for 3 h. After complete consumption of starting material (monitored by LCMS), the reaction was diluted with H2O and the precipitate formed was filtered and washed with cold water followed by pentane-ether to give N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (1.41 g, 78%) as an off-white solid.

[0497] Step 8 : CN-coupling was carried out analogously to the procedure described for Example 7, Step 1, using N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide. Yield 53%.

[0498] 1 H NMR(DMSO-d6)δ:8.59(d,1H),8.29(s,1H),7.79(d,1H),7.77–7.70(m,2H),7.68(d,1H),7.51(dd,1H),7.4 3–7.36(m,2H),7.32(d,2H),7.25(t,2H),7.19–7.13(m,1H),5.21(d,1H),4.33(q,1H),2.83(dt,1H),1.67 1.59(m,2H),1.57(ddd,1H),0.90(ddt,1H),0.73–0.60(m,4H),0.50–0.32(m,2H),0.18–0.01(m,2H)

[0499] Example 127: N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide, Diastereomer 2; and

[0500] Example 130: N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide, Diastereomer 1

[0501]

[0502] Under inert atmosphere, in a dry container, intermediate C1-enantiomer 1 (150 mg, 0.33 mmol) was dissolved in anhydrous THF (3.3 ml). The solution was cooled to -78 °C and a fresh solution of LDA (1 M in THF, 0.825 ml, 2.5 eq) was added dropwise. After stirring at -78 °C for 15 min, (2-iodoethyl)benzene (99.6 mg, 0.429 mmol, 1.3 eq) dissolved in anhydrous THF (1.7 mL) was added dropwise. The mixture was warmed to -20 °C overnight and cooled to -60 °C again before adding additional (2-iodoethyl)benzene (99.6 mg, 0.429 mmol, 1.3 eq) and LDA (1 M in THF, 0.682 ml, 2.0 eq). After stirring at -60 ° C. for 90 minutes, a third amount of (2-iodoethyl)benzene (99.6 mg, 0.429 mmol, 1.3 eq.) was added, followed by LDA (1 M in THF, 0.34 ml, 1.0 eq.). The mixture was stirred again at -20 ° C. overnight and quenched at this temperature with saturated NH4Cl solution, after which the mixture was diluted with ethyl acetate. The crude material was purified via flash chromatography (silica, cyclohexane / ethyl acetate gradient as eluent) and subsequent preparative HPLC (water / acetonitrile gradient) to afford Example 127 (N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide second eluting diastereomer, 6 mg, 0.011 mmol, 3%) and Example 130 (N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide first eluting diastereomer, 12.0 mg, 0.021 mmol, 6%) as white solids.

[0503] Embodiment 127: 11H NMR (DMSO-d6) δ: 8.94 (d, 1H), 8.35–8.28 (m, 1H), 8.01 (d, 1H), 7.83 (dd, 1H), 7.80–7.63 (m, 3H), 7.44–7.23 (m, 9H), 7.26–7.16 (m, 1H), 7.19–7.13 (m, 2H), 7.15–7.03 (m, 1H), 5.26 (d, 1H), 4.52 (ddd, 1H), 2.93 (tdd, 1H), 2.65–2.52 (m, 2H), 1.85–1.68 (m, 2H), 1.24 (s, 1H), 1.18 (s, 1H), 0.90–0.69 (m, 3H).

[0504] Example 128: 1 1H NMR (DMSO-d6) δ: 8.66 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 1.3 Hz, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.74 (ddd, 2H), 7.68 (d, 1H), 7.54 7.48 (m, 1H), 7.43 7.36 (m, 2H), 7.36 7.28 (m, 4H), 7.26 (t, 2H), 7.237.14 (m, 4H), 5.21 (d, 1H), 4.22 (td, 1H), 2.76 (t, 2H), 2.70 (td, 1H), 2.182.06 (m, 2H), 1.88 (dq, 1H), 1.58 (tt, 1H), 0.77 0.62 (m, 4H).

[0505] Example 128 N-(rac-(2R,3R,4R)-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl- 5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide and Example 129 N-((2R,3R,4S)-4-fluoro-1-(1-(4-fluoro phenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0506]

[0507] Step 1: In a 250ml round-bottomed flask under a nitrogen atmosphere, a solution of intermediate A8 (2370mg, 7.31mmol) in acetonitrile (120ml) was added to sodium iodide (6570mg, 43.8mmol, 6 equivalents). Trimethylsilyl chloride (3.71ml, 29.2mmol 4.0 equivalents) was added dropwise to the resulting mixture. After stirring overnight at room temperature, the reaction mixture was added dropwise to ethanol (142ml) and filtered through diatomite. The filtrate was loaded onto a strong cation exchange column (SCX, 5g), rinsed twice with ethanol (15ml each time), and eluted with 2M NH3 (2x10mL) in methanol. The fraction containing the product was used to repeat this procedure twice. The clean fractions were combined and the solvent removed in vacuo to give rac-(3S,4S,5R)-4-amino-3-methyl-5-phenylpyrrolidin-2-one (296 mg, 1.56 mmol, 21%) as a colorless resin.

[0508] Step 2: Rac-(3S,4S,5R)-4-amino-3-methyl-5-phenylpyrrolidin-2-one (328 mg, 1.72 mmol) and cyclopropanecarboxylic acid (297 mg, 3.45 mmol, 2.0 equiv) were dissolved in dichloromethane (17.2 ml) at room temperature. Triethylamine (689 mg, 6.90 mmol, 4.0 equiv) was added dropwise to the mixture and the mixture was stirred until all the starting materials were dissolved. Propylphosphonic anhydride solution (≥50 wt % in ethyl acetate, 2.57 ml, 4.31 mmol, 2.5 equiv) was added to the reaction and stirring was continued at rt. After 3 h, the reaction control system (UPLC) showed complete consumption of the starting materials and the reaction was quenched with 1 M Na2CO3 solution. After stirring for one hour, the product precipitated and was filtered off to give N-(rac-(2R,3S,4S)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (264 mg, 1.02 mmol, 59%) as a white solid. The obtained material was used in the next step without further purification.

[0509] step3: To a suspension of N-(rac-(2R,3S,4S)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (263 mg, 1.02 mmol), triethylamine (206 mg, 2.04 mmol, 2.0 eq.) and 4-dimethylaminopyridine (12.4 mg, 0.102 mmol, 0.1 eq.) in acetonitrile (10 ml) in a sealed tube was added a solution of di-tert-butyl dicarbonate (244 mg, 1.12 mmol, 1.1 eq.) in acetonitrile (2 ml). The reaction mixture was heated to 80° C. for 30 minutes and stirred at room temperature overnight. Additional di-tert-butyl dicarbonate (133 mg, 0.611 mmol, 0.6 eq.) in acetonitrile (2 ml) was added and stirring was continued at room temperature until the reaction control system (UPLC) demonstrated that the reaction was complete (2 h). Dichloromethane and saturated NaHCO3 solution were added to the reaction, the layers were separated, and the aqueous layer was extracted once with dichloromethane. The combined organic layers were dried over magnesium sulfate, and the solvent was removed in vacuo. The crude material was purified by flash chromatography (12 g silica, cyclohexane / ethyl acetate gradient as eluent) to give rac-(3S,4S,5R)-4-(cyclopropanecarbonylamino)-3-methyl-2-oxo-5-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester (234 mg, 0.653 mmol, 64%) as a white solid.

[0510] step4: Under inert atmosphere, in a dry container, rac-(3S,4S,5R)-4-(cyclopropanecarbonylamino)-3-methyl-2-oxo-5-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester (80 mg, 0.223 mmol) was dissolved in anhydrous THF (2.2 ml). The solution was cooled to -78 ° C, and a solution of lithium bis(trimethylsilyl)amide (1 M in THF, 0.446 ml, 0,446 mmol, 2.0 equiv) was carefully added. After stirring at -78 ° C for 15 minutes, a solution of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (70.4 mg, 0.223 mmol, 1.0 equiv) in THF (1 mL) was added dropwise. After stirring at this temperature for 45 minutes, another amount of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (35.0 mg, 0.111 mmol, 0.5 equivalent) in THF (0.5 mL) was added and stirring was continued for 30 minutes. The reaction was quenched with saturated NH4Cl solution at -78 ° C, diluted with DCM, and quickly poured onto a hydrophobic glass frit before the mixture could warm. The organic layer was washed with water and separated again. The crude product was purified via flash chromatography (12 g silica, cyclohexane / ethyl acetate gradient as eluent) to obtain (4R, 5R)-4-(cyclopropanecarboxamido)-3-fluoro-3-methyl-2-oxo-5-phenylpyrrolidine-1-carboxylic acid tert-butyl ester (47 mg, 0.125 mmol, 56%), which is a mixture of diastereomers (3: 1).

[0511] step 5: To a solution of (4R,5R)-4-(cyclopropanecarboxamido)-3-fluoro-3-methyl-2-oxo-5-phenylpyrrolidine-1-carboxylic acid tert-butyl ester (46.0 mg, 0.122 mmol) in dichloromethane (1.22 ml) was added trifluoroacetic acid (0.094 ml, 1.22 mmol, 10.0 equiv) at room temperature. After stirring for 30 minutes, the reaction control system (UPLC) proved that the reaction was complete, and the mixture was quenched with saturated NaHCO3 solution. DCM was added to the mixture and the layers were separated with the aid of a hydrophobic frit. The organic layer was evaporated to give N-((2R,3R)-4-fluoro-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (27 mg, 0.098 mmol, 80%) as a brown oil, which was used without further purification.

[0512] Step 6: In a sealed tube, N-((2R,3R)-4-fluoro-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (27.0 mg, 0.098 mmol), 1-(4-fluorophenyl)-5-iodo-indazole (36.3 mg, 0.107 mmol, 1.1 eq), K3PO4 (41.5 mg, 0.195 mmol, 2.0 eq) and CuI (3.7 mg, 0.020 mmol, 0.2 eq) were dissolved in degassed 1,4-dioxane (1 ml). To the mixture was added (1R,2R)-N,N'-dimethyl-1,2-cyclohexanediamine (5.6 mg, 0.039 mmol, 0.4 eq) and the reaction was heated to 100 °C overnight and to 120 °C for 5 h. The reaction was quenched with saturated NaHCO3 solution and diluted with dichloromethane. The layers were separated with the aid of a hydrophobic frit and the aqueous layer was washed several times with DCM. The organic layers were combined and the solvent was evaporated. The crude material was purified via flash chromatography (silica, cyclohexane / ethyl acetate gradient as eluent) and subsequent preparative HPLC (water / acetonitrile gradient) to afford Example 128 N-((2R,3R,4R)-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (1.8 mg, 0.003 mmol, 4%) and Example 129 N-((2R,3R,4S)-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (5.8 mg, 0.012 mmol, 12%).

[0513] Embodiment 128: 1 H NMR(DMSO-d6)δ:8.11(d,1H),7.78(dd,1H),7.67–7.59(m,2H),7.56(dt,1H),7.48(dd,1H),7.39–7.19(m,6H),7.26–7.16(m,1 H),6.29–6.20(m,1H),5.15(d,1H),4.66(ddd,1H),1.69(d,3H),1.47(tt,1H),1.01(dddd,1H),0.95–0.90(m,1H),0.82(m,2H).

[0514] Embodiment 129: 1H NMR(DMSO-d6)δ:8.69(dd,1H),8.33(d,1H),7.87(d,1H),7.82–7.67(m,3H),7.51(dd,1H),7.45–7.30(m,4H),7.26( t,2H),7.22–7.13(m,1H),5.12(dd,1H),4.68(ddd,1H),1.66(tt,1H),1.54(d,3H),0.77–0.65(m,3H),0.58(dtd,1H)

[0515] Example 131 N-((2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazole-5-yl)- yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide and Example 132 N-((2R,3S,4R)-4-(2,2-difluoro ethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0516]

[0517] Under inert atmosphere, in a dry container, intermediate C1-enantiomer 1 (150 mg, 0.33 mmol) was dissolved in anhydrous THF (3.3 ml). The solution was cooled to -78 °C and a fresh solution of LDA (1 M in THF, 0.825 ml, 2.5 eq.) was added dropwise. After stirring at -78 °C for 15 min, 1,1-difluoro-2-iodo-ethane (82.4 mg, 0.429 mmol, 1.3 eq.) dissolved in anhydrous THF (1.7 mL) was added dropwise. The mixture was warmed to -40 °C and stirred at this temperature overnight. Another amount of 1,1-difluoro-2-iodo-ethane (82.4 mg, 0.429 mmol, 1.3 eq.) was added and the mixture was warmed to -20 °C. At this temperature, saturated NH4Cl solution was added and stirring was continued, after which the mixture was diluted with ethyl acetate. After separation of the layers, the organics were dried over sodium sulfate and the solvent removed in vacuo. The crude material was purified by flash chromatography (12 g silica, cyclohexane / ethyl acetate gradient as eluent) to afford Example 131 N-((2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (9.0 mg, 0.017 mmol, 5%) and Example 132 N-((2R,3S,4R)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (7.0 mg, 0.014 mmol, 4%) as white solids.

[0518] Embodiment 131: 11H NMR (DMSO-d6) δ: 8.30 (d, J = 1.0 Hz, 1H), 7.85–7.64 (m, 3H), 7.68 (d, 1H), 7.56–7.21 (m, 6H), 7.36–7.07 (m, 3H), 5.24 (d, 1H), 4.25 (q, 1H), 2.97 (q, 1H), 2.54–2.34 (m, 1H), 1.25 (s, 2H), 0.81–0.52 (m, 3H).

[0519] Example 132: 1 1H NMR (DMSO-d6) δ: 8.95 (d, 1H), 8.33 (s, 1H), 8.02 (d, 1H), 7.85 (dd, J = 9.2, 2.1 Hz, 1H), 7.87–7.67 (m, 3H), 7.51–7.19 (m, 7H), 5.28 (s, 1H), 4.42 (t, 1H), 3.22–3.02 (m, 1H), 2.25–2.02 (m, 1H), 1.24 (s, 2H), 0.96–0.63 (m, 4H).

[0520] Example 134 N-(rac-(2R,3S,4R)-4-ethyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl 5-(5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0521]

[0522] Step 1: Under an inert atmosphere, Example 46 (50 mg, 0.107 mmol) was dissolved in anhydrous THF (1.1 ml) in a dry container. The solution was cooled to -78 ° C, and a solution of freshly prepared LDA (1M in THF, 0.267 ml, 2.5 eq) was added dropwise. After stirring at -78 ° C for 15 minutes, iodoethane (25.0 mg, 0.160 mmol, 1.5 eq) dissolved in anhydrous THF (0.5 mL) was added dropwise. The mixture was warmed to -60 ° C and stirred at this temperature for 90 minutes. Then, the reaction was cooled to -78 ° C again, and another amount of iodoethane (12.5 mg, 0.080 mmol, 0.75 eq) dissolved in anhydrous THF (0.5 ml) was added. After stirring at -78 ° C for 1 h, the reaction was quenched with saturated NH4Cl solution and diluted with dichloromethane after stirring for 5 minutes. The layers were separated with the aid of a hydrophobic frit. The organic layer was washed with water, separated again and dried over sodium sulfate. After removal of the solvent, the crude material was purified by flash chromatography (silica, cyclohexane / ethyl acetate gradient as eluent) and subsequent preparative HPLC (water / acetonitrile gradient) to afford Example 134 N-(rac-(2R,3S,4R)-4-ethyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (6 mg, 0.012 mmol, 11%) as a colorless resin.

[0523] 1 H NMR(DMSO-d6)δ8.47(d,1H),8.30(d,1H),7.77–7.71(m,3H),7.68(d,1H),7.46(dd,1H),7.39(dd,2H),7.36–7.33(m,2H),7.24(t,2H),7.15(td ,1H),5.15(d,1H),4.33(t,1H),1.72–1.63(m,2H),1.54(dq,1H),1.24( s,3H),0.95(d,2H),0.73–0.67(m,1H),0.63(qt,2H),0.59–0.50(m,1H).

[0524] Example 135 N-((7R,8S)-6-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-7-phenyl-6-nitrogen Heterospiro[3.4]octan-8-yl)cyclopropanecarboxamide

[0525]

[0526] Under an inert atmosphere, in a dry container, intermediate C1-enantiomer 1 (150 mg, 0.33 mmol) was dissolved in anhydrous THF (3.3 ml). The solution was cooled to -78 °C and a fresh solution of LDA (1 M in THF, 0.825 ml, 2.5 eq) was added dropwise. After stirring at -78 °C for 15 min, 1,3-dibromopropane (93.3 mg, 0.462 mmol, 1.3 eq) dissolved in anhydrous THF (1.7 mL) was added dropwise. The mixture was warmed to room temperature overnight. The mixture was cooled to -20 °C again before adding additional amounts of LDA (1 M in THF, 0.330 ml, 1.0 eq) and 1,3-dibromopropane (71.8 mg, 0.355 mmol, 1.0 eq). After stirring for 15 minutes, another amount of LDA (1 M in THF, 0.495 ml, 1.5 equiv) was added. The mixture was warmed to room temperature again overnight and quenched with saturated NH4Cl solution. Stirring was continued for 5 minutes before diluting the mixture with ethyl acetate. After separation of the layers, the organics were dried over sodium sulfate and the solvent was removed in vacuo. The crude material was purified by flash chromatography (12 g silica, cyclohexane / ethyl acetate gradient as eluent) to give Example 135 N-((7R,8S)-6-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-7-phenyl-6-azaspiro[3.4]octan-8-yl)cyclopropanecarboxamide (11 mg, 0.022 mmol, 7%) as a colorless resin.

[0527] 1 H NMR(DMSO-d6)δ:8.09(d,1H),7.99(dd,1H),7.81(dd,1H),7.63(ddd,2H),7.56(dt,1H), 7.43–7.39(m,2H),7.35–7.30(m,3H),7.28–7.24(m,1H),7.24–7.20(m,2H),6.03(d,1H).

[0528] Example 137 N-(rac-(2R,3R,4S)-4-benzyl-2-ethyl-4-fluoro-1-(1-(4-fluorophenyl)-1H-indole oxazol-5-yl)-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide

[0529]

[0530] Step 1: Example 106 (70 mg, 0.141 mmol) was dissolved in anhydrous THF (1.4 ml) in a dry container under inert atmosphere. The solution was cooled to -78 °C and a solution of freshly prepared LDA (1 M in THF, 0.352 ml, 2.5 eq) was added dropwise. After stirring at -78 °C for 15 min, N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (NFSI, 66.7 mg, 0.211 mmol, 1.5 eq) dissolved in anhydrous THF (0.7 mL) was added dropwise. The mixture was stirred at -78 °C for 15 min and quenched with saturated NH4Cl solution. After stirring for 5 min, the mixture was diluted with ethyl acetate and the layers were separated. After removal of the solvent, the crude material was purified by flash chromatography (silica, cyclohexane / ethyl acetate gradient as eluent) to afford Example 137 N-(rac-(2R,3R,4S)-4-benzyl-2-ethyl-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide (4 mg, 0.008 mmol, 6%) as a colorless oil.

[0531] 1 H NMR(chloroform-d3)δ:8.19(d,1H),7.67(dd,,3H),7.57(d,,1H),7.39–7.34(m,3H),7.32 (dd,2H),7.28–7.25(m,2H),7.22(dd,1H),6.01(t,1H),4.97–4.86(m,1H),3.51– 3.42(m,1H),3.34(dd,1H),3.17–3.08(m,1H),1.54(qd,2H),1.42(tt,1H),1.15– 1.09(m,1H),1.10–1.05(m,1H),0.94–0.88(m,1H),0.85(dddd,1H),0.75(t,3H).

[0532] Example 138 N-((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((3-methyl-1,2, 4-oxadiazol-5-yl)methyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0533]

[0534] The preparation of Example 138 was similar to the synthesis described for Example 131, using 5-(bromomethyl)-3-methyl-1,2,4-oxadiazole instead of 1,1-difluoro-2-iodo-ethane. Yield: 9%

[0535] 1H NMR(DMSO-d6)δ:8.55(d,1H),8.29(d,1H),7.77-7.70(m,3H),7.70-7.64(m,1H),7.47-7.36(m,5H),7.24(t,2H) ,7.17-7.10(m,1H),5.27(d,1H),4.41(q,1H),3.46-3.36(m,1H),2.35(s,3H),1.50(tt,1H),0.71-0.50(m,4H).

[0536] Example 139a N-((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((1-methyl-1H- pyrazol-4-yl)methyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide and Example 139b N-((2R,3S, 4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((1-methyl-1H-pyrazol-4-yl)methyl)-5-oxo-2-phenyl Pyrrolidin-3-yl)cyclopropanecarboxamide

[0537]

[0538] Examples 139a and 139b were prepared analogously to the syntheses described for Examples 131 and 132, using 5.0 equivalents of LDA and 4-(bromomethyl)-1-methyl-1H-pyrazole hydrobromide instead of 1,1-difluoro-2-iodo-ethane. Yields: 7% (139a) and 6% (139b).

[0539] Example 139a 1 H NMR(chloroform-d3)δ:8.06(d,1H),7.68(d,1H),7.61-7.54(m,2H),7.51-7.43(m,2H),7.37(dd,1H),7.29(d,1H),7.25-7.13(m,5H),7.07-7. 00(m,2H),6.13(d,1H),5.13(d,1H),4.23(dt,1H),3.87(s,3H),3.08-2.98(m,3H),1.38(tt,1H),1.05-0.93(m,2H),0.79(ddddd,2H).

[0540] Example 139b 1H NMR(chloroform-d3)δ:8.07(d,1H),7.95(d,1H),7.69(dd,1H),7.64-7.58(m,2H),7 .51(d,1H),7.42-7.33(m,5H),7.32-7.27(m,1H),7.26(s,1H),7.25-7.19( m,2H),6.58(d,1H),5.17(s,1H),4.58(t,1H),3.84(s,3H),3.21-3.11(m,2 H),2.92-2.83(m,1H),1.50(tt,1H),1.16-1.07(m,2H),0.94-0.81(m,2H).

[0541] Example 148 N-(rac-(2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazole- 5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0542]

[0543] Step 1: Under an inert atmosphere, in a dry container, Example 46 (71 mg, 0.152 mmol) was dissolved in anhydrous THF (1.5 ml). The solution was cooled to -78 °C and a solution of freshly prepared LDA (1 M in THF, 0.379 ml, 2.5 eq) was added dropwise. After stirring at -78 °C for 15 minutes, 1,1-difluoro-2-iodo-ethane (43.6 mg, 0.160 mmol, 1.5 eq) dissolved in anhydrous THF (0.75 mL) was added dropwise. The mixture was warmed to -50 °C and stirred at this temperature for 45 minutes. Then, another amount of 1,1-difluoro-2-iodo-ethane (11.4 mg, 0.110 mmol, 0.75 eq) dissolved in anhydrous THF (0.5 ml) was added. After stirring at -78 ° C for 1 h, the reaction was quenched with saturated NH4Cl solution and diluted with dichloromethane after stirring for 5 minutes. The layers were separated with the aid of a hydrophobic glass frit. The organic layer was washed with water, separated again and dried over sodium sulfate. After removing the solvent, the crude material was purified by preparative HPLC (water / acetonitrile gradient) to give Example 148 N-(rac-(2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 3.0 mg 0.0056 mmol, 3.7%) as a colorless resin.

[0544] 1H NMR(chloroform-d3)δ:8.07(d,1H),7.63(d,1H),7.60–7.56(m,2H),7.50(dt,1H),7.32( dd,1H),7.29–7.25(m,4H),7.23–7.18(m,3H),6.43(tdd,1H),5.91(dd,1H),4.92 (d,1H),4.78(t,1H),2.50–2.39(m,1H),2.39–2.27(m,1H),1.43–1.37(m,1H),1 .36(s,3H),0.97(dddd,1H),0.86(dddd,1H),0.83–0.77(m,1H),0.74(dddd,1H).

[0545] Example 149 N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-1-(1-(4-fluorophenyl)-1H-indazole-5-yl)- 4-Methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

[0546]

[0547] Step 1: Under an inert atmosphere, in a dry container, Example 121 (150 mg, 0.295 mmol) was dissolved in anhydrous THF (3 ml). The solution was cooled to -78 ° C, and a solution of freshly prepared LDA (1M in THF, 0.737 ml, 2.5 equiv.) was added dropwise. After stirring at -78 ° C for 15 minutes, iodomethane (62.8 mg, 0.442 mmol, 1.5 equiv.) was added dropwise. The mixture was stirred at this temperature for 45 minutes. Then, another amount of iodomethane (42 mg, 0.110 mmol, 1 equiv.) was added. After stirring at -78 ° C for 1 h, the reaction was quenched with a saturated NH4Cl solution and diluted with dichloromethane after stirring for 5 minutes. The layers were separated by means of a hydrophobic glass frit. The organic layer was washed with water, separated again and dried over sodium sulfate. After removal of the solvent, the crude material was purified by preparative HPLC (water / acetonitrile gradient) to give Example 149 N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide (14.0 mg, 0.0268 mmol, 9%) as a colorless resin.

[0548] 1H NMR(DMSO-d6)δ:8.44(d,1H),8.30(d,1H),7.79-7.70(m,3H),7.68(d,1H),7.47 (dd,1H),7.43-7.33(m,4H),7.23(t,2H),7.15(td,1H),5.23(d,1H),4.34(t,1H) ,1.85(dd,1H),1.69(ddd,1H),1.30(s,3H),1.13(dd,1H),1.05(tt,1H),0.71(t dd,1H),0.68-0.58(m,2H),0.55(tdt,1H),0.45-0.36(m,2H),0.08-0.05(m,2H).

[0549] Example 150 N-((2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenyl-4- (Thiazol-2-ylmethyl)pyrrolidin-3-yl)cyclopropanecarboxamide

[0550]

[0551] Step 1: Under inert atmosphere, in a dry container, intermediate C1-enantiomer 1 (150 mg, 0.295 mmol) was dissolved in anhydrous THF (4.7 ml). The solution was cooled to -78 °C and a solution of freshly prepared LDA (1 M in THF, 1.32 ml, 4 eq.) was added dropwise. After stirring at -78 °C for 15 min, 2-(chloromethyl)-1,3-thiazole hydrochloride (67 mg, 0.396 mmol, 1.2 eq.) was added as a solid. The mixture was kept at -40 °C for one hour. Then, another amount of LDA (1 M in THF, 0.165 ml, 1 eq.) was added, followed by 2-(chloromethyl)-1,3-thiazole hydrochloride (28.1 mg, 0.165 mmol, 0.5 eq.). After stirring overnight at -40 °C, the reaction was quenched with saturated NH4Cl solution and diluted with dichloromethane after stirring for 5 minutes. The layers were separated with the aid of a hydrophobic frit. The organic layer was washed with water, separated again and dried over sodium sulfate. After removal of the solvent, the crude material was purified via preparative HPLC (water / acetonitrile gradient) to give Example 150. N-((2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazole-5-yl)-5-oxo-2-phenyl-4-(thiazol-2-ylmethyl)pyrrolidin-3-yl)cyclopropanecarboxamide (26.3 mg 0.0477 mmol 14%) was an off-white solid.

[0552] 1H NMR(600MHz, chloroform-d3)δ:9.22(d,1H),8.06(d,1H),7.77(d,1H),7.72(d,1H),7. 65-7.58(m,2H),7.53-7.46(m,2H),7.45-7.40(m,2H),7.37-7.31(m,3H),7.31 -7.26(m,1H),7.24-7.18(m,2H),5.09(d,1H),4.72(td,1H),3.71(dd,1H),3. 58(td,1H),3.44(dd,1H),1.56(tt,1H),1.09-1.02(m,2H),0.85-0.78(m,2H).

[0553] Example 151 N-((2S,3S)-2-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)- 2-methyl-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide

[0554]

[0555] Step 1: To a stirred solution of 1-(5-chlorothiophen-2-yl)ethan-1-one (20 g, 125 mmol, 1.0 eq.) in EtOH (250 mL) was added NaOAc (50.6 g, 625 mmol, 5.0 eq.) and NH2OH.HCl (25.7 g, 375 mmol, 3.0 eq.) at RT and stirred at 80°C for 16 h. The reaction progress was monitored by TLC. The reaction mixture was evaporated, diluted with H2O, the formed precipitate was washed with H2O (100 mL), and dried under vacuum to give (E)-1-(5-chlorothiophen-2-yl)ethan-1-one oxime (20 g, 94%) as a brown liquid.

[0556] Step 2: at -40 ° C, to a stirred solution of compound (E) -1- (5-chlorothiophene-2-yl) second -1- ketone oxime (10g, 57.14mmol, 1.0 equivalent) in DCM (100mL), TEA (9.2mL, 68.57mmol, 1.2 equivalents) was added, and the mixture was stirred for 15 minutes, followed by addition of chlorodiphenylphosphine (13.8g, 62.85mmol, 1.1 equivalents). Slowly warm to rt reaction and stir for 2h. Monitor reaction progress by TLC. The reaction mixture is diluted with H2O (100mL), and extracted with DCM (2x200mL). The combined organic layer is washed with brine (100mL), dried over Na2SO4 and evaporated. The crude product was purified by flash chromatography (silica, 40-60% EtOAc in petroleum ether as eluent) to give compound (E)-N-(1-(5-chlorothiophen-2-yl)ethylidene)-P,P-diphenylphosphinamide (15 g, 73%) as a brown solid.

[0557] Step 3: To a stirred solution of compound (E)-N-(1-(5-chlorothiophen-2-yl)ethylidene)-P,P-diphenylphosphinamide (15 g, 41.71 mmol, 1.0 eq) in THF (200 mL) was added Cu(OAc)2 (0.377 g, 2.85 mmol, 0.05 eq), TPP (1.0 g, 4.16 mmol, 0.1 eq) at RT under nitrogen atmosphere. The mixture was stirred for 15 minutes, after which diethyl fumarate (18 mL, 104 mmol, 2.5 eq) and pinacol borane (14.8 mL, 116 mmol, 2.8 eq) were added. Stirring was continued for 16 h at RT. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2x100 mL). The combined organic layers were washed with brine (100 mL), dried (Na2SO4) and evaporated. The crude compound was purified by flash chromatography (silica, 40-60% EtOAc in petroleum ether as eluent) to give compound ethyl 2-(5-chlorothiophen-2-yl)-1-(diphenylphosphoryl)-2-methyl-5-oxopyrrolidine-3-carboxylate (15 g, -75%) as a white solid.

[0558] Step 4: Add concentrated HCl (15 mL) to a stirred solution of compound 2-(5-chlorothiophene-2-yl)-1-(diphenylphosphoryl)-2-methyl-5-oxopyrrolidine-3-carboxylic acid ethyl ester (15 g, 30.80 mmol, 1.0 equivalent) in EtOH (150 mL) at RT and stir for 16 h at 90 ° C. Monitor the reaction progress by TLC. The reaction mixture is evaporated, diluted with water (50 mL), alkalized with saturated NaHCO (pH=8), and extracted with EtOAc (2x200 mL). The combined organic layers are washed with brine (100 mL), dried (Na SO ) and evaporated. The crude compound was purified by flash chromatography (silica, 60-70% EtOAc in petroleum ether as eluent) to afford compound rac-(2S,3S)-ethyl 2-(5-chlorothien-2-yl)-2-methyl-5-oxopyrrolidine-3-carboxylate (7.0 g, -81%) as a white solid.

[0559] Step 5: To a stirred solution of compound (2S,3S)-2-(5-chlorothiophen-2-yl)-2-methyl-5-oxopyrrolidine-3-carboxylic acid ethyl ester (7 g, 24.39 mmol, 1.0 equiv) in THF / MeOH / H2O (1:1:1, 75 mL) was added LiOH*H2O (1.7 g, 48.78 mmol, 2.0 equiv) at RT and stirring was continued at the same temperature. The reaction progress was monitored by TLC. The reaction mixture was evaporated, diluted with water (30 mL) and extracted with Et2O (2x50 mL). The aqueous layer was acidified with 1N HCl (pH=4-5), the formed precipitate was filtered and dried to give compound (2S,3S)-2-(5-chlorothiophen-2-yl)-2-methyl-5-oxopyrrolidine-3-carboxylic acid (3.5 g, ~97%) as a white solid.

[0560] Step 6: To a stirred solution of compound rac-(2S,3S)-2-(5-chlorothiophene-2-yl)-2-methyl-5-oxopyrrolidine-3-carboxylic acid (3.4 g, 13.12 mmol, 1.0 equiv) in toluene (70 mL) was added TEA (2.0 mL, 13.78 mmol, 1.05 equiv), DPPA (3.4 mL, 15.74 mmol, 1.2 equiv) at RT. Stirring was continued at 90 °C for 2 h, then the mixture was cooled to RT, after which BnOH (3 mL, 26.25 mmol, 2.0 equiv) was added. The resulting mixture was heated to 120 °C for 16 h. The reaction progress was monitored by TLC. The reaction mixture was evaporated, diluted with water (50 mL), and extracted with EtOAc (2x100 mL). The combined organic layers were washed with brine (50 mL), dried (Na2SO4) and evaporated. The crude compound was purified by flash chromatography (silica, 70-90% EtOAc in petroleum ether as eluent) to give compound benzyl (rac-(2S,3S)-2-(5-chlorothien-2-yl)-2-methyl-5-oxopyrrolidin-3-yl)carbamate (2.0 g, -41%) as an off-white solid.

[0561] Step 7: A stirred solution of compound (rac-(2S,3S)-2-(5-chlorothiophen-2-yl)-2-methyl-5-oxopyrrolidin-3-yl)benzylcarbamate (2.0 g, 5.49 mmol, 1.0 equiv) in HBr in AcOH (20 mL) was stirred at RT for 2 h. The reaction progress was monitored by TLC. The reaction mixture was quenched with NaHCO3 solution and extracted with EtOAc (4x100 mL). The combined organic layers were washed with brine (50 mL), dried (Na2SO4) and evaporated. The crude compound was purified by flash chromatography (silica, 70-80% EtOAc in petroleum ether as eluent) to give compound rac-(4S,5S)-4-amino-5-(5-chlorothiophen-2-yl)-5-methylpyrrolidin-2-one (1.0 g, ~41%) as an off-white solid.

[0562] Step 8: To a stirred solution of compound rac-(4S,5S)-4-amino-5-(5-chlorothiophen-2-yl)-5-methylpyrrolidin-2-one (400 mg, 1.739 mmol, 1.0 eq.) and cyclopropanecarboxylic acid (224 mg, 2.608 mmol, 1.5 eq.) in DMF (10 mL) was added HATU (0.90 g, 2.608 mmol, 1.5 eq.), DIPEA (0.9 mL, 5.217 mmol, 3.0 eq.) at 0°C under nitrogen atmosphere and stirred for 16 h at RT. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x20 mL). The combined organic layers were washed with brine (20 mL), dried (Na2SO4) and evaporated. The crude compound was purified by flash chromatography (silica, 70-90% EtOAc in petroleum ether as eluent) to afford compound N-(rac(2S,3S)-2-(5-chlorothien-2-yl)-2-methyl-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide (210 mg, -40%).

[0563] Step 9: To a stirred solution of compound N-(rac(2S,3S)-2-(5-chlorothiophene-2-yl)-2-methyl-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide (200 mg, 0.671 mmol, 1.0 eq.) and compound 1-(4-fluorophenyl)-5-iodo-1H-indazole (249 mg, 0.738 mmol, 1.5 eq.) in dioxane (10 mL) was added CuI (127 mg, 0.671 mmol, 1.5 eq.), DMEDA (59 mg 0.671 mmol, 1 eq.) and KCO (277 mg, 2.013 mmol, 3.0 eq.) and stirred at 130 ° C for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x20 mL). The combined organic layers were washed with brine (20 mL), dried (Na2SO4) and evaporated. The crude compound was purified by flash chromatography (silica, 70-90% EtOAc in petroleum ether as eluent) followed by preparative HPLC to afford Example 151 N-((2S,3S)-2-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide (50 mg, ~53%).

[0564] 1 H NMR (500MHz, DMSO-d6): δ8.77(d,1H),8.39(s,1H),7.80-7.76(m,3H),7.58(d,1H),7.63(s,1H),7.44-7.40(m,2H),7.22(dd,1H) ,7.01(d,1H),6.93(d,1H),4.71-4.67(m,1H),3.10(dd,1H),2.43-2.36(m,1H),1.64-1.61(m,1H),1.48(s,3H),0.72-0.6(m,4H).

[0565] The examples in the following table were synthesized similarly to Example 1 above using different intermediates.

[0566]

[0567]

[0568] The examples in the following table were synthesized similarly to Example 5 above using different intermediates.

[0569]

[0570]

[0571] The examples in the following table were synthesized similarly to Example 7 above using different intermediates.

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601]

[0602]

[0603]

[0604]

[0605]

[0606] Human Glucocorticoid Receptor (hGR) Ligand Binding Assay

[0607] In a humidified incubator, at 37 ° and 7% CO2, human lymphoblast cell line IM9 (ATCC, Bethesda, MD) was cultured in RPMI 1640 medium containing 10% fetal bovine serum, penicillin (100U / ml), streptomycin (100μg / ml) and 2mM L-glutamine. The cells were centrifuged at 1500g for 10 minutes, washed in PBS and reprecipitated. The cells were then resuspended in a homogenization buffer consisting of: 10mM TES, 10mM sodium molybdate, 1mM EDTA (pH 7.4), 20mM 2-mercaptoethanol and 10% glycerol. Cell disruption was performed by 2x15 minutes of nitrogen cavitation at 600 to 750psi nitrogen in a N2 cavitator at 0°C. The cell preparation was then centrifuged at 27,000 g for 15 minutes, and the resulting supernatant (=cytosol of IM9 cells) was centrifuged at 103,000 g for 60 minutes at 4 ° C. The amount of protein in the supernatant fraction was determined using a BCA assay kit, and aliquots were snap-frozen in a dry ice-acetone bath and stored at -70 ° C. Competitive binding assays were performed in duplicate in a total volume of 200 μl of homogenization buffer. To this end, 1 mg of IM9 cytosol, 0.05 μCi (1.5 nM) of 3H-dexamethasone and 1 μM of unlabeled example compounds as competing compounds were mixed. After incubation at 0 ° C for 16 to 18 hours, the reaction was terminated by adding 100 μl of charcoal-dextran mixture (2% activated charcoal, 0.5% dextran in 10 mM Tris, 1 mM EDTA, pH 7.4). This was followed by another 10-minute incubation step at 0°C, after which the samples were centrifuged at 8200 g for 5 minutes. The radioactivity of 100 μl of the supernatant was finally determined by liquid scintillation spectrometry and the percentage inhibition of 3H-dexamethasone binding was calculated.

[0608] GRE agonists

[0609] The reporter cell line CHO-Gal4 / GR consists of a Chinese hamster ovary (CHO) cell line (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH: ACC-110) containing the firefly luciferase gene under the control of the GR ligand binding domain fused to the DNA binding domain (DBD) of GAL4 stably integrated into CHO cells (GAL4 DBD-GR). This cell line was established by stably transfecting CHO cells with a GAL4-UAS-luciferase reporter construct. In a subsequent step, the ligand binding domain of the GR cloned from pFA-AT2 into pIRES2-EGFP-GAL4 containing the DNA binding domain of GAL4 was transfected. This fusion construct activates firefly luciferase expression under the control of the multimerized GAL4 upstream activation sequence (UAS). The luciferase reporter construct was expressed in 1% luciferase and 1% luciferase was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. TETRA The emitted luminescence signal is recorded. This allows specific detection of ligand-induced activation of the GR, thereby identifying compounds with agonistic properties. The GAL4 / UAS reporter is premixed with a vector constitutively expressing Renilla luciferase, which is used as an internal positive control for transfection efficiency.

[0610] The complete culture medium used for the assay is:

[0611] - DMEM F-12 (1:1) mixture (LONZA catalog number: BE04-687F / U1) 500 mL

[0612] - 5 mL of 100 mM sodium pyruvate (LONZA catalog number: BE12-115E)

[0613] - 25 mL of 7.5% Sodium Bicarbonate (LONZA Cat. No. BE17-613E)

[0614] - 6.5 mL of 1 M Hepes (LONZA catalog number: BE17-737E)

[0615] -5 mL of 100X Penicillin / Streptomycin (LONZA Cat. No. DE17-602E)

[0616] -50mL fetal calf serum (Euroclone catalog number ECS 0180L)

[0617] -0.25 mL of 10 mg / mL puromycin (InvivoGen catalog: ant-pr-1)

[0618] -0.5 mL of 100 mg / mL zeocin (InvivoGen catalog: ant-zn-1)

[0619] Cryopreserved CHO-Gal4 / GR cells were suspended in complete medium and inoculated into the wells of 384-well polystyrene assay plates (Thermo Scientific, catalog number 4332) at 5000 cells / 25 μl / well and cultured at 37°C, 5% CO2 and 95% humidity. After 24 hours, the growth medium was carefully removed and replaced with 30 μl Opti-MEM (GIBCO, catalog number 31985062) as assay buffer. To test compounds, 8-point half-log compound dilution curves were generated in 100% DMSO starting from 2mM stock solution, and then the compounds were diluted 1:50 in Opti-MEM. Then 10 μl of compound was added to the wells containing 30 μl Opti-MEM, resulting in a final assay concentration range of 10 μM to 0.003 μM in 0.5% DMSO. Compounds were tested at 8 concentrations in quadruplicate data points. The cells were incubated with the compounds and beclomethasone (Sigma, catalog number Y0000351) as a control compound for 6 hours at 37°C, 5% CO2 and 95% humidity in a total volume of 40 μl. Finally, the cells were lysed with 20 μl of Triton / fluorescein solution and lysed with 1% Triton / fluorescein at 4 °C for 24 hours. TETRA The emitted luminescence signal was recorded for 2 min.

[0620] The relative potency (% potency) of the compounds was calculated based on the full potency of the agonist beclomethasone:

[0621] - % potency = ((compound – min) / (max – min)) x - 100

[0622] -[min = Opti-MEM only, max = beclomethasone]

[0623] To calculate the EC of each compound 50 , max, min, and slope factor to fit the concentration-response curve by plotting % potency versus compound concentration using the 4-parameter logistic equation:

[0624] -y=A+(BA) / (1+((10C) / x)D)

[0625] -[A=min y, B=max y, C=logEC 50 , D = slope]

[0626] GRE antagonists

[0627] The reporter cell line CHO-Gal4 / GR consists of a Chinese hamster ovary (CHO) cell line (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH: ACC-110) containing the firefly luciferase gene under the control of the GR ligand binding domain fused to the DNA binding domain (DBD) of GAL4 stably integrated into CHO cells (GAL4 DBD-GR). This cell line was established by stably transfecting CHO cells with a GAL4-UAS-luciferase reporter construct. In a subsequent step, the ligand binding domain of the GR cloned from pFA-AT2 into pIRES2-EGFP-GAL4 containing the DNA binding domain of GAL4 was transfected. This fusion construct activates firefly luciferase expression under the control of the multimerized GAL4 upstream activation sequence (UAS). The luciferase reporter construct was expressed in 1% luciferase and 1% luciferase was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. The luciferase reporter construct was expressed in 1% luciferase. TETRA The emitted luminescence signal is recorded. This allows specific detection of the antagonistic properties of the compounds by measuring the ligand-induced inhibition of beclomethasone-activated GR. The GAL4 / UAS reporter is premixed with a vector constitutively expressing Renilla luciferase, which is used as an internal positive control for transfection efficiency.

[0628] The complete culture medium used for the assay is:

[0629] - DMEM F-12 (1:1) mixture (LONZA catalog number: BE04-687F / U1) 500 mL

[0630] - 5 mL of 100 mM sodium pyruvate (LONZA catalog number: BE12-115E)

[0631] - 25 mL of 7.5% Sodium Bicarbonate (LONZA Cat. No. BE17-613E)

[0632] - 6.5 mL of 1 M Hepes (LONZA catalog number: BE17-737E)

[0633] -5 mL of 100X Penicillin / Streptomycin (LONZA Cat. No. DE17-602E)

[0634] -50mL fetal calf serum (Euroclone catalog number ECS 0180L)

[0635] -0.25 mL of 10 mg / mL puromycin (InvivoGen catalog: ant-pr-1)

[0636] -0.5 mL of 100 mg / mL zeocin (InvivoGen catalog: ant-zn-1)

[0637] Cryopreserved CHO-Gal4 / GR cells were suspended in complete medium and seeded into the wells of 384-well polystyrene assay plates (Thermo Scientific, catalog number 4332) at 5000 cells / 25 μl / well and cultured at 37°C, 5% CO2 and 95% humidity. After 24 hours, the growth medium was carefully removed and replaced with 20 μl Opti-MEM (GIBCO, catalog number 31985062) as assay buffer. To test compounds, an 8-point half-log compound dilution curve was generated in 100% DMSO starting from a 2mM stock solution, and the compounds were then diluted 1:50 in Opti-MEM. To test compounds in antagonist mode, 10 μl of the compound was then added to the wells containing 20 μl Opti-MEM and incubated for 10 minutes. After this pre-incubation, 10 μl of the reference agonist beclomethasone (Sigma, catalog number Y0000351) with an EC50 of 2.5 nM was added, resulting in a final assay concentration range of 10 μM to 0.003 μM in 0.5% DMSO in a total volume of 40 μl. Compounds were tested at 8 concentrations in quadruplicate data points. Cells were incubated for 6 hours at 37°C, 5% CO2, and 95% humidity with the compounds and mifepristone (Sigma, catalog number M8046) as a control compound. Finally, cells were lysed with 20 μl of Triton / fluorescein solution and lysed in a FLIPR TETRA The emitted luminescence signal was recorded for 2 min.

[0638] The relative potency (% potency) of the compounds was calculated based on the full potency of the antagonist mifepristone:

[0639] - % potency = ((compound – min) / (max – min)) x - 100

[0640] -[min = Opti-MEM only, max = mifepristone]

[0641] To calculate the IC of each compound 50 , max, min, and slope factor to fit the concentration-response curve by plotting % potency versus compound concentration using the 4-parameter logistic equation:

[0642] -y=A+(BA) / (1+((10C) / x)D)

[0643] -[A=min y, B=max y, C=logIC 50 , D = slope]

[0644] Biological data summary table:

[0645]

[0646]

[0647]

[0648] "na": no activity in either agonistic or antagonistic mode in GR cell-based assays.

[0649] "nd": not determined.

[0650] Prophetic Embodiments

[0651] The prophetic examples summarized in the table below can be synthesized analogously to Example 7 above. One skilled in the art will know how to select appropriate intermediates in order to obtain any of the prophetic examples shown in the table below.

[0652]

[0653]

[0654] In any of the above tables, where the substituents attached to the central pyrrolidone have different relative orientations, such as the phenyl moiety and the methyl moiety pointing upward ("bold bonds" ) and the amide portion is downward ("cleavage bond" ) or vice versa, the example compounds are "trans" diastereomers, which are racemic mixtures of the two corresponding trans enantiomers.

Claims

1. A compound according to general formula (I), in R1 represents phenyl; -C 1-6 -alkylene-phenyl; 5 or 6 membered heteroaryl; -C 1-6 -alkylene-(5- or 6-membered heteroaryl) or -C 1-10 -alkyl; R 1’ Represents H; -C 1-10 -alkyl; or -C 3-10 - cycloalkyl; R2 represents -C(=O)-C 1-10 -alkyl; -C(=O)-C 3-10 -cycloalkyl; -C(=O)-C 1-6 -Alkylene-C 3-10 -cycloalkyl; -C(=O)-(3- to 7-membered heterocycloalkyl); -C(=O)-C 1-6 -alkylene-(3 to 7 membered heterocycloalkyl); -C(=O)-phenyl; -C(=O)-C 1-6 -alkylene-phenyl; -C(=O)-(5- or 6-membered heteroaryl); -C(=O)-C 1-6 -alkylene-(5- or 6-membered heteroaryl); -S(=O) 1-2 -C 1-10 -alkyl; -S(=O) 1-2 -C 3-10 -cycloalkyl; -S(=O) 1-2 -C 1-6 -Alkylene-C 3-10 -cycloalkyl; -S(=O) 1-2 -(3 to 7 membered heterocycloalkyl); -S(=O) 1-2 -C 1-6 -alkylene-(3 to 7 membered heterocycloalkyl); -S(=O) 1-2 -phenyl; -S(=O) 1-2 -C 1-6 -alkylene-phenyl; -S(=O) 1-2 -(5- or 6-membered heteroaryl); or -S(=O) 1-2 -C 1-6 -alkylene-(5- or 6-membered heteroaryl); R3 and R 3’ Independently represent H; F; Cl; -C 1-10 -alkyl; -C 3-6 -cycloalkyl; -CH2-C 3-6-cycloalkyl; 3- to 7-membered heterocycloalkyl; -CH2-(3- to 7-membered heterocycloalkyl); -CH2-phenyl; or -CH2-(5- or 6-membered heteroaryl); Or R3 and R 3’ Together with the carbon atoms to which they are attached, they form C 3-10 -cycloalkyl; or 3 to 7 membered heterocycloalkyl; R4 represents -phenyl; -C 1-6 -alkylene-phenyl; -5 or 6 membered heteroaryl; or -C 1-6 -alkylene-(5- or 6-membered heteroaryl); A, X, Y and Z independently represent N or CH; Where R 1’ , R3 and R 3’ At least one of is not H; Where -C 1-10 -alkyl and -C 1-6 -Alkylene - is in each case independently of one another straight-chain or branched, saturated or unsaturated; Where -C 1-10 -alkyl, -C 1-6 -alkylene-, -C 3-10 -cycloalkyl and 3- to 7-membered heterocycloalkyl are in each case independently of one another unsubstituted or mono- or polysubstituted by one or more substituents selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -CF2Cl; -CFCl2; -C(=O)-C 1-6 -alkyl; -C(=O)-OH; -C(=O)-OC 1-6 -alkyl; -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; =O; -OCF3; -OCF2H; -OCFH2; -OCF2Cl; -OCFCl2; -OC 1-6 -alkyl; -OC(=O)-C 1-6 -alkyl; -OC(=O)-OC 1-6 -alkyl; -O-(CO)-NH(C 1-6 -alkyl); -OC(=O)-N(C 1-6 -alkyl)2; -OS(=O)2-NH2; -OS(=O)2-NH(C 1-6 -alkyl); -OS(=O)2-N(C 1-6 -alkyl)2; -NH2; -NH(C 1-6 -alkyl); -N(C1-6 -alkyl)2; -NH-C(=O)-C 1-6 -alkyl; -NH-C(=O)-OC 1-6 -alkyl; -NH-C(=O)-NH2; -NH-C(=O)-NH(C 1-6 -alkyl); -NH-C(=O)-N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-OC 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-NH2; -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl)2; -NH-S(=O)2OH; NH-S(=O)2-C 1-6 -alkyl; -NH-S(=O)2-OC 1-6 -alkyl; -NH-S(=O)2-NH2; -NH-S(=O)2-NH(C 1-6 -alkyl); -NH-S(=O)2N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-S(=O)2-OH; -N(C 1-6 -alkyl)-S(=O)2-C 1-6 -alkyl; -N(C 1-6 -alkyl)-S(=O)2-OC 1-6 -alkyl; -N(C 1-6 -alkyl)-S(=O)2-NH2; -N(C 1-6 -alkyl)-S(=O)2-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-S(=O)2-N(C 1-6 -alkyl)2; -SCF3; -SCF2H; -SCFH2; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -S(=O)2-OH; -S(=O)2-OC 1-6 -alkyl; -S(=O)2-NH2; -S(=O)2-NH(C 1-6 -alkyl); -S(=O)2-N(C 1-6 -alkyl)2; -C3-6 -cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; 5- or 6-membered heteroaryl; -OC 3-6 -cycloalkyl; -O-(3- to 6-membered heterocycloalkyl); -O-phenyl; -O-(5- or 6-membered heteroaryl); -C(=O)-C 3-6 -cycloalkyl; -C(=O)-(3- to 6-membered heterocycloalkyl); -C(=O)-phenyl; -C(=O)-(5- or 6-membered heteroaryl); -S(=O)2-(C 3-6 -cycloalkyl); -S(=O)2-(3- to 6-membered heterocycloalkyl); -S(=O)2-phenyl or -S(=O)2-(5- or 6-membered heteroaryl); wherein phenyl and 5- or 6-membered heteroaryl are in each case independently of one another unsubstituted or mono- or polysubstituted by one or more substituents selected from the group consisting of: -F; -Cl; -Br; -I; -CN; -C 1-6 -alkyl; -CF3; -CF2H; -CFH2; -CF2Cl; -CFCl2; -C 1-4 -alkylene-CF3; -C 1-4 -alkylene-CF2H; -C 1-4 -alkylene-CFH2; -C(=O)-C 1-6 -alkyl; -C(=O)-OH; -C(=O)-OC 1-6 -alkyl; -C(=O)-NH(OH); -C(=O)-NH2; -C(=O)-NH(C 1-6 -alkyl); -C(=O)-N(C 1-6 -alkyl)2; -OH; =O; -OCF3; -OCF2H; -OCFH2; -OCF2Cl; -OCFCl2; -OC 1-6 -alkyl; -OC 3-6 -cycloalkyl; -O-(3- to 6-membered heterocycloalkyl); -NH2; -NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)2; -NH-C(=O)-C 1-6 -alkyl; -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl; -NH-C(=O)-NH2; -NH-C(=O)-NH(C 1-6 -alkyl); -NH-C(=O)-N(C 1-6 -alkyl)2; -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl); -N(C 1-6 -alkyl)-C(=O)-N(C 1-6-alkyl)2; -NH-S(=O)2-C 1-6 -alkyl; -SCF3; -SC 1-6 -alkyl; -S(=O)-C 1-6 -alkyl; -S(=O)2-C 1-6 -alkyl; -S(=O)2-NH2; -S(=O)2-NH(C 1-6 -alkyl); -S(=O)2-N(C 1-6 -alkyl)2; -C 3-6 -cycloalkyl; -C 1-4 -Alkylene-C 3-6 -cycloalkyl; 3 to 6 membered heterocycloalkyl; -C 1-4 -alkylene-(3- to 6-membered heterocycloalkyl); phenyl or 5- or 6-membered heteroaryl; in the form of a free compound or a physiologically acceptable salt thereof; Provided that the following compounds are not included: N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide; N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide; N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide; N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-[1,2,4]oxadiazole-3-carboxylic acid amide; N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide; N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-4-carboxylic acid amide; and N-[(2S,3R)-4,4-Dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-4-carboxylic acid amide.

2. The compound according to claim 1, having a stereochemistry according to formula (II) or (VI) 3. The compound according to claim 1 or 2, wherein A represents N, X represents CH, Y represents CH; and Z represents CH; or A represents N, X represents N, Y represents CH; and Z represents CH; or A represents N, X represents CH, Y represents N; and Z represents CH; or A represents N, X represents CH, Y represents CH; and Z represents N; or A represents N, X represents N, Y represents N; and Z represents CH; or A represents N, X represents N, Y represents CH; and Z represents N; or A represents N, X represents CH, Y represents N; and Z represents N; or A represents N, X represents N, Y represents N; and Z represents N; or A represents N, X represents N, Y represents N; and Z represents N; or A represents CH, X represents CH, Y represents CH; and Z represents CH; or A represents N, X represents N, Y represents N; and Z represents N; or A represents CH, X represents N, Y represents CH; and Z represents CH; or A represents CH, X represents CH, Y represents N; and Z represents CH; or A represents CH, X represents CH, Y represents CH; and Z represents N; or A represents CH, X represents N, Y represents N; and Z represents CH; or A represents CH, X represents N, Y represents CH; and Z represents N; or A represents CH, X represents N, Y represents CH; and Z represents N; or A represents CH, X represents CH, Y represents N; and Z represents N; or A represents CH, X represents N, Y represents N; and Z represents N.

4. The compound according to claim 1 or 2, wherein R1 represents phenyl; and / or R 1’ Represents H, CH3 or cyclopropyl.

5. The compound according to claim 1 or 2, wherein R2 represents -C(=O)-C 1-10 -alkyl; -C(=O)-C 3-10 -cycloalkyl; -C(=O)-C 1-6 -Alkylene-C 3-10 -cycloalkyl; -C(=O)-(3- to 7-membered heterocycloalkyl); -C(=O)-(5- or 6-membered heteroaryl); -S(=O)2-C 1-10 -alkyl; -S(=O)2-C 3-10 -cycloalkyl; -S(=O)2-C 1-6 -Alkylene-C 3-10-cycloalkyl; -S(=O)2-(3- to 7-membered heterocycloalkyl); or -S(=O)2-(5- or 6-membered heteroaryl).

6. The compound according to claim 1 or 2, wherein R3 and R 3' Both represent -C 1-10 -alkyl.

7. The compound according to claim 1 or 2, wherein R4 represents -phenyl; or a 5- or 6-membered heteroaryl group.

8. The compound according to claim 1 or 2, wherein R1 stands for Phenyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -OCH3, -CH3, -CF3, -CN and cyclopropyl.

9. The compound according to claim 1 or 2, wherein R2 stands for unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl and -Br 1-10 -alkyl; -C(═O)-cyclopropyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH 3 , -CF 3 , -CN and -OCH 3 ; Unsubstituted -C(═O)-2-tetrahydrofuranyl; -C(═O)-(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is selected from the group consisting of thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, 1-oxa-2,4-diazolyl, 1,2,5-oxadiazolyl and isothiazolyl, wherein the 5- to 6-membered heteroaryl is in each case unsubstituted or mono- or disubstituted by substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN, ═O and -OCH3; Unsubstituted -S(=O)2-C 1-10 -alkyl; unsubstituted -S(=O)2-cyclopropyl; Unsubstituted -S(=O)2-CH 2- Cyclopropyl; unsubstituted -S(=O)2-2-tetrahydrofuranyl; or -S(=O)2-(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is selected from the group consisting of thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, 1-oxa-2,4-diazolyl, 1,2,5-oxadiazolyl and isothiazolyl, wherein the 5- to 6-membered heteroaryl is in each case unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN, =O and -OCH3.

10. The compound according to claim 1 or 2, wherein R3 and R 3' All represent -CH3.

11. The compound according to claim 1 or 2, wherein R4 stands for Phenyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3, -CF3, -CN and -OCH3; A 5- to 6-membered heteroaryl group selected from the group consisting of pyridyl, pyrazolyl and pyrimidinyl, wherein the 5- to 6-membered heteroaryl group is in each case unsubstituted or mono- or disubstituted by substituents selected independently of one another from the group consisting of =O, -F, -Cl, -Br, -CH3, -CF3, -CN and -OCH3.

12. The compound according to claim 1 or 2, wherein R1 represents phenyl which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br, -CH3 and -OCH3; and / or R 1’ represents H, CH3 or cyclopropyl; and / or R2 represents -C(=O)-C 1-6 -alkyl; -C(=O)-cyclopropyl; or -C(=O)-(5- to 6-membered heteroaryl) which is unsubstituted or mono- or di-substituted by substituents independently selected from the group consisting of -F, -Cl, -Br and -CH3; and / or R4 represents fluoro-phenyl or N-methyl-2-oxo-pyridyl.

13. The compound according to claim 1 or 2, selected from the group consisting of 1 N-[(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 2 N-[(2S,3R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 3 N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide 4 2,2-Difluoro-N-[(2S,3R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide 5 N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-indol-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide 6 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-2-carboxylic acid amide 7 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-isoxazole-3-carboxylic acid amide 8 N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-2,2-difluoro-propionamide 9 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-2,2-difluoro-propionamide 10 2,2-Difluoro-N-[(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4,4-dimethyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide 12 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide 13 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-oxazole-5-carboxylic acid amide 14 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-[1,2,4]oxadiazole-3-carboxylic acid amide 15 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-5-carboxylic acid amide 16 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 17 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-4-carboxylic acid amide 18 N-[(2R,3S)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-4-carboxylic acid amide 21 N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-oxazole-5-carboxylic acid amide 22 N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-isoxazole-3-carboxylic acid amide 24 N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-thiazole-5-carboxylic acid amide 26 N-[(2S,3R)-4,4-dimethyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-5-methyl-thiazole-2-carboxylic acid amide 30 N-[rac-(6R,7S)-5-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide 31 N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide 32 N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide 33 N-[rac-(6R,7S)-5-[1-(4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl]-4-oxo-6-phenyl-5-azaspiro[2.4]hept-7-yl]-cyclopropanecarboxylic acid amide 34a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)methanesulfonamide 34b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)methanesulfonamide 35a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanesulfonamide 35b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanesulfonamide 36a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)oxazole-5-carboxamide 36b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)oxazole-5-carboxamide 37 N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-1-methyl-1H-pyrazole-3-carboxamide 38a N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methylthiazole-5-carboxamide 38b N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methylthiazole-5-carboxamide 39a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-5-methylthiazole-4-carboxamide 39b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-5-methylthiazole-4-carboxamide 40a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-3-methylisoxazole-4-carboxamide 40b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-3-methylisoxazole-4-carboxamide 41a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-1-methyl-1H-pyrazole-4-carboxamide 41b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-1-methyl-1H-pyrazole-4-carboxamide 42a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)nicotinamide 42b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)nicotinamide 43a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)pyrimidine-2-carboxamide 43b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)pyrimidine-2-carboxamide 44a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-2-methyloxazole-5-carboxamide 44b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-2-methyloxazole-5-carboxamide 45a N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methyloxazole-5-carboxamide 45b N-((2S,3R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4,4-dimethyl-5-oxo-2-phenylpyrrolidin-3-yl)-4-methyloxazole-5-carboxamide 46 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 47 N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide 48 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(3-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 49 N-[rac-(2R,3S,4S)-2-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 60 N-[rac(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 61 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-methanesulfonic acid amide 62 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 63 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 64 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide 65 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 66 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 67 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 68 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 69 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 70 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 71 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 72 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide 73 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 74 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 75 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide 76 N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 77 2,2-Difluoro-N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-propionamide 78 N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 79 N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide 80 2,2-Difluoro-N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide 81 2,2-Difluoro-N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-m-tolyl-5-oxo-pyrrolidin-3-yl]-propionamide 82 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 83 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide 84 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 85 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 86 N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 87 N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 88 N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 89 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 90 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 91 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 92 N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 93 N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 94 N-[rac-(2R,3S,4R)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide 95 N-((2R,3R,4S)-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 96 N-((2R,3R)-4,4-difluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 97 2,2-Difluoro-N-[rac-(2R,3S,4R)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-propionamide 98 2,2-Difluoro-N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-propionamide 99 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 100 2,2-Difluoro-N-[rac-(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide 101 N-[rac-(2R,3S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 102 2,2-Difluoro-N-[rac-(2R,3S)-2-methyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-propionamide 103 N-[rac-(2R,3S)-2-methyl-1-[1-(1-methyl-6-oxo-1H-pyridin-3-yl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 104 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxamide 105 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 106 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 107 N-[rac-(2R,3S,4S)-4-benzyl-2-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide 108 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 109 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 110 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide 111 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 112 N-[rac-(2R,3S,4S)-2-(2-chlorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 113 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 114 N-[(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 115 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 116 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-4-methyl-thiazole-5-carboxylic acid amide 117 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-1-methyl-1H-pyrazole-3-carboxylic acid amide 118 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-pyridine-3-carboxylic acid amide 119 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-pyrimidine-2-carboxylic acid amide 120 2,2-Difluoro-N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-propionamide 121 N-[rac-(2R,3S,4S)-4-(cyclopropyl-methyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 122 N-[rac-(2S,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-2-(1-methyl-1H-pyrazol-3-yl)-5-oxo-pyrrolidin-3-yl]-methanesulfonic acid amide 123 N-[rac-(2S,3S,4S)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide 124 N-[rac-(2S,3S,4R)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 125 N-[rac-(2S,3S,4R)-2-(5-chloro-thiophen-2-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-pyrrolidin-3-yl]-2,2-difluoro-propionamide 126 N-[rac-(2R,3S,4S)-4-ethyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 127 N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide, diastereomer 2 128 N-[rac-(2R,3R,4R)-4-fluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 129 N-[rac-(2R,3R,4S)-4-fluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl-5-oxo-2-phenyl-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 130 N-((2R,3S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-4-phenethyl-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide, diastereomer 1 131 N-((2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 132 N-((2R,3S,4R)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 133 N-[rac-(2R,3S,4S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(4-methoxyphenyl)-4-methyl-5-oxo-pyrrolidin-3-yl]-cyclopropanecarboxylic acid amide 134 N-(rac-(2R,3S,4R)-4-ethyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 135 N-((7R,8S)-6-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-7-phenyl-6-azaspiro[3.4]octan-8-yl)cyclopropanecarboxamide 136 N-(rac(2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 137 N-(rac-(2R,3R,4S)-4-benzyl-2-ethyl-4-fluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide 138 N-((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 139 N-((2R,3S,4S)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-((1-methyl-1H-pyrazol-4-yl)methyl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 142 N-(rac-(2R,3S)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 143 N-(rac-(2R,3R)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 144 N-(rac-(2R,3S)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-2,2-difluoropropionamide 145 N-(rac-(2R,3R)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)-2,2-difluoropropionamide 146 N-(rac-(2R,3S)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)oxetane-3-carboxamide 147 N-(rac-(2R,3R)-2-cyclopropyl-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenylpyrrolidin-3-yl)oxetane-3-carboxamide In each case, it is in the form of the free compound or its physiologically acceptable salts.

14. The compound according to claim 1 or 2, selected from the group consisting of: 148 N-(rac-(2R,3S,4S)-4-(2,2-difluoroethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 149 N-(rac-(2R,3S,4S)-4-(cyclopropylmethyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl-5-oxo-2-phenylpyrrolidin-3-yl)cyclopropanecarboxamide 150 N-((2R,3S,4R)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-5-oxo-2-phenyl-4-(thiazol-2-ylmethyl)pyrrolidin-3-yl)cyclopropanecarboxamide 151 N-((2S,3S)-2-(5-chlorothiophen-2-yl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-5-oxopyrrolidin-3-yl)cyclopropanecarboxamide In each case, it is in the form of the free compound or its physiologically acceptable salts.

15. A pharmaceutical dosage form comprising a compound according to any one of claims 1 to 14.

16. Use of a compound according to any one of claims 1 to 14 for the preparation of a medicament for the treatment and / or prevention of pain and / or inflammation.